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ABSTRACT
Equine Herpesvirus-1 (EHV-1) is an important ubiquitous enzootic equine
pathogen, causing significant economic losses to the horse industry. Despite extensive
vaccination protocols, EHV-1 continues to be a major cause of epidemic abortion, perinatal
mortality, respiratory disease and neurologic disease. EHV-1 infections are usually dealt
with by using management practices that limit spread of the disease and secondary
complications, providing symptomatic relief to infected horses, but no specific treatment is
available. New therapeutic or virucidal agents could have great utility in slowing both the
progression and spread of the disease in an epidemic situation.
A number of porphyrins and their derivatives have been tested to have activity
against HIV, vaccinia, and coronavirus. Porphyrin based compounds were suggested to
inhibit virus infection by reducing the fusogenic potential of the virus (Vzorov et al.,
2002). However, the mechanism of action of porphyrin-based compounds is not well
understood. While current antiherpetic agents target viral DNA replication, interference
with the upstream replicative events such as fusion would not adversely affect the host cell
metabolism, and makes them important targets for chemotherapeutic intervention of virus
dissemination.
We screened a number of porphyrin and platinum compounds for EHV-1 antiviral
activity by testing their ability to interfere with EHV-1 infection of rabbit kidney and
equine cell cultures during the entry and post entry events of the viral life cycle in order to
determine if compounds act at the level of binding, penetration, replication, or egress. We
identified Cu (III) tetrasulfonated phenylporphyrin and Fe (II) tetrasulfonated
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phenylporphyrin as lead candidate antiviral compounds on the basis of their in vitro
efficacy, cytotoxicity and therapeutic index.
These compounds exhibited high antiviral potency during virus-to-cell fusion
events, as well as no apparent cytotoxicity in cell culture assays at EHV-1 inhibitory
concentrations. Specifically, selected porphyrin compounds inhibited free virus, gBmediated virus entry, reduced the extent of virus spread, and cell-to-cell fusion in the virusfree cell fusion system. The EHV-1 antiviral properties and other pharmacological
characteristics make porphyrins auspicious candidates for the treatment of EHV-1
infections and may promote understanding of membrane fusion events of EHV-1 life
cycle.

xxii

CHAPTER I. INTRODUCTION
STATEMENT OF PROBLEM
Equine Herpesvirus-1 (EHV-1) is an important ubiquitous enzootic equine
pathogen, causing significant economic losses to the large (hundred billion dollars) horse
industry. Despite extensive vaccination protocols, EHV-1 continues to be a major cause of
epidemic abortion, perinatal mortality, respiratory disease and occasionally neurological
disease in horses. Furthermore, with increasing interactions within the equine industry, the
potential losses during EHV-1 outbreaks are no longer confined to individual farms. In
devastating recent outbreaks, an unusually high number of horses exhibited the
neurological form of the disease, EHV-1 Myeloencephalopathy (EHM). There is a growing
concern in the U.S. horse industry over the increased number of neurologic cases of EHV1 reported in recent years, as well as the occurrence of several high-profile outbreaks. The
Center for Emerging Issues, part of the Department of Agriculture's Animal and Plant
Health Inspection Service, recently labeled the neurologic form of EHV-1 as a potentially
emerging disease.
There is a pressing need for potent antiviral compounds to treat both disseminated
as well as neurological forms of infections. EHV-1 infections are usually dealt with using
management practices that limit spread of the disease, providing symptomatic relief to
infected horses, including the use of steroids, non-steroidal anti-inflammatory agents,
antibiotics for secondary bacterial infections as well as other compounds used to treat
EHV-1-associated neurological symptoms like paresis, paralysis, distention of the urinary
bladder, stiffness of pelvis or ocular damage, but no specific treatment is available. The
current antiviral treatments options are based on extrapolation from established regiments
1

for nucleoside analogs such as acyclovir used for treatment of human infections with HSV1 and VZV and have not been shown to change the outcome of EHV-1 infections
significantly. There are no controlled studies reporting on the efficacy of the known
antiherpetic agents in the treatment or prevention of EHM, nor describing their
pharmacokinetics, bioavailability, and safety in horses. New therapeutic or virucidal agents
could have great utility in slowing both the progression and spread of the disease in an
epidemic situation.
While, current antiherpetic agents target viral DNA replication, fusion events of
virus entry are the upstream replicative event, interference with which does not adversely
affect the host cell metabolism, and makes them important targets for chemotherapeutic
intervention of virus dissemination. The molecular events of the membrane fusion at the
onset of herpesvirus infection are currently under extensive investigation in multiple
laboratories and are still undetermined. Multiple viral surface glycoproteins are known to
participate in the fusion events that may occur via endocytosis as well as pH-independent
membrane fusion. Preliminary data indicates that the porphyrin based compounds inhibit
virus infection by reducing the fusogenic potential of the virus (Dairou et al., 2004).
Substantial work performed by Dr. Marzilli of the LSU Department of Chemistry and his
collaborators at Emory University, Atlanta, GA has shown that specific porphyrin-based
compounds exhibited strong and specific antiviral activities against different viruses such
as HIV. Additional preliminary work in our laboratory has confirmed the antiviral
properties of porphyrin compounds against coronaviruses, vaccinia, HSV-1 as well as
EHV-1. The molecular basis for these antiviral activities is not known and it is the subject
of the proposed investigations.
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HYPOTHESIS
The central hypothesis of the investigations was that select porphyrin compounds
can specifically inhibit membrane fusion phenomena required for virus entry and virus
spread through specific interactions with one or more viral glycoproteins required for
membrane fusion.

STATEMENT OF RESEARCH OBJECTIVES
The overall objective of the current investigation was to determine what specific stage
of EHV-1 infection and viral components are affected by the porphyrin compounds.

Objective I
To conduct screening tests to determine preliminary antiviral and cytotoxic effects
of the available chemical compounds, including porphyrin, pthalocyanine, and platinum
derivatives.

Specific Aims
1. To screen available chemical compounds for EHV-1 antiviral activity and to
identify lead candidate compounds on the basis of their low in vitro toxicity and
antiviral potency.
2. To elucidate the mechanism of action of the antiviral compounds by localizing
the effect of the compounds to the specific stages of virus life cycle such as
attachment, virus to cell fusion, replication, assembly, or cell to cell spread.

Objective II
To conduct definitive tests to measure the antiviral effects of porphyrins and to
unequivocally identify potential antiviral substances and the stage and components of
EHV-1 viral infection that they affect.
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Specific Aims
1. To quantify the EHV-1 antiviral activity and cytotoxicity of the lead candidate
antiviral compounds by determining the 50% effective concentration, 50%
cytotoxic concentration, and therapeutic index of the compounds.
2. To assay the effects of antiviral compounds on virus entry, infectious virus
production and plaque formation.
3. To determine whether selected porphyrin compounds specifically inhibit gBmediated virus entry and virus spread.

LITERATURE REVIEW
Historical Perspective
In medicine one must pay attention not to plausible theorizing, but to experience and
reason together.

~Hippocrates

If your horse says no, you either asked the wrong question, or asked the question wrong.
~Pat Parelli

Origins of Herpes
More than 25 centuries have passed since investigations of herpesviruses have
begun. Over the centuries, the inquiry has progressed from the basic classification of
human cutaneous lesions and the individual accounts of animal diseases to be attributed to
herpesviruses later, to the description of epidemiology of herpes infections, the discovery
of etiological agents responsible for the disease, and ultimately, to the molecular
characterization of the Herpesviridae family.
The first written documentation of the herpesvirus infection is dating back to
ancient Greece. The word 'herpes' comes from the Greek word herpein, used by
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Hippocrates (460 BC-377 BC) to describe lesions that creep or crawl, referring to the
sequential appearance and local extensions of lesions in human HSV-1 infection (Wildy,
1973). Description of lesions resembling human herpes was also mentioned in Sumerian
Tablet dated to 3rd millennium BC and the Egyptian Ebers Papyrus, around 1500 BC
(Roizman and Whitley, 2001). Then, from Avicenna (880-1036 AD) and Gulielmus
Salicetto (13th century) until the beginning of the 19th century, the term ‘herpes’ have
changed to ‘formica’ (Latin: ant), ‘furfur’ (Latin: bran, scales) and, then, back to ‘herpes’
(Beswick, 1962). While historical account of human herpesvirus infections are dated far
back, the clinical conditions caused by Equine Herpes Virus -1 and other animal
herpesviruses have only been described over the past four centuries. Nonetheless,
understanding the nature of the members of Herpesviridae family took centuries and paved
the way to the discovery and our current knowledge of EHV-1.

Horses in Human History
Until about 1 million years ago, there were artiodactyls, the one-toed horses of
Equus species including the domestic horse, Equus caballus, all over Africa, Asia, Europe,
North America, and South America, in enormous migrating herds that must easily have
equaled the great North American bison herds, or the huge wildebeest migrations in Africa.
In the late Pleistocene there was a set of devastating extinctions that killed off most of the
large mammals in North and South America. All the horses of North and South America
died out, along with the mammoths and saber-tooth tigers. These extinctions seem to have
been caused by a combination of climatic changes and overhunting by humans, who had
just reached the New World. To date, only two truly "wild" groups survived Przewalski's
horse and the Tarpan. The Tarpan became extinct in the 19th century and Przewalski's,
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discovered in 1879 in Mongolia, is endangered and until recently was considered extinct in
the wild (Galosi et al., 2001).
Humans of Paleolithic period left visual record of their fascination with horses and
other large herbivorous mammals, whose images were predominant over other animals.
One of the most common subjects of Ice Age art is the horse; the wild animal that was
sometimes used for food and whose speed and grace was admired by early humans. The
earliest known cave wall art is in Chauvet Cave at Vallon-Pont d’Arc near Avignon,
France. It is dated to be about 32,000 years old and depicted large elaborate scenes of
horses (Bednarik, 1998; Clottes, 2002). Horses were immortalized in sculptures, as in
35,000 year old small ivory horse carving found at Hohle Fels Cave in southwestern
Germany. The earliest domestication of horses is most likely to have occurred in the 8000
BC to 5000 BC window. The earliest evidence of domestication is in Ukraine at
approximately 4,000 BC as seen by the fenced enclosures and the specific wear of the
equine teeth consistent with a bid use. The earliest uncontroversial evidence of horses used
as trained animals are the chariot burials of the Sintashta-Petrovka culture of Southern Ural
Mountains in northern Kazakhstan, dating to around 2000 BC. The horse first appears in
written history in 1700 BC, while the Trojan War of 1218 BC and Hippocrates 460-377
BC were yet to come. In about 1000 BC riding was initiated in the civilized lands of the
Near East, and ever since, the horses have carried our civilization on their backs.

Earliest Identification of the Diseases Attributed to the Pathogen
Horses were the foundation of veterinary medicine. In the 19th century practice, the
horse continued to be the main focus of veterinary work in peace and war. As the cities
grew, increase in the number of horses made the manure disposal too difficult, and thus,
6

the horse has lost to bicycles in major cities and to the railroads for distance travel. Then,
with invention of internal combustion engine, the generated “horsepower” no longer
required veterinary services. Horses still held their own on the farm, for local transport,
and for sport for those who could afford them.
Herpes viruses of humans and horses co-evolved with their hosts. While modern
EHV-1 causes respiratory disease, epidemic abortion as well as perinatal mortality, and
occasionally neurological disease in horses, it should be considered that the historic
accounts of human and equine clinical conditions now attributed to the herpesviruses,
could actually have had other etiology: viral, bacterial, fungal, or even now an extinct
pathogen.
In North America, the record of animal diseases was seldom mentioned in the
literature of the colonial period (Berjeau, 1864; Leonard, 1979; Robertson, 1890;
Rockwell, 1868). Noah Webster in his “Brief History of Pestilential Diseases”, published
at Hartford in 1799, and George Fleming, prominent British veterinarian, in his “Animal
Plagues”, published at London in 1871, left the best and most complete descriptions of
animal plaques that occurred in America prior to 1800 (Flemming, 1871). Horses
commonly had conditions called colds, with clogged sinuses, copious defluxions that could
have been easily attributed to respiratory disease caused by EHV-1 and secondary bacterial
infections. These were treated by steaming the upper respiratory tract by means of a nose
bag with boiling water as an early advent of modern nebulization. The respiratory tract was
often subject to inflammation in the form of bronchitis, congestion of the lungs, or
pneumonia. In “The Illustrated Horse Doctor”, Edward Mayhew attributed many such
cases to neglect, for example, letting an animal stand for hours in cold, wet weather after
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subjecting the animal to hard labor (Mayhew, 1861). Herpes virus reactivation from
latency upon stress and immune suppression could have easily been to blame. Aside of
continuous steaming, a poultice was held with bandage around the throat. A waterproof
jacket applied to the thorax, and a flannel kept moist in cold water was wrapped around the
chest. Diethyl ether, a general anesthetic and analgesic and laudanum, an opium tincture,
medications were also used. In pneumonia, the standard treatment was steam and dosing
with solution of diethyl ether, aconite (a local topical analgesic in neuralgia, sedative in
acute laryngitis, antipyretic, negative chronotrope) and belladonna (atropine, also an
antidote of aconitum), the latter two being toxic hallucinogenic compounds at higher
doses. Brain disorders, such as EHV-1 myeloencephalopathy, must have been truly
frightening to horse owners, with phrenitis (old term for encephalitis) often leading to
violent behavior and was said to be the result of an injury caused by the carter flailing the
head with the butt of his whip. An infectious abortion of mares was a veritable scourge to
horse breeders. In 1889-90, the virulence reached its climax in North America. In Illinois,
nearly 2,500 foals were lost to EHV-1 with about 5,000 surviving. In some towns the
losses reached 75% (Williams, 1889).

EHV-1 Discoveries
The discovery of etiological agents responsible for disease goes alongside the
development of technology (Table I-1). In the 1890s, advances in microbiology, pathology,
and immunology have impacted the veterinary medicine. The first virus was discovered in
1882, the agent of tobacco mosaic disease by Dmitry Iosifovich Ivanovsky (1864-1920), a
Russian-Ukrainian scientist considered the father of Virology (Ivanovsky, 1882).
However, the viral etiology of the epizootic abortion of mares as differentiated from
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bacterial abortion was not determined until 1936 by William Wallace Dimock and Phil
Edwards at the Kentucky Agriculture Experimental Station, Lexington (Dimock and
Edwards, 1933; Dimock and Edwards, 1936). They described the gross pathological
changes of aborted fetuses, including intranuclear inclusion bodies in the fetal lungs and
livers, and gave clinical observations of viral abortions (Dimock et al., 1942). Later, the
equine abortion virus was cultivated in laboratory animals and tissue culture (Anderson
and Goodpasture, 1942; Doll et al., 1953; Randall et al., 1953), and a more extensive
pathological findings were made by Drs. Westerfield and Dimock (Westerfield and
Dimock, 1946). Only, in 1963, the virus was shown by electron microscopy to be a
member of the herpes group (Plummer and Waterson, 1963).

History of Antiherpetics
The first successful demonstration of antiviral therapy for a herpesvirus infection is
attributed to the reduction in mortality in HSV encephalitis achieved with vidarabine
therapy (Whitley et al., 1977). This therapy introduced an entirely new era of antivirals, but
was associated with toxicity and difficulties in drug administration. For mucocutaneous
and visceral HSV infections, the real advance was the discovery of acyclovir and the
demonstration of its mechanism of action, attributed to Dr. Gertrude Elion, a Nobel Prize
winner in medicine for the discovery of modern antivirals (de Miranda et al., 1982; Elion,
1982, 1983). Her approach was revolutionary, she used her understanding of the structure
of nucleic acids to synthesize molecules to specific targets, rather than simply screening
randomly chosen molecules, method still often relied on today. In fact, it was researchers
trained by Elion who first saw the anti-HIV potential of 3'-azido-3'-deoxythymidine
(AZT), at the time an unused anti-cancer drug from the 1960s (Sepkowitz, 2001).
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Acyclovir was the first selective inhibitor of herpes replication. Having one of the
most remarkable safety profiles of any therapeutic agent, acyclovir became the treatment
of choice for all HSV and VZV infections. Twenty years after the success of acyclovir, it is
now a generic medication and remains the foundation of antiherpetic therapeutics. Other
medications have been licensed, the most widely known are valaciclovir and famciclovir
(Crumpacker, 1996; De Clercq, 1993; Stein, 1997).

History of Porphyrins
The answer to the ancient questions of why the grass is green and the blood is red
was given by Hans Fischer, for which he earned the Nobel Prize for Chemistry in 1930,
“for his researches into the constitution of haemin and chlorophyll and especially for his
synthesis of haemin” (Fischer, 1999). Both haemin (the oxidized ferric form of heme, also
called hematin) and chlorophyll are members of a family of vivid compounds, the
modified tetrapyrroles or porphyrins, which were dubbed the “pigments of life”(Battersby,
2000; Battersby et al., 1980) and which Nature uses in numerous roles in the biosphere
among the broad array of its varied life forms. The origin of word porphyrin comes from
Greek word for purple, porphuros. Hemin crystals were discovered in 1853 (Olbrycht,
1953).
Porphyrias are a group of inherited and acquired metabolic disorders of heme
biosynthetic pathway enzymes, leading to overproduction and accumulation of porphyrin
derivatives that manifest in skin, neurologic, cardiovascular, and digestive disturbances
accompanied by extremely severe pain. The severe forms of condition has been suggested
as an explanation for vampire and werewolf legends, due to photosensitization, sensitivity
to sulfur containing garlic, increased hairgrowth, and other symptoms.
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Table I-1. Historical landmarks of understanding the nature of Herpesviridae and
EHV-1 infection
Date

484 425 BC
25 BC50 AD
129200 AD
1847
1882
1883
1893
1910
1930s

1936
19381939
1940
1941
1942
1950
1953
1954
1956
1953
and
1963
1961
1963
1969
1974
1992
1959
1961
2002
2002
2003

Event

First accounts of a herpesvirus when Herodotus drew an association between
cutaneous eruptions and fever caused by HSV-1
Celsius described an actual herpetic lesion caused by VZV
Galen recognized that recurrent HSV lesions develop at the same anatomical
location, regional distribution now understood to be due to the infection of the
nerve innervating the specific area
First infectious disease control technique in human hospital, a hand scrub
between patients
Discovery of the first virus, tobacco mosaic virus, by Ivanovsky
The most enlightening description of HSV recurrences was published by Unna
Although previously well characterized, the HSV transmissibility was first
recognized
Isolation of human and veterinary patients with contagious diseases became
standard as well as the use of sterile instruments, gowns, masks, and gloves for
surgical procedures in large university human hospitals
The milestone of HSV biology, an observation was made by Andrews and
Carmichael that recurrent infections occurred only in adults who carried
neutralizing antibodies, an occurrence in sharp contrast to the behavior of other
known infectious agents of that time.
Viral etiology of the epizootic abortion of mares was differentiated from
bacterial abortion
Doerr and Burnet and Williams understood the true nature of HSV latency and
reactivation
Description of gross pathological changes of aborted fetuses, including
intranuclear inclusion bodies in the fetal lungs and livers, and clinical
observations of viral abortions
First report of HSV-1 infection in the brain
Equine abortion virus was cultured in laboratory animals and tissue culture
Complement-fixation test for equine virus abortion
Adaptation of equine abortion virus in Syrian hamsters
Early steps to recognition of equine rhinopneumonitis and abortion as clinical
conditions caused by a single agent.
Agglutination of horse erythrocytes by tissue extracts from hamsters infected
with equine abortion virus
EHV-1 was isolated as two presumably serologically distinct herpesviruses
EHV-1, as equine abortion in 1953 and rhinopneumonitis virus, EHV-2,
isolated from the respiratory tract of a colt with a runny nose and a cough in
1963
Electron microscopic study of equine abortion virus 13 years post HSV-1
visualization in 1948
Virus was shown by electron microscopy to be a member of the herpes group
EHV-1 and EHV-4 recognized as separate strains
Isolation of latent herpes viruses in horses
EHV-1 genome cloned
Live-attenuated vaccine developed
Preventative vaccination against EHV abortion introduced
Myeloencephalopathy outbreaks
Acyclovir used as a treatment for EHV-1 infections
Preliminary results indicated EHV-1 myeloencephalopathy is due to atypical
stain of EHV-1
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Reference

(Roizman and Whitley,
2001)
(Roizman and Whitley,
2001)
(Roizman and Whitley,
2001)
(Best and Neuhauser,
2004)
(Ivanovsky, 1882)
(Unna, 1883)
(Whitely et al., 1998)

(Andrews and
Carmichael, 1930)
(Dimock and Edwards,
1933)
(Roizman and Knipe,
2001)
(Dimock, 1940)
(Smith et al., 1941)
(Anderson and
Goodpasture, 1942)
(Doll and Hull, 1950)
(Doll et al., 1953)
(Doll et al., 1954)
(McCollum et al., 1956)
(Doll et al., 1953;
Plummer and Waterson,
1963)
(Tajima et al., 1961)
(Plummer and Waterson,
1963)
(Plummer et al., 1969)
(Iurov and Sologub, 1974)
(Telford et al., 1992)
(Doll et al., 1959)
(Doll, 1961)
(Stierstorfer et al., 2002)
(Wilkins, 2003)
(Goehring et al., 2006)
(Allen, 2006)

Taxonomy of EHV-1
Method of Classification and Properties of Subfamilies
As discussed earlier, although the diseases caused by herpesviruses have been
known for centuries, the discovery of etiological agents responsible goes alongside the
development of technology. HSV-1 has been isolated in 1940, but the big development
occurred between 1950 and 1956 with the application of tissue culture to isolate the other
members of the Herpesviridae family. Identifying these new and apparently related viruses
was what led to a scientific desire for them to be classified. Current classification of
Herpesviridae family came into being in 1981.
Equine herpes virus 1 (EHV-1) is a member of family Herpesviridae, subfamily
Alphaherpesvirinae, genus Varicellovirus as classified by the Herpesvirus Study Group of
the International Committee on the Taxonomy of Viruses (ICTV) (Fauquet and Mayo,
2001). Herpesviruses are highly disseminated in nature and most animal species have at
least one herpesvirus (Table I-2). Of nearly 160 herpesviruses that have been characterized,
seven herpesviruses have been isolated so far from horses and are divided into two
subfamilies: the alphaherpesvirinae (equine abortion virus (EHV-1), equine arterivirus
(EHV-3), equine rhinopneumonitis virus (EHV-4), EHV-8, and EHV-9) and the
gammaherpesvirinae (EHV-2, EHV-5). In each subfamily the viruses belong to the same
genus, varicellovirus (EHV-1,-3,-4,-8, and -9) and radinovirus (EHV-2 and -5)
respectively.
Herpesviridae classification scheme is used to depict evolutionary relatedness and
to predict biological properties of newly identified members in relation to well known
ones. As such, human herpesvirus 1 is considered a model for properties of the viruses that
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belong to the Alphaherpesvirinae subfamily including EHV-1, although it belongs to a
different genus than the EHV-1. On the other hand, Pseudorabies Virus (PRV) of swine
and Varicella Zoster Virus (HSV-3, VZV; human chicken pox virus) are the other two well
studied viruses that are members of the Varicellovirus genus and are often used for
extrapolation of some of EHV-1 properties yet unknown.
Memberships in the Herpesviridae family are assigned based on the architecture of
the virion and include large, dsDNA genome, enveloped viruses. The family is subdivided
into three subfamilies – the Alphaherpesvirinae, the Betaherpesvirinae, the
Gammaherpesvirinae, and Ictalurivirus – on the basis of biological properties (Roizman et
al., 1981). The subfamilies are further subdivided into genera based on DNA sequence
homology, similarities in genome sequence arrangement, and relatedness of important viral
proteins.
Members of Alphaherpesvirinae subfamily are associated with variable host range,
relatively short reproductive cycle, rapid spread in culture with efficient destruction of
infected cells (cytolytic), and capacity to establish latent infections primarily, but not
exclusively in the sensory ganglia, and therefore, significant primary and recurrent
infection. The subfamily contains the genera Iltovirus, Mardivirus, Simplexvirus, and
Varicellovirus.
By comparison, members of Betaherpesvirinae are characterized by restricted host
range, long reproductive cycle, and slow infectious cycle with cytomegalia in cell culture.
The virus can be maintained in latent form in secretory glands, lymphoreticular cells,
kidneys, and other tissues. The subfamily consists of the genera Cytomegalovirus,
Muromegalovirus, and Roseolovirus (van Regenmortel et al., 2000).
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Table I-2. Select members of the Herpesviridae family. Well studied or clinically
significant viruses are represented.
Subfamily

Genus

Iltovirus
Mardivirus

Gammaherpesvirinae
(lymphoproliferative

Betaherpesvirina
e

Alphaherpesvirinae

Simplexvirus

Species

Vernacular Name/Disease Condition

Gallid herpesvirus 1
Gallid herpesvirus 2
Gallid herpesvirus 3
Meleagrid herpesvirus 1
Ateline herpesvirus 1
Bovine herpesvirus 2
Cercopithecine
herpesvirus 1
Human herpesvirus 1
Human herpesvirus 2

Varicellovirus

Bovine herpesvirus 1

Mardivirus
Iltovirus
Cytomegalovirus

Bovine herpesvirus 5
Suid herpesvirus 1
Equid herpesvirus 1
Equid herpesvirus 3
Equid herpesvirus 4
Equid herpesvirus 8
Equid herpesvirus 9
Canid herpesvirus 1
Caprine herpesvirus 1
Felid herpesvirus 1
Duck herpesvirus 1
Human herpesvirus 3
Phocid herpesvirus 1
Gallid herpesvirus 2
Gallid herpesvirus 1
Human herpesvirus 5

Roseolovirus

Human herpesvirus 6

Rhadinovirus

Ictalurivirus

bovine mammillitis and pseudo-lumpy skin disease
also known as Herpes B virus, causes a Herpes
simplex-like disease in Macaques
(Herpes simplex virus type 1) oral and/or genital
herpes (predominantly orofacial)
(Herpes simplex virus type 2) oral and/or genital
herpes (predominantly genital)
infectious bovine rhinotracheitis, vaginitis,
balanoposthitis, and abortion in cattle
encephalitis in cattle
(pseudorabies virus) PRV
Equine rhinotracheitis virus, abortion in horses
coital exanthema in horses
rhinopneumonitis in horses

severe hemorrhagic disease in puppies
conjunctivitis and respiratory disease in goats
viral rhinotracheitis and keratitis in cats
duck plague
Varicella-zoster virus, chickenpox and shingles

Human herpesvirus 7
Lymphocryptovirus

Marek's disease virus type 1
Marek's disease virus type 2
Turkey herpesvirus

Suid herpesvirus 2
Human herpesvirus 4
Alcelaphine herpesvirus 1
Bovine herpesvirus 4
Equid herpesvirus 2
Equid herpesvirus 5
Human herpesvirus 8
Ictalurid herpesvirus 1
Acipenserid herpesviruses
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Marek's disease
infectious laryngotracheitis in birds
(Human cytomegalovirus) CMV: causes
infectious mononucleosis, retinitis, etc.
Human B-cell lymphotrophic virus or roseolovirus:
causes "sixth disease" (known as roseola infantum
or exanthem subitum)
closely related to HHV-6; causes roughly the same
symptoms
inclusion body rhinitis in swine
(Epstein-Barr virus) lymphocryptovirus: causes
infectious mononucleosis, Burkitt's lymphoma and
nasopharyngeal carcinoma
wildebeest herpesvirus
bovine malignant catarrhal fever
equine cytomegalovirus infection
Kaposi's sarcoma-associated herpesvirus – KSHV,
primary effusion lymphoma and some types of
multicentric Castleman's disease
Channel catfish virus
1, 2, & 3

Gammaherpesviruses infect T or B lymphocytes, produce no infectious progeny,
and are implicated in neoplastic transformation of lymphocytes. The host range of
members of Gammaherpesvirinae subfamily is limited to the taxonomic family or order of
their natural host. Latent virus is frequently demonstrated in lymphoid tissues. Subfamily
includes Lymphocryptovirus and Rhadinovirus genera (van Regenmortel et al., 2000).
At first, EHV-1 was isolated as two presumably serologically distinct herpesviruses
EHV-1, an equine abortion or rhinopneumonitis virus (e. g. (Doll et al., 1953)) and EHV-2,
isolated from the respiratory tract of a colt with a runny nose and a cough (Plummer and
Waterson, 1963). The type 1 thought 4 virus designations were proposed by Plummer in
1969 (Plummer et al., 1969). First report of HSV-1 infection in the brain dates to 1940s
(Smith et al., 1941).

Evolutionary Relatedness and Coevolution with the Host
The herpesviruses are believed to be of ancient origin, at least 300 million years old
(Davidson, 1993). They have coevolved with their hosts, mainly mammals, birds, and fish,
with possible multiphyletic origins and lateral transfers. Evolution occurred via three
mechanisms - cumulative point mutations, gene duplication, and gene capture (McGeoch
et al., 2006). Another ancestral relationship of herpesviruses links them to bacteriophages
via similarities of their capsid proteins and assembly mechanisms (Steven et al., 2005;
Steven and Spear, 1997). Phylogenetic reconstruction of herpesvirus evolution is generally
based on nucleotide or amino acid sequence comparisons of specific proteins and varies
depending on the particular protein chosen for analysis (Figure I-1). The analysis of DNA
polymerase, major capsid protein, DNA-packaging tegument protein and glycoprotein B
sequences revealed that the genome closest to a consensus herpesvirus genome is that of
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human herpesvirus 6, suggesting that this genome is closest to a progenitor herpesvirus
(Karlin et al., 1994). Chicken and other avian species were found to be more natural or
more ancient hosts of herpesviruses.
Originally, by DNA-DNA hybridization studies, the EHV-1 and EHV-3 types
exhibit only 2 to 5% homology. As much or more genetic relatedness was reported
between herpesviruses of other animal species, 8-10% base sequence homology between
HSV-1 and PRV (Ludwig et al., 1972) and 14% between HSV-1 and BHV-1 (Sterz et al.,
1973). The DNA homology among alphaherpesviruses supports the hypothesis that the
alpha class is of relatively recent ancestry (Alba et al., 2001; Karlin et al., 1994). The equid
herpesvirus 1 has the most random herpesvirus genome and stands out as the consensus
alphaherpesvirus, suggesting it may approximate an ancestral alphaherpesvirus. The most
similarity among alphaherpesviruses is between EHV-1 and PRV-1. There is also great
similarity between VZV, HSV-1 and EHV-1 (Karlin et al., 1994; Telford et al., 1992).
Other studies suggest that closely related EHV-1 and EHV-4 are evolutionary nearest to
BHV-1, then VZV, then, HSV-1 and HSV-2, and at last GHV-2 (Alba et al., 2001).
Complete genomes are often a mosaic, where genes were acquired from different
sources and have undergone lateral transfer, transposition, and recombination events in the
course of evolution. When genomic comparison was followed by protein sequence
alignments, again the sequence closest to the consensus sequence of Herpesviridae was
HHV-6, with EHV-1 identified as being second to dominate the hierarchy. Similarities
among EHV-1 and HHV-6 include the fact that both viruses are lymphotropic and can
infect T-cell,s but are also associated with infection of monocytes, epithelial cells and the
central nervous system.
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Alpha Herpesviruses

PRV
EHV-4 EHV-1
EHV-2 EHV-5 EBV HHV-6 HCMV HSV-1 VZV
BHV-1
< 5 million
years ago

83.4 million
years ago
92 million
years ago

Ancestral EHV-1
-like Herpesvirus
180-220 million
years ago

Ancestral HHV-6
-like Herpesvirus

300 million
years ago

Figure I-1. Evolutionary relatedness of herpesviruses.
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It could be speculated that herpesvirus ancestors inhabited the avian species first,
and later, underwent transfer from birds to mammals, and then, potentially from humans to
horses and back to humans. The estimates of the time of virus transfer between host species
indicate a considerable antiquity, close to the end of the Cretaceous period. The three
subfamilies are estimated to have arisen 180 to 220 million years ago (McGeoch et al.,
1995), before major mammal evolution and therefore became a diverse group of viruses.
Within the subfamilies, the phylogenetic tree patterns reflect patterns in the tree lineages of
mammalian hosts, suggesting coevolution (cospeciation) of the host and virus lineages, and
thus enabling to estimate the division between EHV-1 and EHV-4 to be less than 5 million
years ago, separation from PRV and BHV-1 at 83.4 million years ago when artiodactyls
(“even-toed”) and perissodactyls (“odd-hoofed” mammals) have evolved, and from VZV
and HSV-1 more than 92 million years ago when primates and ungulates (hoofed animals)
advanced (Karlin et al., 1994; McGeoch and Cook, 1994; McGeoch et al., 1995; McGeoch
et al., 2000). Molecular resource partitioning principle is that coexisting life forms strive to
establish independent niche with respect to resources, to avoid competition for host
resources. Therefore, avoidance of competition between ancestral viruses, led to spatial
and/or temporal isolation aka distinct host specificity, cellular tropism, sites of
reactivation, and latency.

Clinical Isolates and Laboratory Strains
EHV-1 field isolates were obtained by culture of diagnostic material (nasal swab or
blood or tissue samples) on Rabbit kidney (RK-13), equine dermal (NBL-6) cell lines, or
primary equine (equine embryonic lung or equine fetal kidney) cell types (Table I-3).
Strains can be adapted to grow on bovine and hamster cells with mutation in gC (Sugahara
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et al., 1997). The majority of EHV-1 field isolates are archive material held at the Animal
Health Trust (United Kingdom isolates) and the Gluck Equine Research Center (U.S. and
Canadian isolates). Additional isolates, or purified DNA from isolates, originating from
outbreaks in other countries are maintained by G. Fortier (Laboratoire Frank Duncombe,
France), M. Studdert (University of Melbourne, Australia), S. Raidal (Murdoch University,
Australia), C. van Maanen (Animal Health Service, The Netherlands), C. Galosi (Cátedra
de Virología, UNLP, Argentina), and K. van der Meulen (University of Ghent, Belgium).
Neuropathogenic strain AB4 and nonneuropathogenic strain V592 and other strains
were compared on a DNA level to identify a variation in a single amino acid that is
strongly associated with neurologic versus nonneurologic disease outbreaks. The amino
acid is located within a highly conserved region of the genome that encodes a key viral
enzyme, the DNA polymerase gene, which is conserved in all herpesviruses (Nugent et al.,
2006). Mutation did not alter the kinetics of viral replication, and therefore, had minimal
effect on viral shedding that is important for horizontal spread in a population (Goodman
et al., 2007).
Table I-3. Known EHV-1 parental strains.
Virus
Kentucky A
Kentucky D
Ab4
V592
Ab1
HSV25A
Kentucky T431
Karpas
438/77
HH-1
2104

Isolation, year & place
1953, Kentucky
1952, Kentucky
1980, England
England
England
Australia
1980, Kentucky
1966, France
1981, Australia
1967, Hokkaido
1986, Hokkaido

Passage, cells & #
Hamster 400, LM
Hamster 94
ED 12

ED 4
EK
FHK3

∗

Reference
PubMed 13944111
PubMed 1318606
PubMed: 10805982
PMID: 9870583
PubMed 5909615
PubMed 6270790
∗

EQ-Primary equine kidney cells, ED – equine dermal cells, FHK – fetal horse kidney cells, BK – primary
bovine kidney cells, MDBK – Madin-Darby bovine kidney cells, LM – mouse L cells
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Architecture of Herpes Virion
EHV-1 has been studied in the laboratory for more than 50 years (Girard et al.,
1963; Reczko et al., 1965; Reczko and Mayr, 1963) and its properties have been well
characterized either directly or by extrapolation of the findings with HSV-1, VZV, or of its
closest relatives, PRV and BHV-1. Alphaherpesvirinae family is usually represented by
Herpes simplex virus type 1 (HSV-1). However, HSV-1 is a Simplexvirus genus member.
Varicellovirus genus of the Alphaherpesvirinae is typifed by Varicella Zoster Virus
(VZV). In subsequent review of the architecture and life cycle of EHV-1, the findings that
are true for all alphaherpesviruses and those specific to the varicellovirus genus or EHV-1
will be described and noted accordingly. However, the review is broadened to include the
most detailed knowledge of herpesvirus virology, even if certain aspects have not been
confirmed specifically for EHV-1. Therefore, a collective knowledge of herpes virology
researchers is reviewed below as related to Equine Herpes Virus 1.
EHV-1 virion consists of four structural units: DNA core, capsid, tegument, and the
envelope (Figure I-2). All herpesviruses have the same basic structure, a rigid icosahedral
capsid surrounded by a membrane envelope. The capsid is encircled by the tegument
proteins and contains the virus DNA in a highly condensed form in which it is protected
from mechanical and other damage.

The Envelope
Equine herpesvirus 1 virions are about 120-200 nm in diameter, slightly
pleomorphic, spherical and are enveloped in a cell-derived bilipid membrane. Outer
covering of the virion has a typical trilaminar appearance (Epstein, 1962), and appears as if
an arrangement of patches of altered cellular membranes (Armstrong et al., 1961; Falke et
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al., 1959; Morgan et al., 1968). Projected from the surface of the envelope are roughly 800
distinct spikes of viral glycoproteins (Table I-4) dispersed over the entire surface varied in
length, spacing, and in the angles at which they emerge from the membrane (Abodeely et
al., 1970; Abodeely et al., 1971; Grunewald et al., 2003; Klingeborn and Pertoft, 1972), in
clusters, and/or in transmembrane contact with tegument proteins (Grunewald et al., 2003).
Their distribution was nonrandom, suggesting functional clustering. Gycoprotein B, for
example, contributes about 5% of the envelope spikes. At least 11 membrane proteins are
present on the surface of the virion envelope (Roizman and Knipe, 2001). The copy
number of individual proteins can exceed 1,000 per virion (Spear, 2004; Steven and Spear,
1997). These proteins are the target for neutralizing antibodies and therefore, the potential
targets for viral vaccines.
Herpesvirus envelope proteins play essential roles in the initial stages of virus
infection, i.e., virion attachment and penetration (Spear and Longnecker, 2003) to select
cell types. Additionally, they are also important in mediating proper assembly and egress
of virus particles in the late phase of the replicative cycle (Mettenleiter, 2004), and their
function will be discussed in further detail in the review of EHV-1 life cycle.
Lipid rafts, specific microdomains on the surface of cellular membranes were found
to play a critical role in virus replication because of localizing and concentrating viral
components in such microdomains for entry, assembly, and budding of the virus. Rapid
redistribution of cell-surface anchored viral protein such as gB within membrane lipid rafts
would bring protein species in the proximity of each other to form multimers and to
interact with cellular receptors during early stages of virus infection, serving as a platform
for cell signaling and entry (Bender et al., 2003).
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Envelope proteins (gB-gN)

Lipid envelope

Tegument

DNA

Nucleocapsid
Figure I-2. EHV-1 virion. Herpesvirus virion consists of a core containing a linear,
double stranded DNA, an icosadeltahedral capsid, approximately 100-110 nm in diameter,
comprised of 162 capsomeres with a fissure running down the long axis as well as an
amorphous, sometime asymmetric material that surrounds the capsid, designated as the
tegument, and an envelope containing viral glycoprotein spikes on its surface. The arrow
shows a transmembrane contact between a glycoprotein and the tegument.
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Table I-4. Herpesviridae glycoproteins.
Characteristics
Envelope glycoprotein (gK)
Envelope protein (gN)
Tegument/type 2 membrane protein, required for gB
fusion
Envelope glycoprotein (gC) ; role in cell entry
Probable integral membrane protein, along with US3
role in disrupting the nuclear lamina during egress
Membrane-associated phosphoprotein
Envelope glycoprotein (gB); role in cell entry
Envelope glycoprotein (gH) complexes with gL; role
in cell entry
Integral membrane protein ; role in virion egress,
multiple membrane spanning protein
Envelope glycoprotein (gM) type 3
Envelope glycoprotein (gL)
Envelope glycoprotein (gG)
Envelope glycoprotein (gp300)
Envelope glycoprotein (gD)
Envelope glycoprotein (gI) type 1
Envelope glycoprotein (gE) type 1
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EHV-1
ORF

HSV-1

PRV

VZV ORF

6
10
15

UL53
UL49.5
UL45

gp04
gp08
-

5/gp06
9A/gp10.5
±

16/gp13
17

UL44
UL43

gp30/gIII
gp29

14/gp16/gpV
15/gp17

26
33/gp14
39

UL34
UL27
UL22

gp20
gp14/gII
gp36

24
31/gp33/gII
37/gp39

41

UL20

gp38

39/gp41

52
62
70
71
72
73
74

UL10
UL1
US4
US5
US6
US7
US8

gp48
gp56
gp67
gp68
gp69
gp70

50/gp51
60/gp61
67/gpIV/gp68
68/gpI/gp69

The Tegument
The tegument is a term originally introduced by Roizman and Furlong, to describe
the amorphous protein structures contained between the capsid and the envelope that
serves as a delivery compartment for proteins that are required early in the course of
infection. These structures had no distinctive features in electron-microscopic sections but
appeared to be fibrous on negative staining (Morgan et al., 1959). Subsequently,
immunoelectron microscopy indicated that the tegument is an ordered structure with
structural polarity, but is devoid of a unique geometrical organization (Stefan et al., 1997).
Tegument surrounds the nucleocapsid and consists of proteinaceous globular material
which may be variable in amount, thus leading to variation in virion size. The tegument
occupied about two-thirds of the volume enclosed within the membrane, and the capsid
occupied about one-third (Grunewald et al., 2003). Innermost portion of the tegument
located adjacent to the capsid exhibits icosahedral symmetry, resulting from the interaction
of a large tegument protein, UL36, with the pentons (VP5) of the capsid (Machtiger et al.,
1980; McNabb and Courtney, 1992a; Newcomb et al., 1996; Zhou et al., 1999). The
outermost part interacts with virus envelope membrane, sometimes in transmembrane
contact with envelope glycoproteins.
The tegument of HSV-1 and EHV-1 contains about 20 proteins, including VP1/2
(UL36), VP11/12 (UL46), VP13/14 (UL47), VP16 (UL48, -trans-inducing factor, alphaTIF), VP22(UL49), ICP0, ICP4, and the virion host shutoff protein (UL41) as well as the
products of the genes US2, US3, US10, US11, UL11, UL13, UL14, UL16, UL17, UL21,
UL37, UL51, and UL56 shown in Table I-5 (Copeland et al., 2008; Mettenleiter, 2002b;
Mettenleiter, 2004; Schimmer and Neubauer, 2003).
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PRV tegument proteins UL36 and UL37 have been shown to physically interact
and UL36 possibly interacts with the major capsid protein (Klupp et al., 2002). UL36 is
present in the deepest layers of the tegument and attaches to the major capsid protein
(VP5) on capsid vertixes (McNabb and Courtney, 1992b; Zhou et al., 1999). UL48 located
within both the inner and outer tegument layers (Schmitz et al., 1995), has been shown to
interact with cytoplasmic tail of gH (Gross et al., 2003). In PRV, there is evidence of UL49
interaction with gE/I and M (Fuchs et al., 2002). New tegument protein interactions which
could be potential targets for future antivirals are UL11-UL16, UL36-UL48, UL46-UL48,
UL47-UL48, and UL48-UL49 (Vittone et al., 2005).
Table I-5. Tegument proteins of Herpesviridae.
Characteristics

EHV-1 ORF

Latency associated transcript, EICP0

Tegument protein
Tegument phosphoprotein; transactivator of
immediate-early genes
Tegument protein
Tegument protein
Tegument/envelope protein
Tegument protein ; virion host shutoff protein
Tegument protein
Large tegument protein
Tegument protein
ORF 45
Tegument protein
ORF 48
Tegument protein, probable serine-threonine protein
kinase
Myristylated tegument protein, role in virion
envelopment
ORF 68
Serine-threonine protein kinase
Tegument protein, type 2 membrane protein
Virion protein
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63
64
3?
8
11
12

HSV-1

VZV

13
14
15
19
23
24
40
45
46
48
49

ICP0
ICP4
UL56
UL51
VP22(UL49)
alphaTIF (Vmw65)
VP16 (UL48)
VP13/14 (UL47)
VP11/12 (UL46)
UL45
VHS(UL41)
UL37
VP1/2 (UL36)
UL21
UL17
UL16
UL14
UL13

51

UL11

49

68
69
76
66

US2
US3
US9?
US10
US11

66
65
64

2?
7
9
10
11
12
±
17
21
22
38
43
44
46
47

The Nucleocapsid
The morphologically distinctive herpesvirus capsid has been well studied in order
to understand the dynamics of virus assembly (Baker et al., 1990; Newcomb et al., 2003).
A thick-walled, spherical, ~ 120 nm in diameter nucleocapsid is isometric and composed
of 162 capsomers arranged in 5:3:2 axis of symmetry, triangulation class T = 16
icosahedral symmetry as shown in Figure I-3 (Caspar and Klug, 1962; Wildy et al., 1960).
Twelve capsomers at the vertices are "pentons". The remainder 150 capsomers are
“hexons”, 9.5x12.5 nm in longitudinal section with a channel of 4 nm in diameter running
from the surface along their long axis (Watson et al., 1963). Hexons are located at the
edges and faces of the capsid and fall into three classes (P – peripentonal, E- edge, and Ccenter), depending on their positions on the surface lattice (Steven et al., 1986). EHV-1
hexons are composed of six molecules of major capsid protein (hexamers of VP9 (148
kDa)) and six of VP26 (UL35, 12kDa), which occupy the top of each hexon (Newcomb et
al., 1989) (Table I-6).
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P
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C
S

5

P
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Figure I-3. Types of capsomers present on the T-16 capsid surface lattice. P –
peripentonal hexon, E- edge hexon, C-center hexon, 5 penton.
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Eleven of the 12 pentons are pentamers of VP9, while the 12th is a unique vertex, a
portal, cylindrical structure composed of twelve UL6, and contains an axial channel
through which DNA is introduced into the capsid. By further extrapolation from HSV-1,
portal protein UL6 interacts with the DNA cleavage and packaging proteins (putative
terminase subunits) UL15 and UL28. Capsomers are connected in groups of three by 320
triplexes, heterotrimers formed from two copies of VP23 (34kDa) protein and a single
copy of VP19c (50kDa) that lie above capsid floor (Okoye et al., 2006; Trus et al., 1996).
Scaffolding protein UL26.5 participates in capsid formation but thereafter is lost and is not
found in the mature capsid or virion. EHV-1 capsids also contain several other proteins,
including, VP19 (59 kDa, -360 copies), VP23 (36 kDa, -660 copies), and VP26 (12 kDa, 1,300 copies) (Newcomb et al., 1989; Perdue et al., 1975). The number of polypeptide
species contained in the virions generally varies from 35 to 45. Virus capsid assembly is
under the control of tightly regulated program that includes the involvement of viral
scaffolding proteins and cellular chaperonins, maturational proteolysis, and conformational
changes on an epic scale.
Table I-6. Protein components of capsid shell.
Components of capsid shell required
for capsid assembly

Major capsid protein
Assemblin (protease), capsid assembly protein
/capsid scaffold protein (Peptidase family
S21)
Form triplexes to connect capsomers
Portal protein
DNA packaging protein
Terminase subunits, DNA cleavage and
packaging proteins, form part of the terminase

EHV-1
ORF 42 (VP9)
ORF 35 (protease) and
ORF 35.5 (capsid
assembly protein)

ORF 27

VP19, VP9, VP23, VP26
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HSV-1
VP5 (UL19)
VP21 (UL26) and VP22a
(UL26.5)
VP23 (UL18) and VP19c
(UL38)
UL6
UL33
VP26 (UL35)
UL15 and UL28
VP24 (UL26)

The Core
The core of mature virion consists of a fibrillar spool on which one molecule of
linear double stranded DNA is wrapped in a form of a torus with regularly spaced (~26 Å
for HSV-1) concentric layers (Furlong et al., 1972; Zhou et al., 1999), the arrangement
similar to those in dsDNA bacteriophages such as λ, T4, and P22 (Brown, 2002; Prevelige
and King, 1993). DNA is densely coiled in a “liquid crystalline” arrangement (Booy et al.,
1991) with the ends of the proteinaceous fibers anchored to the underside of the capsid
shell.

The Viral Genome
EHV-1 has a double-stranded linear DNA genome of approximately 150 kbp
(96x106 Da), has a base composition of 56.67% G + C, and contains 80 open reading
frames able to encode proteins for the production of progeny genomes and mRNAs as
shown in Table I-7 (Telford et al., 1992; Whalley et al., 1981). All herpesvirus genomes
have a unique long (UL) and a unique short (US) region, bounded by inverted repeats
(Figure I-4). After infection of susceptible cells, the linear viral genomes of herpesviruses
form circular molecules via ligation of the genomic ends.
Table I-7. Genome characteristics of clinically important alphaherpesviruses
Genome
EHV-1
EHV-4
HSV-1
HSV-2
VZV (HSV-3)
SVV (CeHV-9)
CeHV-1 (B Virus)
PRV-1 (SuHV-1)
BHV-1
BHV-5
MDV (GHV-2)

Genus
Varicello
Varicello
Simplex
Simplex
Varicello
Varicello
Simplex
Varicello
Varicello
Varicello
Mardi

Strain
Ab4
NS805567
17
HG52
Dumas
Delta
E2490
Several
several
SV507/99
1

Length,nt
150,224
145,597
152,261
154,746
124,884
124,784
156,789
143,461
135,301
137,821
177,874
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G+C%
56
50
68
70
46
40
74
73
72
74
44

Protein
80
79
77
77
73
74
75
69
70
70
105

% coding
83
85
79
79
89
88
76
73
84
83
77

29
29

Figure I-4. Map of the EHV-1 genome. (A) General structure of the genome. Note the unique
long (UL) and unique short (US) coding regions and the repeats designated a, b and c. (B)
Alignment of the open reading frames in a physical map that is collinear with the genome.

The EHV-1 genome is is divided into segments of a long unique region, UL (112.9
kbp); an internal repeat, IRS (12.7 kbp); a unique short segment, US (11.9 kbp); and a
terminal repeat, TRS (12.7 kbp). In addition, UL is flanked by a short inverted repeat of 32
bp (TRL/IRL) (Telford et al., 1992; Yalamanchili and O'Callaghan, 1990). An organization
of TRL-UL-IRL-IRS-US-TRS is typical of an alphaherpesvirus. US region is found in either
possible orientation relative to the fixed UL segment. As a consequence, virus DNA
consists of an equimolar mixture of the two isomeric forms (P and I). The same genome
arrangement and isomerization are also reported for BHV-1 (Hammerschmidt et al., 1988),
EHV-3 (Atherton et al., 1982; Sullivan et al., 1984), PRV (Stevely, 1977), and VZV
(Davison, 1984).

EHV-1 Glycoproteins
Through the use of multiple glycoproteins and other virus-specified proteins
alphaherpesviruses have evolved mechanisms to deal with multiple membrane barriers
during entry via fusion of the viral envelope with cellular membranes, intracellular virion
morphogenesis and egress, cell-to-cell spread, and virus-induced cell fusion (Mettenleiter,
2002a; Mettenleiter, 2002b; Roizman and Knipe, 2001; Spear, 2004; Spear and
Longnecker, 2003). The EHV-1 specifies at least 14 glycoproteins: gB/gp14 (Guo, 1990;
Osterrieder et al., 1996; Pilling et al., 1994), gC/gp13 (Allen and Coogle, 1988; Allen and
Yeargan, 1987; Matsumura et al., 1993), gD (Audonnet et al., 1990), gE (Audonnet et al.,
1990), gG (Colle et al., 1992), gH (Robertson et al., 1991), gI (Audonnet et al., 1990),
gK/UL4 (Zhao et al., 1992), gL (Telford et al., 1992), gM (Osterrieder et al., 1996; Pilling
et al., 1994), gN(HSV-1 UL49.5), gp10, gp2, and gp21/22a, most of which share high
homology to those of herpes simplex virus type 1 (HSV-1) as prototypic virus for studying
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the Alphaherpesvirinae subfamily (Audonnet et al., 1990; Birch-Machin et al., 2000;
Crabb et al., 1991; Elton et al., 1991; Flowers et al., 1995b; Kukreja et al., 1998a;
Osterrieder et al., 1995; Stokes et al., 1996; Tewari et al., 1994; Wellington et al., 1996b;
Whalley et al., 1995; Whalley et al., 1989). In addition to those glycoproteins similar to
HSV-1, EHV-1 also possesses at least three unique glycoproteins, designated gp10, gp2,
and gp21/22a (Allen and Coogle, 1988; Allen and Yeargan, 1987). The functions of
several individual EHV-1 envelope proteins, such as glycoprotein B (gB), gC, gD, gE, and
gM, have been analyzed in some detail. EHV-1 also encodes several non-glycosylated
membrane associated proteins: UL20, ORF76/US9, ORF37/UL24, 17/UL43, and
26/UL34.
Viral glycoproteins have three parts: the external ectodomain, which interacts with
the host; a transmembrane segment, typically a single alpha-helix, and the internal part, the
endodomain (Figure I-5). All known glycoproteins that are capable of membrane fusion
are trimers for at least part of the infectious cycle. Viral glycoproteins are also key
determinants of membrane-associated events occurring during virion morphogenesis and
egress from infected cells.

Glycoprotein B
EHV-1 gB (gp14) is highly conserved with the gB (HSV, CMV, EBV) and gpII
glycoproteins (PRV, VZV) of other herpesviruses, suggesting that this glycoprotein has a
similar overall structure, synthesis, maturation, and function in each virus (Bell et al.,
1990; Guo, 1990; Whalley et al., 1989).
The gene encoding gB includes a transcription unit composed of a CAT box, a
TATA box, a ribosome-binding sequence, a polyadenylation signal and an open reading
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UL20
gH/gL
gD

gB

gK

Figure I-5. Herpesviridae glycoproteins and their putative orientations in the cellular
membrane.

32

frame (ORF) 33 of 3.4 kb beta-gamma gene transcribed from left to right (Bell et al., 1990;
Guo, 1990). The primary translation product is 980 amino acids, 118K molecule which is
cotranslationally glycosylated to the large precursor molecule of 138K form by the
addition of high mannose oligosaccharides. The 138K form is then proteolytically cleaved
to two smaller forms, 77-75K and 55-53K, linked by a disulfide bond(s) to form a 145K
complex. The 77-75K species contains both high mannose and hybrid oligosaccharides
while the 55-53K form of gB contains some complex oligosaccharides (Sullivan et al.,
1989). The amino acid sequence of gB has the characteristic features of membrane
glycoprotein including a 20-aa signal sequence at the N-terminus, marking it for
translocation into the lumen of the endoplasmic reticulum (ER) (McGeoch et al., 1987;
Perlman and Halvorson, 1983; Wellington et al., 1996a), a 743-aa surface domain, a 40-aa
membrane anchoring region, a 108-aa hydrophilic cytoplasmic domain at the C-terminus
and eleven potential sites for N-linked glycosylation (Guo, 1990; Sullivan et al., 1989;
Whalley et al., 1989). The cytoplasmic domain of gB is the longest among HSV-1
glycoproteins, implying a crucial role for this domain in gB-mediated functions. HSV-1 gB
contains at least one Pleckstrin homology (PH) domain, a large family of cellular proteins
implicated in lipid binding and signaling functions (DiNitto et al., 2003).
Alphaherpesvirus gB possess similar secondary and tertiary structures (Riggio et
al., 1989). The glycoprotein has three-stranded coiled coils at the trimer axis, reminiscent
of class I, and a long three-stranded beta-sheet with a structure similar to that of a class II
motif but with different strand topology (Steven and Spear, 2006). Members of both
classes accomplish fusion through a large-scale conformational change, triggered by a
signal from a receptor-binding component.
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EHV-1 gB is essential for virus growth and is required for direct cell-to-cell spread
in vitro since gB-negative virus exhibits significant reduction in viral titers and no plaque
formation when grown and titrated on noncomplementing cells (Neubauer et al., 1997b).
gB monoclonal antibodies also inhibit cell-cell fusion via complement-dependent
neutralizing antibody (Wellington et al., 1996c). There is a variety of evidence indicating
that gB plays important roles in membrane fusion phenomena during virus entry and virusinduced cell fusion. Single amino acid substitutions and truncations of the carboxyl
terminus of HSV-1 gB cause extensive virus-induced cell fusion (Baghian et al., 1993;
Bzik et al., 1984b; Cai et al., 1988b; Gage et al., 1993). Transient co-expression of gB with
gD, gH and GL causes cell-to-cell fusion, which is substantially increased by carboxyl
terminal truncations of gB (Foster et al., 2001b; Haan et al., 2001; Klupp et al., 2000;
Pertel, 2002). These results suggest a direct role for gB in membrane fusion and that
perturbations of the carboxyl terminal domains of gB facilitate gB-mediated cell-to-cell
fusion.
Alphaherpesviridae gB is viewed as the primary component of herpesvirus
membrane fusion machinery. HSV-1 mutant viruses lacking gB are not able to enter into
cells (Cai et al., 1987) due to a post-attachment defect that can be resolved by polyethelene
glycol (PEG) mediated fusion of viral and cellular membranes (Cai et al., 1988a).
Interesting is that attachement of the gB-negative EHV-1 virions to target cells is similar to
that of the wild type virus (Neubauer et al., 1997b), but treatment with PEG, a fusogen,
while enhances the virus production does it to a lesser extend than in a similar experiment
with gB-negative PRV, suggesting that EHV-1 gB might not be as stringently required for
virus penetration as are its homologs in other Alphaherpesvirinae (Neubauer et al., 1997b).
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Glycoprotein B has been shown to interact with a paired immunoglobulin-like type 2
receptor (PILP) alpha to gain entry into the cells devoid of other herpes virus entry
mediators (Satoh and Arase, 2008).
Glycoprotein B along with major nucleocapsid protein are some of the most
antigenic EHV-1 proteins (Ahmed et al., 1993). An antigenic determinant recognized by an
anti-gB monoclonal antibody is present in the N-terminus of the surface domain (Guo,
1990). Strong virus-neutralizing activity of antibodies to the extracellular portion of gB,
amino acids 1 to 844, expressed in insect cells using a recombinant baculovirus, showed
that post-translational modification of the EHV-1 gp14 is important for the expression of
epitopes necessary for the induction of neutralizing antibodies (Osterrieder et al., 1994).
A number of studies of EHV-1 gB have addressed immune responses to and
vaccine potential of recombinant gB. Plasmid DNA recombinant intramuscular vaccines
expressing the gB, gC and gD glycoproteins of EHV-1 significantly reduced virus
excretion but failed to protect against cell-associated viremia following respiratory
challenge of ponies with EHV-1 virulent Ab4 strain (Minke et al., 2006). In another study,
vaccination of mice with baculovirus-expressed gB prevented clinical signs of infection,
induces rapid clearance of virus from the lungs, reduced pulmonary lesions, and increased
T cell peribronchiolar and perivascular aggregations in mice challenged with EHV-1
(Packiarajah et al., 1998). Baculovirus-expressed EHV-1 glycoprotein B vaccinated mice
also showed significantly higher rate of litter survival, increased body weight of young,
and no virus presence in the fetal tissues when challenged during pregnancy (Kukreja et
al., 1998b). Mice infected with EHV-1 (RacL11) gB-negative virus, did not develop
disease, even when viruses were grown on complementing cell lines, and gB-negative
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virus immunization, protected animals from developing disease inducing both virusneutralizing antibodies and EHV-1-specific splenic T-cell response following challenge
with wild-type EHV-1 (Neubauer et al., 1997a).

Glycoprotein C
Glycoprotein C, gp13, is a gamma-1 gene product, encoded by of ORF 16, a 2.8-kb
mRNA (Matsumura et al., 1993). The protein has the characteristic features of a
membrane-spanning protein: an N-terminal signal sequence, a hydrophobic membrane
anchor region, a charged C-terminal cytoplasmic tail, and an exterior domain with nine
potential N-glycosylation sites (Allen and Coogle, 1988).
The glycoprotein C of EHV-1 and other alphaherpesviruses functions as a major
virus attachment protein through binding to glycosaminoglycans (GAG), heparan sulfate
(HS), a heparin-like moiety on the cell surface (Herold et al., 1991; Kari and Gehrz, 1992;
Li et al., 1995; Mettenleiter et al., 1990; Okazaki et al., 1991). The main function of gC
binding to GAGs seems to be to aid concentration of the virus on cell surfaces, enabling
the more stable interaction of gD with an entry receptor. It has also been shown that while
PRV gC binds to heparin only in conjunction with gB (Mettenleiter et al., 1990), EHV-1
gC binds to heparin separately from gB, similarly to that in HSV-1 (Herold et al., 1994;
Sugahara et al., 1997). Hydrophilic regions of the gC may be responsible for binding to
heparin (Sugahara et al., 1997). Interestingly, that the gC of strains adapted to non-equine
cells have been shown to have higher affinity for heparin due to amino acid substitutions of
the hydrophilic regions gC, amino acid residues 92 to 175, resulting in the glycoprotein
becoming more cationic(Sugahara et al., 1997). This and other cell attachment and entry
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adaptations of EHV-1 may explain the expansively broad cell tropism of EHV-1 compared
to other alphaherpesviruses.
Another important function of gC is its ability to to bind and inactivate the C3b
component of complement facilitating immune evasion (Eisenberg et al., 1987; Friedman
and Nashold, 1984; Huemer et al., 1995; Huemer et al., 1993; Lubinski et al., 1999;
Lubinski et al., 1998). Since complement is one of the most critical defence mechanisms of
the innate immunity against cerebral infection by viruses, the function EHV-1 gC is
important in myeloencephalopathy presentation of EHV-1 disease.
Glycoprotein C is an important virulence factor of alphaherpesviruses in vivo.
Infection of mice with a EHV-1 mutant virus that lacked gC ORF does not cause EHV-1related disease, while wild-type virus infected mice exhibit massivie body weight losses,
high virus titers in the lungs, and viremia (Osterrieder, 1999). Amino acids 152 to 275 of
EHV1 gC specifies one of EHV-1 type-specific epitope (Crabb and Studdert, 1995).
Immunization of mice with EHV-1 gC shows accelerated clearance of EHV-1 by virus
specific antibodies, high levels of virus neutralising antibodies, and by cell mediated
immune responses from the respiratory tissues following intranasal challenge (Packiarajah
et al., 1998; Tewari et al., 1995). IgG2b is the predominant antibody isotype produced in
BALB/c (H-2K(d)) mice against gC derived from EHV-1-infected cells, while equal
amounts of IgG2a/2b are found in the serum of C3H mice (H-2K(k)), indicative of a Thelper(1) response (Alber et al., 2000).

Glycoprotein D
The envelope glycoprotein D (gp17/18, gp60?), a 392 amino acids EHV-1 protein
is encoded by a unique short (Us) segment of the EHV-1 genome with 26% and 20% of its
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residues matching PRV gp50 and HSV-1 gD, respectively (Audonnet et al., 1990; Colle
and O'Callaghan, 1995; Elton et al., 1992; Flowers et al., 1991; Flowers and O'Callaghan,
1992; Love et al., 1992; Whalley et al., 1991; Whittaker et al., 1992),(Elton et al., 1992;
Whalley et al., 1991). A 3.8-kb mRNA encoding gD is synthesized as a late (beta-gamma)
transcript. It initiates 91 and 34 nucleotides downstream of the CCAAT and TATA
elements, respectively (Flowers and O'Callaghan, 1992). Glycoprotein D exhibits features
typical of a transmembrane protein: a hydrophobic N-terminal signal sequence followed by
a cleavage site (Arg35 and Ala36), four potential N-linked glycosylation sites, and a
hydrophobic membrane-spanning domain near the carboxyl terminus followed by a
charged membrane anchor sequence (Flowers et al., 1991; Wellington et al., 1996a).
Glycoprotein D proteins are first detected at 6 hr after infection with maximal
synthesis of gD between 5 and 8 hr post-infection, resulting in 43.206-kDa polypeptide
which then undergoes processing (Flowers et al., 1995a). Polypeptides of 55 and 58 kDa
are detectable in EHV-1-infected cells 2.5 hr apart. A 55-kDa protein is a high-mannose Nlinked oligosaccharides precursor to the 58-kDa species, a mature polypeptide possessing
complex type oligosaccharides and observed in the membrane fraction of EHV-1
virions(Flowers et al., 1995a; Flowers and O'Callaghan, 1992).
Importantly, gD has been shown to act as the viral ligand for entry receptors
expressed on cell surface (Spear et al., 2000). As a result, gD is essential for replication in
vitro gene, absolutely required for virus entry and virus-induced cell-to-cell fusion to occur
(Csellner et al., 2000). As discussed earlier, HSV-1 gD has the ability to bind HVEM,
nectin-1, nectin- 2, and other cell surface receptors to mediate virus entry. In addition, cells
that express gD are resistant to herpes infection in a dose-dependent manner due to a
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saturation of the corresponding entry receptors (Campadelli-Fiume et al., 1988b; Johnson
et al., 1990). No gD receptor for EHV-1 have been isolated to date and studies show that
EHV-1 may utilize a unique unknown to date cellular receptor or employ an alternate entry
strategy in the absence of the gD receptor. Noteworthy, is that several dozens of
mammalian species encode already identified and cloned herpes virus entry mediators on
their cell surface, just as most mammals possess the specie-specific herpes virus. It is
likely that EHV-1 cell surface receptor of gD can be identified in the near future.
X-ray structures of HSV-1 gD alone and in complex with HVEM have been
determined, revealing that a portion of gD assumes an Ig-like fold with unconventional
disulfide-bonding patterns (Carfi et al., 2001) and a hairpin loop in the complex with
HVEM (Spear and Longnecker, 2003). N-terminal end of gD has a critical role in its
functional interactions with all but nectin-1 entry/fusion receptors (Yoon et al., 2003; Zago
and Spear, 2003).
Glycoprotein D plays an important role in eliciting the protective immune response
against EHV-1 infection, and numerous studies using various expression systems that
included Escherichia coli, baculovirus and plasmid DNA evaluated its potential as a
subunit vaccine (Flowers et al., 1995b; Ruitenberg et al., 2001; Wellington et al., 1996b).
Regardless of the expression system and therefore, despite the lack of glycosylation,
inoculation of gD protein alone or in combination with gD DNA evoked neutralizing
antibody responses and protected vaccinated mice against a challenge with EHV-1,
reducing clinical signs of infection such as lung pathology, fetal loss and fetal damage,
showing accelerated clearance of virus from the lungs, and inducing accumulation of
mononuclear cells, predominantly lymphocytes (T cells) (Packiarajah et al., 1998; Walker
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et al., 2000; Weerasinghe et al., ; Zhang et al., 1998). The protective effects of primarily
CD4+ T cells, were confirmed by adoptive transfer from spleen of baculovirus gDimmunized donors to recipients that were challenged with live EHV-1. (Tewari et al.,
1994). EHV-1 gD DNA induces IgGa antibody production consistent with T-helper 1
(Th1) type of immune response which is maintained after the protein boost, despite the gD
protein alone to directing a Th2 response (Love et al., 1993; Ruitenberg et al., 2000;
Ruitenberg et al., 1999; Tewari et al., 1994). Antibody isotype can also be species specific,
where immunization elicited predominantly an IgG1 response in BALB/c mice (indicative
of a T-helper(2) response) and an IgG2a/2b response (indicative of a T-helper(1) response)
in C3H mice(Alber et al., 2000).
Phenotypically complemented gD-negative EHV-1 also induces protective immune
responses following intranasal or intramuscular inoculation of mice (Csellner et al., 2000).
Glycosylation was also not required to elicit EHV-1 gD-specific antibodies including
virus-neutralizing antibody in horses (Weerasinghe et al., 2006). In foals and adult horses,
recombinant baculovirus-expressed EHV-1 gD induces virus-neutralizing antibody,
including colostrally-derived, and significantly decreases viral shedding, however does not
protect foals born from vaccinated mares (Foote et al., 2005; Freeman and Ellis, 1984).
Isotype analysis revealed elevated gD-specific equine IgGa and IgGb relative to IgGc,
IgG(T) and IgA (Foote et al., 2005).
Entry of EHV-1 has been suggested to also occur via endocytic/phagocytic
pathway, as an alternative way to infect important cell populations. Interaction between
integrins and RSD motif of EHV-1 gD were shown to be important in such entry of the
virus into CHO-K1, the chinese hamster ovary, cells (Van de Walle et al., 2008).
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Glycoprotein H and Glycoprotein L
The 2517 bp UL22 gene encodes the 838 aa glycoprotein H (gH). gH is a type I
membrane glycoprotein containing an 18 aa signal peptide, a long 785 aa ectodomain, a
single 21 aa transmembrane hydrophobic domain close to the C-terminus, and a 14 aa Cterminal cytoplasmic tail. The 675 bp UL1 gene encodes the 224 aa glycoprotein L. gL
contains a 25 aa signal peptide; however, unlike other herpesvirus glycoproteins, gL does
not contain a transmembrane domain. It appears that gL is not an integral membrane
protein; rather, its membrane association and incorporation into virus particles is
dependent on its heterodimer interaction with gH (Dubin and Jiang, 1995). When gH is
expressed in transfected cells in the absence of gL, the resulting gH polypeptide is neither
folded or processed correctly. The malformed gH remains in the endoplasmic reticulum
and undergoes self-aggregation (Foa-Tomasi et al., 1991; Forrester et al., 1991; Roberts et
al., 1991). Similarly, cells infected with a gL-null virus do not produce virions containing
gH. When cells are infected with a gH-null virus, gL is neither correctly processed nor
incorporated into the plasma membrane or viral envelope (Hutchinson et al., 1992; Roop et
al., 1993). Due to the lack of a transmembrane region, the gL polypeptide is secreted into
the medium (Dubin and Jiang, 1995). When both UL22 and UL1 genes are cotransfected
into cells, the antigenic conformation of the gH/gL heterodimer is identical to that of virus
infected cells, indicating that no other viral proteins are necessary for heterodimer
formation. The mutual interaction of both glycoproteins is mediated by the N-terminal
region of the first 69 aa of gL after cleavage of the 25 aa signal peptide (Roop et al., 1993),
while gH interacts through a central region of the its extracellular domain. A properly
formed gH/gL heterodimer is required for both attachment virus entry and virus-induced
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cell-to-cell fusion. Although viruses lacking gH/gL are unable to enter cells, they are able
to attach to the cell surface. Therefore, the role of gH/gL in virus entry is during the virus
envelope plasma membrane fusion event and is not required for virion or receptor binding.

The Herpes Virus Life Cycle
Virus Attachment and Entry
Binding Receptors
Recent developments in molecular studies of HSV-1 entry, maturation, and spread
have contributed to deeper understanding of EHV-1 life cycle and pathogenesis (Figure I6). Initial contact of the virus to the cell surface membrane is through receptor binding
(Figure I-7), where positively charged residues of glycoprotein C and to a lesser extend
glycoprotein B, attach to the glycosaminoglycan proteoglycans on cell surface, primarily to
the heparan sulfate moieties of ubiquitous in mammals heparin sulfate proteoglycans
(Osterrieder, 1999; Shieh et al., 1992; Sugahara et al., 1997; WuDunn and Spear, 1989).
The receptor interaction at this point is reversible and the changes in the virion envelope
required for fusion and entry do not occur. Presence of heparin sulfate is not essential for
virus entry, while gC is also dispensable for either virus entry or replication; their
interaction however, confers approximately 10-fold increase in the efficiency of virus
attachment (Banfield et al., 1995; Heine et al., 1974).
After initial attachment via gB and gC, alphaherpesvirus gD binds additional cell
surface receptors, and thus, confers susceptibility of a certain cell type to the virus
infection. Interaction of gD with specific cellular receptors results in its conformational
changes and subsequent interaction with gH/gL and gB initiating the fusion of viral and
cellular membranes (Csellner et al., 2000).
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The importance of alphaherpesvirus gD-receptor binding for virus entry and spread
is exemplified by the fact that soluble forms of these receptors (HveA, HveC, and HIgR
variants) inhibit virus entry into susceptible cells via their interaction with gD. (Cocchi et
al., 1998a; Krummenacher et al., 1998; Rux et al., 1998). Only alphaherpesviruses (except
VZV) encode members of the gD family.
Betaherpesvirus and gammaherpesviruses rely on other viral proteins to serve as
ligands for cellular receptors. Also, as will be discussed below, endocytic uptake of HSV
virions from the cell surface is rapid and independent of any known gD receptor (CassianiIngoni et al., 2005), EHV-1 can potentially employ the same strategy during entry of nonequine cells lacking herpes virus entry mediators. No specific gD receptor have been
identified for EHV-1 at this time (Frampton et al., 2005). The increase of EHV-1 gBnegative titers by polyethylene glycol (PEG) treatment, is considerably lower compared to
gB-negative pseudorabies virus, suggesting that EHV-1 gB might not be as stringently
required for virus penetration as are its homologs in other Alphaherpesvirinae (Neubauer et
al., 1997b).
Several human and animal cellular receptors have been identified for various
alphaherpesviruses, by their ability to mediate virus entry into normally herpesvirus
resistant Chinese hamster ovary (CHO) cells (Figure I-8). These receptors include HveA, a
member of the TNF receptor family (Montgomery et al., 1996), as well as several nectins,
which are members of the immunoglobulin superfamily (Cocchi et al., 1998a; Cocchi et
al., 1998b; Geraghty et al., 1998; Warner et al., 1998). Various homologs of some of these
receptors have also been isolated from other cell-types (Foster et al., 1999; Shukla et al.,
2000). HSV-1 gD and by analogy all gD homologues specified by alphaherpesviruses bind
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Only viral attachment can occur in the absence of an HSV entry receptor.
these receptors and facilitate virus entry into susceptible cells. The importance of gD
binding to receptors for virus entry and spread is exemplified by the fact that soluble forms
of HveA, nectin-(HveC, and HIgR variants) have been shown to bind to HSV-1 gD
(Cocchi et al., 1998a; Cocchi et al., 1998b; Krummenacher et al., 1999) and inhibit virus
entry into susceptible cells. HveA and nectin-1 (HveC) are associated with lipid rafts
during herpes simplex virus entry (Cassiani-Ingoni et al., 2005).
Immunoglobulin-like type 2 receptor (PILR) alpha is a cellular receptor associates
with gB and required for HSV-1 infection (Satoh et al., 2008). HSV-1 infection of human
primary cells expressing both HVEM and PILRalpha was blocked by either anti46

PILRalpha or anti-HVEM antibody, suggesting that both gB and gD receptors are required
for HSV-1 infection.
The corresponding receptors in the equine cells have not been yet identified.
However, unlike EHV-4, EHV-1 has a remarkably broad cell tropism and is known to
infect and replicate efficiently in dozens of cell lines empowered by unknown mechanism
in the otherwise common to alphaherpesviruses entry process. One study, noted the
flexibility of EHV-1 to adapt to a non-equine cell line by incorporation of mutations in
glycoprotein C that strengthened its affinity to heparan sulfate moieties (Sugahara et al.,
1997). gC and gB of EHV-1 strains bound to heparin regardless of their passage history,
whereas heparin markedly interfered with infection only by the strains adapted to nonequine cells. Therefore, gC may function as a major viral attachment protein in EHV-1
entry into non-equine cell cultures. Another study proposed that EHV-1 utilizes a unique
gD-binding receptor for entry into the cells, different from known mediators of herpes
simplex virus, based on studies that EHV-1 was able to enter efficiently into CHO cells
lacking HveA as well as HveB and HveC (Frampton et al., 2005). Additional consideration
is that current EHV-1 strains used have been passaged solely in non-equine cell lines. The
receptors of alphaherpesvirus entry described below have been studied extensively and
identified for dozens of mammalian cells, therefore, a brief review of the current
knowledge is included for completeness.
Tumor Necrosis Factor Receptor Family
Herpesvirus entry mediator A (HveA), also known as HVEM, TNFRSF14, ATAR,
LIGHTR, TR2, and CD40-like protein precursor, is a member of the tumor necrosis factor

47

receptor (TNFR) family and is present and expressed at high levels in lymphocytes. It has
been studied by various disciplines of biology under various designations.
HveA is also found on some epithelial cells, carcinomas, lymphoid dendritic cells,
other leukocytes, and fibroblasts (Cassiani-Ingoni et al., 2005). Human HveA is expressed
in various tissues including liver, lung, kidney, spleen, and peripheral leukocytes, and it is
the principal mediator for HSV-1 entry into human lymphoid cells, but not a primary
mediator in other cell types (Montgomery et al., 1996). The cytoplasmic region of this
receptor was found to bind to several TNFR-associated factor (TRAF) family members,
which may mediate the signal transduction pathways that activate the immune response.
Although a TNF receptor, HveA binds ligands with no structural similarity to TNF.
The natural ligands for HveA include LIGHT, lymphotoxin-alpha, and B and T
lymphocyte attenuator (BTLA) (Mauri et al., 1998; Sedy et al., 2005). LIGHT can function
as a second signal for T-cell activation, and the interactions between LIGHT and HveA are
the focus of investigations into the regulation of immune responses (Jung et al., 2003).
HveA binding to BTLA, an Ig family member, which inhibits T cell proliferation is
probably an important pathway regulating lymphocyte activation and/or homeostasis in the
immune response (Sedy et al., 2005). The interaction between HveA and gD has been
suggested to initiate the signaling pathway leading to nuclear factor (NF)-kappaB
activation (Teresa Sciortino et al., 2007).
Immunoglobulin Superfamily
The second family of herpes simplex virus entry receptors is a part of the
immunoglobulin superfamily and includes several isoforms present in various mammalian
cells, each diverse due to alternative mRNA splicing. The prototype molecule of the family
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is the poliovirus receptor, PVR/CD155. Nectin1, also known as poliovirus related receptor
type 1(PRR1), is assigned to CD111 as a member of a new family of receptors
(Campadelli-Fiume et al., 2000).
The family also includes nectin2/PRR2 and nectin3/PRR3. All members are
structurally related and consist of three immunoglobulin (Ig) domains, one variable (V)type domain and two constant (C)-type domains. Nectins are highly conserved among
mammalian species in respect to structure, function, and the ability to mediate herpesvirus
entry (Milne et al., 2001; Shukla et al., 2000). The nectins are expressed in a variety of cell
types including epithelial cells, fibroblasts, keratinocytes, and neural and hematopoietic
cells (Cocchi et al., ; Geraghty et al., 1998; Takai et al., 2003). As adhesion molecules,
nectins localize to cell-to-cell junctions of endothelial and epithelial cells, in which the
carboxyl-terminal domains bind to L-afadin, a PDZ-binding protein that anchors the
receptors to the cytoskeleton and adherens junctions (Takahashi et al., 1999). Nectin-1α,
also known as herpesvirus entry mediator C (HveC) and the mRNA splice variant isoform,
nectin-1β, Herpesvirus Immunoglobulin-like receptor (HIgR), contain common
ectodomain and are capable of mediating entry of human and animal alphaherpesviruses,
including HSV-1 and -2, pseudorabiesvirus (PRV-1), and Bovine herpesvirus (BHV-1)
(Geraghty et al., 1998). HveC and HIgR are expressed in human cells of epithelial and
neuronal origin and are therefore the primary candidates for co-receptors that mediate entry
into epithelial cells at the initial site of infection and into neuronal cells for the
establishment of latency (Cocchi et al., 1998a; Geraghty et al., 1998). Nectin-2α, Herpes
Virus Entry Mediator B (HveB), and nectin-2δ are also mRNA splice variants, and they
mediate the entry of HSV-2, PRV, and certain viable mutant forms of HSV-1 but not wild49

type HSV-1 (Lopez et al., 2000; Warner et al., 1998). Other nectin splice variants have
been identified (Cocchi et al., 2004b; Takai and Nakanishi, 2003).
3-O-sulfated Heparan Sulfate
Heparan sulfate proteoglycans can function as entry mediators for HSV-1as
modification of heparan sulfate by D-glucosaminyl 3-O-sulfotransferase isoforms-3 and/or
-5, creates 3-O-sulfated heparan sulfate (3-OS HS) generates a gD-binding site. 3-Osulfated heparan sulfates are broadly distributed on human cells and tissue and mediate
HSV-1 but not HSV-2 entry (Shukla et al., 1999).
By analogy with other alphaherpesviruses, EHV-1 was suspected to attach to cells
through a nonessential interaction of gC with heparan sulfate proteoglycan and through an
essential interaction of gD with one of three cellular receptors: nectin-1, herpesvirus entry
mediator (HVEM), or a specifically modified heparan sulfate (Spear, 2004). Binding of
gD and HveA receptor causes the former to undergo a conformational change in which a
C-terminal segment of the ectodomain polypeptide chain is released from a strong
intramolecular contact (Carfi et al., 2001; Krummenacher et al., 2005) and may interact
with gB or the gH/gL complex to trigger molecular rearrangements and, ultimately, fusion
(Figure I-9). The precise functions of gB and gH/gL in entry process are unknown. Both
are required for entry and both receive the signal from gD, to which they respond, by
undergoing a conformational change. gD itself is thought not to participate in the fusion
process (Cocchi et al., 2004a; Jones and Geraghty, 2004). Neither gB nor gH/gL has an
obvious fusion peptide, but an indication that gB might be a fusion effector comes from the
notable syncytial phenotype caused by certain mutations within the cytoplasmic domain of
gB (Bzik et al., 1984a; Foster et al., 2001a; Gage et al., 1993; Heldwein et al., 2006).
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Figure I-9. Sequential protein-protein interactions during EHV-1 entry into the cell.
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Virus-to-Cell Membrane Fusion
After binding of gD to a HSV-1 virus entry receptor, the last step in virus entry is
fusion of the virion envelope with the plasma membrane of the target cell (Morgan et al.,
1968). Potentially, receptor binding triggers a conformational change in gD that translates
to a change in gB and gH/gL, resulting in activation of the HSV-1 membrane fusion
machinery (Figure I-9). Alphaherpesviruses can utilize two distinct entry pathways,
depending on the type of cell encountered, entering some cells through pH-independent
fusion with plasma membrane and other cells through an endocytic pathway, where lowpH environment of the endosome triggers fusion of the virion envelope with cellular
membranes. Studies of HSV-infected cells at early times post infection using electron
microscopy (EM) have detected virions fusing with the plasma membrane as well as
virions inside membrane-bound vesicles (Campadelli-Fiume et al., 1988a; Fuller et al.,
1989; Fuller and Spear, 1987; Sodeik et al., 1997). The details of the fusion mechanism are
unknown but have been under investigation for quite some time (Campadelli-Fiume et al.,
2000; Spear et al., 2000). Entry via endocytosis is a recent postulate, based on the study in
which inhibitors of endocytosis (energy depletion or hypertonic medium) and endosome
acidification (weak base ammonium chloride or the ionophore monensin), blocked virus
entry into the cells expressing herpesvirus entry receptors (Nicola et al., 2003; Nicola and
Straus, 2004). Endocytic uptake of HSV virions from the cell surface is rapid and
independent of any known gD receptor (Cassiani-Ingoni et al., 2005).
Herpes simplex virus entry into cells requires four glycoproteins, gB, gD, gH, and
gL, regardless of the entry pathways taken. Glycoprotein B is in the form of a trimer, while
gH forms a noncovalent complex with gL (Cairns et al., 2005; Farrell et al., 1994;
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Heldwein et al., 2006; Hutchinson et al., 1992; Ligas and Johnson, 1988; Peng et al., 1998;
Sarmiento and Spear, 1979). Virus-induced membrane fusion is subdivided into three
sequential phases (Figure I-10Figure I-10). During Phase I, two membranes are brought
into close proximity through viral glycoprotein binding of cellular receptors. In
alphaherpesviruses, such as EHV-1, gC interacts with heparan sulfate glycosaminoglycans
(HSGAG) (Osterrieder, 1999), gB interacts with HSGAG and paired immunoglobulin-like
type 2 receptor (PILR) alpha (Roller et al., 2008), and gD interacts with HveA and other
receptors on cell surface (Spear et al., 2000). Glycoprotein D is the only interaction
required for Phase I. Binding of gD to one of its receptors triggers conformational change
that exposes the normally hidden receptor binding residues of gD. This results in transient
interaction between gD and gH/gL, where gH/gL carries out Phase II hemifusion, followed
by stable complex between gD and gB, where gB completes Phase III full fusion.

Figure I-10. Phases of virus-induced membrane fusion. During Phase I, two membranes
are brought into close apposition. Phase II marks the mixing of the outer membrane leaflets
leading to formation of a hemifusion intermediate. A fusion pore stably forms and expands
in Phase III, thereby completing the fusion process.
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Specifically, Phase II involves the initiation of lipid mixing between the two
apposed membranes and is completed when the outer membrane leaflets are mixed to form
an intermediate called hemifusion. In Phase III the mixing of the inner membrane leaflets
continues from hemifusion to the pore formation and expansion and until completion of the
fusion process (Atanasiu et al., 2007; Subramanian and Geraghty, 2007). Interestingly,
Varicella zoster virus (VZV) fusion formation occurs upon expression of the gH/gL
complex alone. In contrast, Pseudorabies virus (PRV) requires expression of gH, gL and
gB, while the Herpes simplex virus (HSV) types 1 and 2 require the quartet of gH, gL, gB
and gD. EHV-1 core fusion complex is not defined, but suspected to parallel the HSV-1
model and include gH, gL, gB and gD.

Virion Transport to the Nucleus
After fusion of the virion envelope with the plasma or endosome vesicle membrane
of the infected cell, the capsid and the associated tegument complex are deposited into the
cytoplasm. Some tegument proteins disassociate from the complex and remain in the
cytoplasm. The remaining capsid-tegument complex is then transported along the
microtubule network utilizing the cell’s dynein motor to be docked at the nuclear pore
complex (NPC), potentially disrupting the microtubule interactions in the process (Sodeik
et al., 1997; Ward et al., 1998). VP1/2 gene is required for the release of the DNA from
nuclear pore associated capsids and its deposition into the nucleus (Batterson and
Roizman, 1983; Copeland et al., 2008; Knipe et al., 1979; Ojala et al., 2000). Change in
NPC conformation allows translocation of the genome as a densely packaged, rod-like
structure, rapidly and efficiently ejected through dilated NPCs towards the nucleus into the
nucleoplasm, where it is transcribed and replicated to propagate the infection. After release
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of the genome, empty capsids dissociate from the NPC (Batterson and Roizman, 1983;
Lycke et al., 1988; Sodeik et al., 1997).

Biosynthesis
Coordinate Gene Expression
During the course of infection, more than 80 genes are expressed in highly
regulated cascade fashion. As with other alphaherpesviruses such as herpes simplex virus
type 1 (HSV-1), varicella-zoster virus (VZV), bovine herpesvirus 1 (BHV-1), and
pseudorabies virus (PRV), expression of EHV-1 genes is temporally regulated and
coordinately expressed in an immediate-early (IE or α), early (E or β), and late (L or γ)
fashion. The regulation of this cascade of gene expression is governed by the action of at
least four characterized EHV-1 regulatory proteins: the sole IE protein (IEP), the EICP22
protein (formerly known as IR4), the EICP27 protein (formerly known as UL3), and the αgene transactivating factor (α-TIF). α-TIF protein, a γ gene product present in the
tegument, activates initial transcription of alpha genes, which contain the
“TAATGArATT” promoter response element, which binds cellular Oct-1 bound to viral
DNA. Meanwhile, VP16 is released from its interaction with VHS and the tegument
complex and binds to a cellular protein, the host cell factor (HCF) or C-1 (Katan et al.,
1990; Kristie and Sharp, 1990). HCF carries VP16 into the nucleus and the VP16-HCF
complex binds to Oct-1. The viral gene expression is then autoregulated, expression of β
genes activated, then γ gene expression is activated by α and β genes, viral genome
replication is initiated as γ genes turn off α and β genes late in infection (Roizman and
Knipe, 2001). RNA polymerase II transcription of viral DNA takes place in the nucleus
(Alwine et al., 1974; Costanzo et al., 1977).
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Viral alpha genes are expressed at peak levels at 2 to 4 hours post infection. Out of
six α genes: ICP0, ICP4, ICP22, ICP27, ICP47, and US1.5, five stimulate viral β gene
expression in at least some cell types. In particular, ICP4 is required for all post-α gene
expression (Clements et al., 1977; Dixon and Schaffer, 1980), and its effect is exerted at
the transcriptional level (Godowski and Knipe, 1986). ICP4 or possibly it’s also
responsible for downregulation of itself and ICP0, gene products of ORF P and ORF O
(Gelman and Silverstein, 1987; Petzoldt et al., 1987). The absence of ICP4 at low grade
infection leads to a 100 fold decrease in virus yield (Sinclair et al., 1994; Stow and
Davison, 1986).
The β genes products, involved in viral DNA replication and nucleotide
metabolism, are produced at peak levels between 4 and 8 hours post infection, and are
subdivided into two groups based on timing of expression. β1 genes such as single-stranded
DNA binding protein, ICP8, and the large subunit of ribonucleotide reductase, ICP6, are
expressed shortly after the synthesis of the alpha proteins. The β2 genes such as viral
thymidine kinase encoded by UL23, are expressed with a certain delay after α gene
expression possibly due to presence of ICP27 requirement for expression (Roizman and
Knipe, 2001).
The γ (late) genes are produced at peak levels only after viral DNA replication has
started, and require ICP4, ICP27 and ICP8 for efficient levels of transcription. γ1 (leakylate) genes, are expressed throughout infection and their transcription is increased only a
few fold after DNA replication has occurred. γ2 genes, which do not accumulate in
appreciable amounts until after DNA replication (Wagner et al., 1985). Typical γ1 genes
include the major capsid protein ICP5, gB, gD, and ICP34.5, whereas typical γ2 genes
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include gC, UL41 (VHS), UL36, UL38, UL20, and gK. Over 30 viral structural proteins
have been identified in the alphaherpesvirus particle, eight of which are associated with the
capsid (McNab et al., 1998; Steven and Spear, 1997; Thurlow et al., 2005).
Viral Inhibition of Host Protein Synthesis
While making their own proteins, herpesviruses shut off the synthesis of cellular
proteins through degradation as well as inhibition of further synthesis and processing of
host mRNA. The virion host shutoff protein (VHS) is a structural component of the virion
and functions without the need for de novo protein synthesis upon infection (Fenwick and
Walker, 1978; Nishioka et al., 1978). In complex with the translation factor eIF-4H
protein induces endoribonucleolytic cleavage of 5’ end of mRNA (Frink et al., 1981)
(Elgadi and Smiley, 1999; Karr and Read, 1999; Kwong et al., 1988; Roizman and Knipe,
2001; Zelus et al., 1996). Early in the infection VHS accelerates the degradation viral
mRNAs as well as cellular, thus facilitating the transition from α to β to γ gene expression
(Kwong and Frenkel, 1987; Oroskar and Read, 1987). As a γ1 gene product, newly made
VHS accumulates late in infection. VHS is unable to degrade the viral mRNAs that
predominate at this late stage of infection as it is immediately incorporated with VP16 into
a tegument complex to be delivered to the next cell for inhibition of protein synthesis (Lam
et al., 1996)
Viral Genome Replication
Parental viral DNA is circularized upon being deposited into the nucleus of the
infected cell. After the β genes have been expressed and translated, several proteins
assemble on the parental circular viral DNA initiating replication in a “theta” structure,
which then transitions to a rolling circle mechanism producing head-to-tail concatemers of
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viral DNA (Ishov and Maul, 1996; Jacob et al., 1979; Uprichard and Knipe, 1996). There
are seven viral proteins absolutely required and sufficient for viral DNA replication. These
are the viral DNA polymerase, UL30 (Purifoy et al., 1977), its accessory protein, UL42
(Conley et al., 1981), an origin-binding protein, UL9, the single stranded DNA binding
protein , ICP8, and the helicase-primase complex of UL5, UL8, and UL52 (Challberg,
1986; Wu et al., 1988). Host DNA polymerase α- primase, DNA ligase, and topoisomerase
II are also required. Although only one origin of replication (Ori) is needed for replication
in vitro, viral genomes of alphaherpesviruses has three. Studies in vivo have shown that the
origins have distinct functional properties. OriS, a palindromic sequence of ~45 bp that is
located in the “c” repeats flanking the unique short (US) region of the genome and present
in two copies. OriL, a palindromic sequence of ~144 bp, is located at the center of the
unique long (UL) region of the genome (Deb and Doelberg, 1988; Igarashi et al., 1993;
Knopf et al., 1986; Lockshon and Galloway, 1986; Polvino-Bodnar et al., 1987; Roizman
and Knipe, 2001). OriL contributes significantly to morbidity and mortality of HSV-1
infection in mice and is required for efficient viral replication and reactivation in neurons
(Balliet and Schaffer, 2006). Both oriL and oriS contain palindromic sequences as core
elements, share greater than 90% homology, and reside within the promoter/enhancer
regions of genes essential for viral replication. UL9 binds to either oriL or oriS and begins
to unwind the viral DNA. UL9 then recruits the single stranded DNA binding protein,
ICP8, to the unwound portion of the viral DNA. At this point, UL9 and ICP8 engage the
remaining five proteins to the replication forks. The helicase–primase and viral DNA
polymerase complexes assemble at each replication fork and initiate theta form replication
that switches the rolling circle form of replication through an unknown mechanism. UL9 is
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not required for rolling circle replication because it is not origin dependent. The rolling
circle replication forms long head-to-tail concatemers of viral DNA, which become
cleaved into individual units during packaging of viral DNA into capsids (Roizman and
Knipe, 2001).

Capsid Assembly and DNA Packaging
Following initiation of DNA replication and transcription γ genes encoding capsid
proteins, capsid assembly proceeds by way of small oligomers of major capsid (VP5) and
scaffold proteins added to the edges of the growing capsid and secured in place by
triplexes (VP23) (Nicholson et al., 1994; Rixon et al., 1996). Assembly requires the
individual subunits to be synthesized in an assembly-inactive form that is subsequently
triggered to polymerize, either by recognition of a growing surface or by binding to a
scaffolding protein (Figure I-11).
The process is initiated in the cytoplasm and is completed in the nucleus, so most
of the proteins are able to localize to the nucleus on their own, while VP5, VP26 (outer tip
of hexons), and VP23, can be carried to the site. VP5 uses a triplex protein VP19C or a
scaffolding protein pre-VP22a. VP23 uses VP19C, while VP26 uses both VP5 and VP19C
or pre-VP22a (Nicholson et al., 1994; Rixon et al., 1996). Once in the nucleus, VP5-preVP22a complexes come together as a result of self assembly of pre-VP22a, which is lost as
DNA is packaged. The triplex proteins VP19C and VP23 are then added to form a partial
capsid. Hexons and pentons made up of VP5. The individual capsomers are linked by
triplex structures consisting of VP19C and VP23, the two minor capsid proteins. Each
triplex consists of one molecule of VP19C and two molecules of VP23 (Newcomb et al.,
1993).
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Figure I-11. Packaging of viral DNA.
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Eventually a single portal complex (comprised of 12 copies of UL6) is incorporated
into the growing structure at a unique vertex (Dasgupta and Wilson, 1999; Newcomb et al.,
2001) and nascent capsid closes forming the procapsid. The portal complex is an integral
part of the capsid structure and harbors the binding sites for the terminase complex (UL15
with UL28 and possibly UL33) (Adelman et al., 2001; Beard et al., 2002; Davison, 2002;
White et al., 2003; Yu and Weller, 1998). The portal not only functions as a DNAtranslocating machine in conjunction with nonstructural viral factors (terminase/ATP) but
also interacts with the minor proteins that seal the portal after DNA packaging and reopen
it for genome ejection at onset of infection. Procapsid matures undergoing structural
transformation. This process results in the conversion of the spherical procapsid into a
more angular form. The internal protein scaffold (VP21 and VP22a) is cleaved by the viral
protease and is displaced from inside the capsid as the DNA genome is packaged into the
capsid (see Figure I-11). The internal protein VP24 is retained (Sheaffer et al., 2000).
Many aspects of capsid assembly and DNA packaging in the herpesviruses are
similar to those in dsDNA bacteriophages such as λ, T4, and P22 (Brown, 2002; Prevelige
and King, 1993) (Figure I-11). Cleavage of DNA concatemers by the terminase complex)
occurs at specific sites and requires the pac1 and pac2 packaging signals to generate unitlength genomes (Deiss et al., 1986; Smiley et al., 1990; Varmuza and Smiley, 1985). The
process of encapsidation of viral DNA requires several gene products, including UL6,
UL15, UL17, UL28?, UL32, UL33, UL36? and UL37? (Brown, 2002; Lamberti and
Weller, 1998; Roizman and Knipe, 2001; Taus et al., 1998). UL17 and UL32 have been
implicated in targeting of capsids or capsid proteins to the sites of DNA packaging
(Lamberti and Weller, 1998; Taus et al., 1998). Of the three capsid-associated DNA
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packaging proteins, UL17, UL25, and UL6, only UL17 and UL6 appear to be components
of the procapsid (Thurlow et al., 2006). Subsequent to DNA cleavage, UL25 is required
and added for packaging process for retention of DNA within the capsid, potentially
sealing it (McNab et al., 1998; Stow, 2001). By further extrapolation from HSV-1, portal
protein UL6 interacts with the DNA cleavage and packaging proteins (putative terminase
subunits) UL15 and UL28 to form part of the terminase enzyme, a protein complex
essential for the cleavage of newly synthesized, concatemeric herpesvirus DNA and
packaging into preformed capsids (Ladin et al., 1980; Ladin et al., 1982). Another DNA
cleavage and packaging protein is encoded by the UL 33 gene associates with capsids
(Beard and Baines, 2004). The mature capsid is then able to proceed along the viral egress
pathway.
According to separation by density gradient centrifugation, three capsid species
have been identified for EHV-1 based on their sedimentation properties, Lights which are
abortive and correspond to A-capsids of HSV-1, Intermediate - (B-capsids), and Heavy minor component (C-capsids) containing packaged DNA. Both A and B capsids represent
dead-end products of infection. In the absence of DNA packaging, cleavage of the protein
scaffold and structural transformation of the procapsid still occur forming B capsids,
devoid of DNA as are lights but containing an additional protein, VP22, (Newcomb et al.,
1989; Newcomb et al., 1993). Abortive light (A) capsids contain neither DNA nor the
scaffolding proteins (Baker et al., 1990).

Egress and Envelopment
The egress occurs via a two-step process, the “de-envelopment re-envelopment”
pathway. Primary envelopment occurs at the inner nuclear membrane, followed by the
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fusion of primary envelope with the outer nuclear membrane and subsequent deenvelopment and loss of the envelope, primary tegument, UL31, and UL34 and
translocation of the capsid into the cytoplasm of the infected cells (Enquist et al., 1998;
Mettenleiter, 2000). (Gershon et al., 1994; Granzow et al., 2001; Harms et al., 2000;
Reynolds et al., 2002; van Genderen et al., 1994). The mechanism and the role of major
glycoproteins in virion de-envelopment from the perinuclear space is unclear (Cai et al.,
1987; Granzow et al., 2001; Jayachandra et al., 1997; Steven and Spear, 1997; Steven et
al., 1997). Final tegumentation and envelopment (re-envelopment) occur in cytoplasmic
compartments.
Herpesvirus tegument is highly complex. At least 15 proteins have been identified
that are part of the HSV-1 tegument. Even more proteins make up the tegument of other
herpesviruses such as VZV or CMV (Gibson et al., 1996; Spengler et al., 2001).
Tegumentation is an intricate pattern of redundant protein-protein interactions
(Mettenleiter, 2002a). The tegument proteins interact with the capsid on one side and the
viral envelope proteins on the other side linking the structural components of the virus
particle (Mettenleiter, 2002b).
The steps in capsid tegumentation are still largely undefined. Virion morphogenesis
still proceeds in the absence of several tegument proteins, including UL13, US3, UL41,
UL46, UL47, and UL49 (Frame et al., 1987; Mettenleiter, 2002a; Rafield and Knipe, 1984;
Roizman and Knipe, 2001). UL36 and UL37 appear to be the only tegument proteins
conserved in all herpesvirus subfamilies, and the absence of the HSV-1 UL36 and UL37
proteins abolishes virus maturation (Desai et al., 2001; Desai et al., 2000; Klupp et al.,
2001). The absence of UL48, (α-TIF), which is responsible for transducing α gene
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promoters and makes up a major part of the virus tegument, interferes with virion
assembly, affecting tegumentation and reenvelopment in the cytoplasm (Batterson et al.,
1983; Heine et al., 1974; Mossman and Smiley, 1999). UL48 has been shown to interact
with other tegument components, UL49 and UL41 (VHS), and may potentially interact
with gB, gD, and gH (Read et al., 1993; Smibert et al., 1994; Zhu and Courtney, 1994).
UL39 or PRV interacts with gE/I &M. HSV-1 capsid protein VP26 interacts with dynein
light chains RP3 and Tctex1 and also plays a role in retrograde cellular transport (Douglas
et al., 2004).
Following tegumentation in the cytoplasm, capsids acquire their final envelope by
budding into endosomes or cytoplasmic vesicles derived from the trans-Golgi Network
(TGN). Following the final envelopment step, nascent virions egress to extracellular
spaces, potentially utilizing the cellular transport machinery. The late stages in viral egress
are still unclear and may differ depending on the cell type that is infected.
In the absence of capsids, tegument assembly could proceed anchored on UL49
instead of UL36 and UL37, resulting in the formation of light (L) particles, that
(McLauchlan and Rixon, 1992; Mettenleiter, 2002b; Rixon et al., 1992). L particles appear
to contain the full complement of tegument proteins as well as an authentic envelope
containing all appropriate glycoproteins.

Latency
Productive infection of respiratory epithelial cells, endothelial cells and
lymphocytes is characterized by active expression of all viral genes in a highly ordered
temporal cascade as described above. In contrast, latent infection of sensory neurons is
characterized by profoundly restricted viral-gene expression, the failure to synthesize viral
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DNA, and the absence of infectious virus. In the trigeminal ganglia, circulating Tlymphocytes and lymphoid tissues draining the respiratory tract of their hosts,
Trigeminal ganglia, circulating T lymphocytes and lymphoid tissues draining the
respiratory tract, are the sites for establishment and maintenance of the lifelong state of
latency characteristic of all herpesviruses. In latently infected animals, reoccurrence of
viremia and shedding of the virus in nasal secretions of horses has been produced by
immune suppression through the administration of corticosteroids (Slater et al., 1994). The
cycle of a persistent latent infection with intermittent reactivation and shedding is thought
to keep EHV circulating within the equine population. Viremia occurring in primary and
all recrudescing infections occurs subclinically and poses a threat of inducing abortion, as
well as neurological disease.
Many different stressors, such as parturition, transportation, inclement weather,
corticosteroid treatment, or mixing of social groups, can result in the reactivation of
previously latent EHV-1 infection (Slater et al., 1994). The virus remains latent in the
trigeminal nerve ganglia and lymphocytes of infected horses for life.

EHV-1 Economic, Epidemiologic, and Clinical Significance
Economic Significance
Horse industry is large and diverse involving recreation, showing, racing, sport,
breeding, as well as work, and impacts national, state, and local economies. There are
about 9.2 million horses in the United States. The recreational segment accounts for $31.9
billion of the total economic impact, followed by the horse show segment at $28.7 billion
and the racing segment at $26.1 billion. The horse industry pays $1.9 billion in taxes to all
levels of government. In terms of total effect on the gross domestic product, California
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leads the way at $6.97 billion a year, followed by Texas ($5.23 billion), Florida ($5.15
billion), Kentucky ($3.54 billion), and Louisiana ($2.45 billion). Texas has the most horses
with 978,822, followed by California (698,345), Florida (500,124), Oklahoma (326,134),
and Kentucky (320,173). There are 164,000 horses in Louisiana, and 54,200 Louisianans
are involved in the industry as horse owners, service providers, employees, and volunteers,
while even more participate as spectators (LLP, 2005).
World-wide equine herpesvirus-1 continues to be a major cause of epidemic
abortion, perinatal mortality, respiratory disease and occasionally neurological disease in
horses (Allen et al., 2000; Bryans, 1989; Whalley, 1998). Herpes virus infections are
economically detrimental to the industry. Abortion is the most dramatic outcome of EHV-1
infection, and an epidemic outbreak can be financially disastrous for breeders, with loss of
clients and large insurance payments. Equine herpesvirus infection also renders horses
more susceptible to other diseases, and in young animals, strangles (Streptococcus equi)
and rattles (Rhodococcus equi) are already of significance to the industry. In addition,
considerable losses are encountered due to quarantine of the racing facilities during
respiratory herpesvirus outbreaks in adult equine population. Neurologic cases have been
on the rise, and demand advanced and costly veterinary care. Nonetheless, with the animal
health as the outmost goal, the effort and the expense to combat EHV-1 infection has been
considerable throughout past decades.

Epidemiology
Equine herpesvirus-1 (EHV-1) is an alpha herpesvirus which causes upper
respiratory tract infections in horses. These infections may be mild or asymptomatic and
can result in serious sequelae such as abortion, neonatal syndrome, peracute pulmonary
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vasculitis, myeloencephalopathy, ocular disease and secondary bacterial infections. As a
primary respiratory pathogen, no contributing factors are necessary for the outbreak of
disease. However, environmental and management factors still play a role in the incidence
of disease and its prevention (Sellon, 2001). Risk factors contributing to an outbreak
include: overcrowding, heavy parasite burden, poor nutritional state, climatic extremes, the
presence of concurrent disease and mixing of horse populations (Allen et al., 2002b). In
addition, air quality, sanitation, storage and quality of feed and prolonged periods of
transport impact the incidence of infection and disease (Sellon, 2001).
EHV-1 is enzootic in most equine populations with horses being exposed early in
life to the virus. It is estimated that 80%-90% of horses are infected by EHV-1 or its close
relative, EHV-4, by two years of age (Allen et al., 2002a; Gilkerson et al., 1999b),
determined that 30% of broodmares and racehorses on a stud farm were positive for EHV1 antibodies. Once a horse is infected with EHV-1 it is infected for life (Figure I-12). The
virus becomes latent in the trigeminal nerve ganglia and in the T lymphocytes of the
lymphoid tissue draining the upper respiratory tract (such as the submandibular and
retropharyngeal lymph nodes) (Allen et al., 2002b). Under periods of stress the virus can
be reactivated. Stressors include parturition, lactation, weaning, inclement weather,
prolonged transportation times, surgery, mixing of different groups of animals as well as
the use of certain medications such as corticosteroids (Huang Ja et al., 2002). The animal
with a reactivated infection may or may not show obvious clinical signs but it can shed
virus in its nasal secretions and potentially infect other horses. The ability to become latent
is one of the factors contributing to the amplification and maintenance of the virus within
equine populations (Huang Ja et al., 2002). A latently infected mare can pass the infection
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to her foal that then also can become latently infected. Periodically throughout the horse’s
life the infection can become reactivated and be passed horizontally to other horses. The
cycle of infection, latency, reactivation, viral shedding and infection or re-infection
maintains the virus within the population. It should be noted that as the risk of re-infection
or reactivation remains with the horse throughout its life, so does the risk of development
of any of the sequelae associated with EHV-1 infection. The risk of abortion, neurological
disease and severe respiratory disease does not diminish with time (Huang Ja et al., 2002).
The virus is transmitted via close contact with an infected horse shedding virus in
its nasal secretions or through aerosolized respiratory secretions. Fomites and the ingestion
of contaminated feed are possible sources of infection with virus. An important source of
infection for pregnant mares is the fetus, placenta or any birth fluids from an aborted EHV1 infected fetus (Leblanc, 1999). The incubation period for the respiratory form of EHV-1
infection is 2 to 10 days.
EHV-1 upper respiratory tract infection is primarily a disease of young horses aged
from weaning to 2-3 years. It is unusual for foals under the age of 3 months to show
clinical signs (unless they were congenitally infected), especially if their mothers were
vaccinated. Maternal antibodies are most likely responsible for the protection of these foals
(Huang Ja et al., 2002).
The virus is circulated year round within the horse population. As mentioned
above, the virus goes into latency and can be reactivated at times of stress, providing a
source of infection for other horses. The immunity to the virus is weak and short-lived (3
to 5 months) whether a horse is vaccinated or not, so it is possible for horses to be reinfected (Carman et al., 1997). Respiratory tract infections are a major cause of lost
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training days in thoroughbred race horses (Wood et al., 1999). Respiratory tract infections
may be caused by a variety of different pathogens, including bacterial and viral agents.
Which respiratory pathogen is responsible at any given time in any year varies depending
on the particular population of horses involved and the management practices employed,
but EHV-1 is one of the more common viral pathogens. There is no data available that
gives the annual incidence of infections caused by EHV-1 or the proportion of upper
respiratory tract infections attributable to EHV-1 (Huang Ja et al., 2002). In addition to the
economic losses secondary to lost training days within the racing industry, EHV-1 is
significant because of the potentially serious sequelae that may follow infection with the
virus. These sequelae include abortion, neonatal death, myeloencephalopathy, severe
respiratory disease, ocular disease and secondary bacterial infections.
The presence of EHV-1 carriers in the horse population makes eradication of EHV1 difficult. Therefore, management should focus on disease prevention, through
vaccination and management strategies, rather than eradication or treatment regimes.

Recent Outbreaks
There is a growing concern in the U.S. horse industry over the increased number of
neurologic cases of EHV-1 reported in recent years, as well as the occurrence of several
high-profile outbreaks. The Center for Emerging Issues, part of the Department of
Agriculture's Animal and Plant Health Inspection Service, recently labeled the neurologic
form of EHV-1 as a potentially emerging disease.
Despite the availability and use of currently approved vaccination protocols for
EHV-1, in January of 2003, EHV-1 swept through the University of Findlay’s English
riding facility, infecting 90% of the 138 horses. During the outbreak, both respiratory and
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neurological forms of the disease were seen. Forty-two of these horses exhibited severe
neurological symptoms and were admitted to the Ohio State Veterinary Hospital where
they all subsequently died or were euthanized (Cassiani-Ingoni et al., 2005). Significant
outbreaks prior to Ohio have been reported in Southwestern Virginia, March 1998;
Johnson County Wyoming, July 2001; Northern Virginia, April 2002; and Canada,
October 2002 and January 2003. Most recently, a subsequent outbreak of respiratory and
neurological disease has been reported in horses at the Pennsylvania National Racecourse
outside of Philadelphia (Grantville, PA). The recrudescence of latent infections may lead to
disease despite maintenance of closed populations. Furthermore, with increasing
affiliations within the equine industry, the potential devastating losses during EHV-1
outbreaks are no longer confined to individual farms.
Minimum four cases of equine herpes closed the Northville Downs racetrack in
February 2005, cancelling the live horse racing for a month. In December prior to that, the
racetrack was quarantined after two horses were found to have equine herpes and were
euthanized. A third horse was discovered to have the disease in January in a separate barn,
which alarmed state officials and the barn was under quarantine until February (CassianiIngoni et al., 2005).
Several cases of equine herpes virus were reported at Truro Raceway N.S. in
February 2005, and the local Racing Commission sent out a cautionary advisory to
racetracks (Cassiani-Ingoni et al., 2005). In 2006, 11 outbreaks of the neurologic form of
EHV-1 were reported, four in Maryland and one each in Colorado, Florida, Georgia,
Michigan, New Jersey, Pennsylvania, and Wisconsin (AVMA News Bulletin March 6,
2007). Early 2007 outbreaks included six horses in Virginia, one in Maryland and others.
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Transmission and Seroprevalence
Transmission of EHV-1 occurs via the respiratory route after contact (direct or
indirect) with infected nasal secretions, aborted fetuses, placenta, or placental fluids
(Timoney, 1992). Indirect contamination is also possible through fomites such as human
hands, endoscopes, and feed and water buckets (Huang Ja et al., 2002). Within a few hours
of infection the virus penetrates the epithelial surfaces of the upper and lower respiratory
tracts (Figure I-13). It replicates and disseminates into the stroma, causing collapse of the
lamina propria. Infection then spreads to the draining lymph nodes of the respiratory tract
where the virus infects lymphocytes, monocytes and dendritic cells. The infection of these
immune cells causes immunosuppression and thereby increases the likelihood of secondary
bacterial infections. Cell associated viremia results in the dissemination of the virus
throughout the body. The virus is endothelialtropic, and the interleukin-2 molecules
released during inflammation induce the expression of leukocyte adhesion molecules on
endothelial cells. Virus is passed onto vascular endothelial cells by the attached infected
leukocytes. Infection of the blood vessels occurs within 24 hours of exposure (Mair, 1999).
Endothelial cell infection and ensuing virus replication causes vasculitis and thrombosis.
Vasculitis and thrombosis can cause abortion when it occurs in the vessels supplying the
fetus and placenta, and it can cause neurological disease when it occurs in the CNS
(Wilson, 1997).
An important mechanism by which herpesviruses evade the immune system is
through the suppression of class I MHC molecules. Herpesviruses also evade the immune
system through latency, which is established in the neurons of the trigeminal nerve ganglia
and in the T lymphocytes of the lymphoid tissue draining the upper respiratory tract
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(Huang Ja et al., 2002). During latency only one viral gene is expressed, thereby
preventing neuron apoptosis. When the host undergoes stress of any nature, proteins made
by the host under these conditions activate expression of the herpesvirus. The virus
replicates, travels down the axons, and reinfects epithelial cells. It is then shed by the host
and infects other hosts.
EHV-1 is enzootic in most equine populations world-wide. The seroprevalence of
EHV-1 has been increasing over the past decade, reaching approximately 30% according
to a 1999 survey (Gilkerson et al., 1999a). Studies showed that vaccinations do not alter
the prevalence of EHV-1 antibody-positive foals, such that the cycle of EHV-1 infection
continues in vaccinated mares and their unvaccinated unweaned foals. Foals as young as
11 days old become infected (Foote et al., 2003; Foote et al., 2004). The virus also can be
carried and spread in fetal tissues, the placenta, and the uterine fluids from mares that have
aborted. Virus spread via nasal secretions among weanlings and adults completes the cycle
of EHV-1 transmission to incorporate entire horse population.
Prophylaxis
EHV-1 infections are usually dealt with using management practices that limit
spread of the disease, providing symptomatic relief to infected horses, and treating
potential secondary bacterial infections with antibiotics. Treatment of neurologic outbreaks
with the anti-HSV-1 agent acyclovir (inhibitor of viral DNA replication) did not produce
substantial benefits. Of particular importance to the management of EHV infections is the
fact that these viruses establish latency or unapparent infection that can recur in times of
immune suppression. Upon primary infection of young horses, many will develop
rhinopneumonititis, but all will remain subclinically infected throughout their life
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periodically shedding the virus to infect new horses. Vaccination against EHV-1 helps to
reduce the severity of illness, but it does not prevent the latent infection or the neurological
disease caused by EHV 1.
Vaccination
Of particular importance to the management of EHV infections is the fact that these
viruses establish latency or unapparent infection that can recur in times of immune
suppression. EHV-1 circulates in vaccinated populations of mares and their unweaned
unvaccinated foals, continuing the infectious cycle (Foote et al., 2004). Upon primary
infection of young horses, many will develop rhinopneumonititis, but all will remain
subclinically infected throughout their life, periodically shedding the virus to infect new
horses.
As of molecular interest, generally, all herpesviruses have evolved mechanisms to
facilitate virus-entry into cells through the use of multiple glycoproteins embedded within
their viral envelope. The glycoproteins are efficient primary targets of virus-specific
neutralizing antibody, development of which is coincident with resolution of clinical signs
and resistance to homologous reinfection for 3 to 4 month. When used in conjunction with
appropriate management practices, the current EHV-1 vaccines help to curtail the
respiratory disease and abortion but are ineffective to prevent the neurological form of
disease (Allen et al., 1999a). Horses become seriously ill despite regular vaccinations in
very short intervals. In devastating recent outbreaks, an unusually high number of horses
exhibited the neurological form of the disease. This is alarming because this form of EHV1 infection used to be sporadic and contained to individual animals of an affected herd.
Better treatment options are in high demand.
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Since 1930s, there is ongoing research to design the vaccination programs for
EHV-1, but still numerous limitations are encountered. At its simple, vaccine
administration is complicated by practical difficulty to match the duration of immunity and
the risk period for the disease.
A modified live EHV-1 vaccine of monkey cell line origin was shown to be
associated with neurologic disease in 486 of 60,000 recipients, prompting its withdrawal
from the US market in 1977 (Studdert et al., 1981). There are no reports of EHV-1
myeloencephalopathy associated with use of a modified live vaccine currently approved
for use in horses in the United States. However, there are several limitations with the
current vaccine regimen. Immunity induced by the vaccine only lasts two to three months,
and thus, a year round vaccination program must be administered (Cassiani-Ingoni et al.,
2005). Additionally, whereas these vaccines have been shown to experimentally reduce
disease, the efficacy of vaccination against EHV-1 in the field has yet to be firmly
established.
Although both sporadic and epizootic EHV-1 abortions occurred in immunized
mares, the numbers of fetal and neonatal foal losses decreased significantly (chi 2 = 15.75;
p less than 0.001) from 11.8% (343 of 2897 pregnancies) during the seasons 1969-1973 to
8.9% (334 of 3763 pregnancies) in the years 1975-1982 during which EHV-1 vaccinations
had been carried out (Frymus et al., 1986).
All horses at risk of contracting an EHV-1 infection should be vaccinated.
Vaccinating young horses against EHV-1 does not prevent respiratory infection; however,
vaccination does reduce the severity of clinical signs and the level and duration of viral
shedding. Therefore, goals of vaccination against EHV-1 respiratory infection should
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include minimizing the intensity of clinical signs and limiting spread of the virus within
the population. As immunity arising from EHV-1 vaccination is short lived, booster
vaccinations are required. A typical vaccination schedule begins with two vaccinations, 3
weeks apart, just prior to weaning followed by a booster every 3 to 6 months, depending
on the risk of exposure. Athletic horses that compete in shows and/or races will require
more frequent vaccination. Vaccination should be given 7-10 days prior to an event in
case a local vaccine reaction occurs (Huang Ja et al., 2002).
In order to prevent abortions, pregnant mares can be vaccinated with a killed EHV1 vaccine. Modified live virus vaccines should not be given to pregnant mares. As the
neurological form of the disease may be immune mediated, vaccination is unlikely to offer
protection against this EHV-1 manifestation (McClure and Lunn, 1999). No vaccines to
date have demonstrated definite protection against the neurological form of EHV-1
infection (Huang Ja et al., 2002), (Goodman et al., 2006)
Management
Overcrowding, heavy parasite burdens, poor feed and air quality, transportation,
inclement weather, and mixing of horse populations have been associated with a higher
incidence of infection and disease with EHV-1. Management regimes aimed at preventing
EHV-1 infections should include isolating incoming horses from the resident population
for a minimum of three weeks and minimizing stressors. Regular vaccination and
deworming programs can contribute to reducing the risk of infection. Maintaining the
general health of horses can be achieved by providing good quality nutrition, a clean
environment and protection from the elements (Huang Ja et al., 2002; Sellon, 2001).

75

Mares that have aborted should be isolated, contaminated stalls and paddocks
should be cleaned and disinfected, bedding burned, staff should use protective wear to
avoid animal to animal transfer, and facility quarantined for 30 days after the last abortion
(Leblanc, 1999; Mair, 1999). Booster vaccination (inactivated) during an outbreak may
limit the spread of infection and protect some horses (Mair, 1999).
Prevention is achieved by segregating horses based on age (young horses away
from the mares) and keeping mares in small groups isolated from temporary or new
populations. Any newly acquired animals should be placed in quarantine for 3 weeks
before being introduced to the resident population (Mair, 1999). Minimizing the stress on
mares (stressors, such as parturition, transportation, inclement weather or mixing of social
groups), especially later in gestation, may be of benefit in preventing reactivation of a
latent infection. Vaccinating pregnant mares with an inactivated vaccine at 5, 7 and 9
months gestation has helped reduce the incidence of EHV-1 related abortion. The mares in
addition should receive a yearly booster. If other horses are kept on the property, the
pregnant mares preferably should be handled first (Mair, 1999).
In any presentation of EHV-1 infection isolation of infected horses and a 3 week
quarantine of the farm are paramount. Facilities must be either left empty for three weeks
or disinfected appropriately. The most effective strategy to curtail the infection is to keep
horses minimally stressed and physically segregated, the method poorly applicable to the
modern horse industry with densely populated intermingling high stress environments of
race tracks, boarding stables, and show events. It is important that large equestrian events
have requirements for entry of the horse into a facilty and a good plan for temporary
quarantine of new arrivals as well as rapid infection and disease control response.
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Figure I-12. Pathogenesis of EHV-1 infection.
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Viremia

EHV-1 Pathogenesis and Clinical Presentation
Respiratory
Of the two most common viruses, EHV-4 is by far more commonly isolated from
cases of herpesvirus respiratory disease (Foote et al., 2004; van Maanen, 2002), while
respiratory infection by EHV-1 has the greater potential for clinically severe sequelae
including abortion, neonatal foal death, neurological disorders, peracute pulmonary
vasculitis, and ocular disease. Disease severity depends on previous exposure or infection,
health status, concurrent infections and the virulence of the particular EHV-1 strain (Huang
Ja et al., 2002). Among the eight equine herpesviruses identified to date, EHV-1 is one of
the most pathogenic herpesviruses of horses.
Equine respiratory disease associated with EHV-1 infection of the upper airway
mucosal epithelium is a condition routinely seen primarily in young horses, weanlings and
up to 2 year old horses in training or performing (Timoney, 1992). Clinical signs include
depression, poor appetite, nasal discharge and cough. Clinical upper respiratory tract
disease (URTD) caused by EHV-1 is acute and infection spreads rapidly within a
population via aerosolized respiratory secretions or virus-contaminated fomites. The
majority of respiratory infections run a subclinical course. Older horses generally show
mild or subclinical signs, while younger horses are usually protected by passive immunity
(Mair, 1999). Diagnosis cannot be made on the basis of presenting clinical signs alone and
requires laboratory confirmation.
Natural infection with EHV-1 occurs by inhalation or ingestion, after which the
virus attaches to, and rapidly replicates in, cells of the nasopharyngeal epithelium and
associated lymphoreticular tissues, causing necrosis, exudation, and infiltration of
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phagocytic cells (Figure I-13). The incubation period is from 2 to 10 days (Timoney,
1992). Bronchial and pulmonary tissues also become infected, particularly in foals,
predisposing them to secondary bacterial pneumonia. The respiratory form is referred to as
rhinopneumonitis and is characterized by rhinopharyngitis and tracheobronchitis.
Clinical signs are the most severe and viral shedding greatest during the first few
days of infection. Bilateral nasal discharge is most common clinical finding. Initially the
discharge is serous, in 2-3 days of infection, the discharge becomes mucopurulent with
inflammatory cells and desquamated respiratory cells, and commonly progresses to
purulent with an advent of a secondary bacterial infection (Huang Ja et al., 2002). Affected
horses may be febrile (39˚ - 42˚C) and the viremia may coincide with a second fever spike
(Timoney, 1992). For 9–14 days starting from 4–6 days post EHV-1 infection, an extensive
cell-associated viremia is detectable (Gibson et al., 1992).
Migration of virus-infected phagocytes into the circulation results in a T
lymphocyte associated viremia. Viremia is associated with, T-cell lymphopenia and
appearance of blastic cells (McCulloch et al., 1993) and may occur in the presence of virusneutralizing antibodies (Doll and Bryans, 1963; Mumford et al., 1987). T-lymphocytes are
the most susceptible of the peripheral blood mononuclear cells (PBMC) and carry EHV-1
to distal organs (Scott et al., 1983). Both neutropenia and lymphopenia are often present.
Other clinical signs include mandibular and/or retropharyngeal lymphadenopathy,
conjuctivitis with mild ocular discharge, depression, anorexia, coughing, and respiratory
distress (Huang Ja et al., 2002; Timoney, 1992). Juvenile horses may develop vesicular and
erosive lesions in the mucous membranes of the upper respiratory tract (van Maanen,
2002). By contrast, infections with EHV-4 are restricted to respiratory tract epithelium and
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associated lymphatic glands. Leukocyte associated viremia is not found with EHV-4
infections (Timoney, 1992). Complete recovery from uncomplicated infection generally
occurs within several weeks, (Mair, 1999).
EHV-1 viremia occurring in primary and all recrudescing infections occurs
subclinically, but poses a threat of inducing abortion, as well as neurological disease. The
ability of EHV-1 to spread from cell-to-cell without an extracellular phase, via virus
mediated cell-to-cell fusion, enables it to avoid inactivation by circulating neutralizing
antibody and permits dissemination to other tissues. Trigeminal ganglia, circulating T
lymphocytes and lymphoid tissues draining the respiratory tract, are the sites for
establishment and maintenance of the lifelong state of latency characteristic of all
herpesviruses. Immunity following recovery lasts only 3-6 month and reinfection and
asymptomatic viral shedding may occur at these times (Timoney, 1992).
The cycle of a persistent latent infection with intermittent reactivation and shedding
keeps EHV-1 circulating within the equine population.

Peracute Pulmonary Vasculitis
This is a more recently described, sporadic condition affecting young adult horses,
where EHV-1 induces nonneurological fatal disease, characterized by prominent
vasculotropism. In this syndrome, horses exhibit high fever, depression, loss of appetite,
and respiratory distress with no neurological signs. Clinical deterioration is rapid and
mortality rates from respiratory failure are high (Huang Ja et al., 2002; van Maanen,
2002). The main target of the virus in this condition is the pulmonary endothelium, and
post-mortem examination shows severe pulmonary vasculitis with acute edema,
leukocytosis, and perivascular hemorrhage (Blunden et al., 1998; Hamir et al., 1994).
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Figure I-13. Virus spread among tissues and body systems. In response to infection, reinfection or reactivation from latency, the respiratory epithelium is invaded by the virus,
which gains access to the subepithelium and lamina propria. Here the virus is able to infect
the monocytes, endothelial cells of the blood vessels as well as lymphocytes in route for
lymphatic vessels. Once the lymph nodes are infected, infected lymphocytes leave the node
resulting in a cell-associated viremia and spread of the virus to various sites around the
body via the blood and lymph vessels. Endothelial cells at distal sites are then infected
resulting in inflammation and vasculitis. Thrombosis, ischemia, and infarction lead to
further tissue necrosis and organ dysfunction.
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Abortion and Neonatal Disease
Equine herpesvirus type-1 is the most common cause of infectious abortion in
horses (Leblanc, 1999), accounting for diagnosed 10% of abortions in thoroughbreds (van
Maanen et al., 2000). The prevalence of EHV-1 abortion varies and it may appear as
sporadic cases or as abortion “storms” on stud farms, with few to large number of mares
affected. The risk for abortion is increased if the mares are kept in crowded conditions and
if they are exposed to new horses (Leblanc, 1999). An infected, re-infected or reactivated
mare can then provide a source of infection for non-immune mares resulting in abortion
storms and cases of neonatal syndrome and death (Murphy et al., 1999).
The period between infection and abortion varies from 9 days to 4 months but most
mares abort within 21 days (Powell, 1991). Ninety-five percent of abortions usually occur
late in gestation, typically between 7 to 11 months (Powell, 1991) in a mare showing no
clinical signs. The mare is potentially infectious to other horses for 4 weeks. While the
future reproductive ability of a mare is not compromised (Huang Ja et al., 2002), it is
recommended not to re-breed the mare for 30 days. The risk of abortion remains in future
pregnancies due to reactivation of a latent infection or re-infection at that time. The aborted
fetus, placenta and birth fluids are a potential source of infection for other mares and
should be removed and disposed (Powell, 1991).
To result in abortion, EHV-1 must infect in sequence three separate types of cell
and three separate organ systems. In response to infection, re-infection or reactivation from
latency, as described previously, the respiratory epithelium of the affected mare is invaded
by the virus, which gains access to the subepithelium and lamina propria. Here the virus is
able to infect the monocytes, endothelial cells of the blood vessels as well as lymphocytes
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reaching lymphatic vessels. Once the lymph nodes are infected, infected lymphocytes
leave the node resulting in a cell-associated viremia and spread of the virus to various sites
around the body via the blood and lymph vessels. Endothelial cell infection triggers
inflammatory cascade which combined with direct cell damage may lead to thrombosis,
ischemia, and infarction.
Consequently, microcotyledons of the placenta undergo necrosis and premature
separation of the placenta may be triggered. If the thrombosis and infarction are severe, the
fetus dies of hypoxia and is expelled. He may not be positive for viral antigen. If the
thrombosis is localized and is not severe, the virus may reach the fetus and affect various
organ systems. The foal then dies because of viremia, interstitial pneumonia, and focal
liver necrosis (Leblanc, 1999) and is expelled. It is also possible for thrombosis and
infarction to be minimal and cleared, allowing for the birth of a normal foal (Allen et al.,
1999b).
Foals that are infected by EHV-1 in the mare and are born alive, are either sick at
birth or become ill within the first few days and up to 2 weeks from birth. Clinical signs
may include weakness, depression, difficulty nursing, pyrexia, lymphopenia, and
respiratory distress secondary to interstitial pneumonia. The foals may also have evidence
of gastrointestinal disease (watery diarrhea) and neurological signs such as visual and
vestibular (Dixon et al., 1978). Secondary bacterial infections with Salmonella species and
Escherichia coli are common. EHV-1 has a predilection for vascular epithelium of the
nasal mucosa, lung, adrenal, thyroid, and CNS. The disease progression is rapid and
mortality due to interstitial pneumonia that results in hypoxia and respiratory failure is at
100%.
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Myeloencephalopathy
The neurological form of EHV-1 is an uncommon but serious manifestation of
infection with the virus. Neurologic outbreaks occur concurrently with respiratory illness
or abortion, or they may occur alone (Hahn et al., 1999; Timoney, 1992). The exact
reasons why some EHV-1 infections are associated with a high incidence of neurological
disease, whereas others are not, or why horses show different clinical manifestations of
infection during an outbreak are still under investigation (Wilson, 1997).
There is no breed or sex selectivity to EHV-1 myeloencephalopathy, though
pregnant mares in early to mid gestation may be more susceptible. Route of infection and
the immune status of the horse seem to be contributing factors. While foals may develop
the disease; it is much more common in older horses. The majority of EHV-1 infections
that lead to neurologic sings represent reinfection rather than a primary infection (Wilson,
1997). Therefore, immunological reaction to the EHV-1 infection leading to vasculitis and
thrombosis was thought to be partially responsible for the observed neurological damage.
Supporting this, one study showed that vaccinated horses were significantly more
likely to develop a neurological manifestation of infection than were non-vaccinated
animals (Wilson, 1997). In contrast another study showed that vasculitis was not present in
vessels in which endothelial cells did not support viral replication, suggesting that certain
EHV-1 strains may be particularly neurotropic. Although unproven, it was proposed that
the 1-p and 1-b substrains may preferentially produce the neurological form (Wilson,
1997). The propensity of certain EHV-1 isolates to induce myeloencephalopathy was also
considered to be a reflection of marked endotheliotropism rather than specific
neurotropism (Hasebe et al., 2002). Thus, virus recognition and infection of specific cell
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types, neuronal, endothelial, or lymphocytic, through various cellular receptors may be the
ultimate basis for the specific clinical manifestations associated with EHV-1 infection
outbreaks.
The acute onset of clinical signs of diffuse multifocal hemorrhagic
myeloencephalopathy usually peaks within 48 hours and appears to be the result of
vasculitis and thrombosis of arterioles in the brain and especially the spinal cord (Hasebe
et al., 2002; Wilson, 1997). The primary lesion is a vasculitis (arteritis), with neural
parenchyma affected by secondary hemorrhagic and ischemic infarction. The vasculitis
and thrombosis of arterioles in the brain and especially the spinal cord lead to functional
impairment of blood flow and metabolic exchange. Sometimes hypoxic degeneration and
malacia with hemorrhage into adjacent neural tissues of the white and to a lesser extent, the
grey matter occurs (Wilson, 1997).
Clinical signs are variable and depend on the location and severity of the lesions
(Wilson, 1997). A fever occurs (up to 41.1 ˚C), with or without a cough and serous nasal
discharge. The horse may begin to show signs of clumsiness or stiffness, progressing to
paresis and ataxia of the trunk and limbs with dog sitting and lateral or complete
recumbency (Timoney, 1992). Paralysis or paraplegia of the hind limbs leading to
recumbency, if it occurs, is usually within the first 24 hours. Paralysis may be so severe
that the horse cannot lift its head, though appetite and mentation remain normal. Conscious
proprioceptive deficits can be observed (Wilson, 1997) as well as loss of sensation and
sensory reflexes in the perineal area, inguinal areas and hind limbs(Timoney, 1992).
Hindlimb edema is a frequent sign, and may be accompanied by scrotal edema (Wilson,
1997). There is often bladder distention that leads to urinary incontinence and vulvar or
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penile flaccidity with cystitis as a common complication. Tail elevation, decreased or loss
of tail tone is inconsistent finding. Depression, nystagmus, eye deviation, and other signs
of brainstem involvement may occur (Hahn et al., 1999).Clinical signs are most commonly
bilaterally symmetrical, though may be unilateral (Wilson, 1997).
Morbidity rates range from less than 1% to almost 90% of exposed horses, while
mortality rates range from 0.5% to 40% (Wilson, 1997). Time to recovery depends on
severity of first signs and ranges from several days to 18 months (Hahn et al., 1999),
clinically varying from complete recovery, through recovery with retention of neurological
deficits, to death (Timoney, 1992).. Horses that are only mildly affected may recover in as
little as hours to days. Recumbent horses may die in coma or convulsion, and many are
euthanised due to secondary complications, however recumbent horses should not be
preemptively euthanised, as many can make a full recovery (Wilson, 1997). Recurrence of
neurological signs in recovered horses has not been documented (Wilson, 1997).

Ocular Disease
A potentially serious complication following equine herpesvirus -1 infection,
particularly in foals, is severe ocular disease. Upon recovery from mild, transient EHV-1
infection foals may develop visual impairment secondarily to chorioretinitis (Slater et al.,
1992). Uveitis and chorioretinitis have also been reported in foals following an outbreak of
EHV-1 myeloencephalopathy (McCartan et al., 1995), with nursing foals of mares with
EHM being at highest risk of developing this manifestation of EHV-1. Virus is capable of
producing ocular and neural damage, even without obvious neurological impairment
(Slater et al., 1992). Currently, it is unclear whether ocular disease represents a separate
complication in itself or whether it is another manifestation of EHM.
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Laboratory Diagnosis
Respiratory
Respiratory EHV-1 infection can be diagnosed by virus isolation from
nasopharyngeal swabs or PCR. PCR is a more sensitive method. Antigen capture ELISA
can be used, but it is the least sensitive approach. Samples should be taken in the early
febrile period of the disease (van Maanen, 2002). Differentiation from equine influenza,
equine viral arteritis, EHV-4, and other respiratory infections can only be made with acute
and convalescent serum samples in addition to virus isolation (Timoney, 1992). Virus can
be isolated in a variety of cell cultures, including those derived from the horse, monkey
(Vero), and rabbit (RK-13). By contrast EHV-4 cannot be propagated in cell lines of nonequine origin, providing additional method of virus differentiation.
Abortion
The diagnosis of EHV-1 abortion is made through history, the gross and
histological findings on necropsy, virus isolation and evidence of viral antigen in fetal
tissues (Timoney, 1992). An aborted fetus secondary to EHV-1 infection will usually not
be autolyzed. Clinical specimens for viral abortion diagnosis include placenta, fetal lung,
liver, thymus, adrenal glands and spleen sent for virus isolation, immunofluorescence, PCR
and histological examination. One set of tissues is submitted on ice and a second set in
formalin. The chance of diagnosing a viral abortion is cut in half if the placenta specimen
is not provided. Gross lesions at necropsy include severe pulmonary edema, interstitial
pneumonia, myocardial and adrenal gland petechiation, multifocal hepatic necrosis and
thymic necrosis. On histological examination, focal hepatic necrosis, pulmonary
inflammation and lymphoid necrosis in the lymph nodes, spleen, thymus and Peyer’s
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patches are characteristic. The finding of eosinophilic intranuclear inclusions in fetal
tissues by histopathologic examination of the liver, thymus and bronchial epithelium is
supportive (Leblanc, 1999). Confirmation is most easily and rapidly obtained by the
demonstration of viral antigens in infected cells by immunofluorescence examination of
cryostat sections of affected tissue. Serology from aborted mares is not very useful because
of the delay between infection and abortion (Powell, 1991).
Neonatal Disease
As for abortion cases, the diagnosis of neonatal disease secondary to EHV-1
perinatal infection is often based on history, clinical signs, necropsy findings as well as
immunofluorescence and virus isolation from tissue at necropsy. If a foal has not had
colostrum, it may have significant virus neutralizing antibodies demonstrable by serology.
(Leblanc, 1999). As compared to septic and premature foals, EHV-1 infected foals
commonly have higher mortality, white blood cell counts less than 3x109/L, and icterus.
Despite common profound hepatic necrosis in the herpes positive foals, liver enzymes may
not be elevated (Perkins et al., 1999). On gross examination at necropsy, foals will have
interstitial pneumonia with heavy edematous lungs and potentially, areas of atelectasis and
evidence of secondary bacterial infection. Splenic and thymic hypoplasia, adrenocortical
hyperplasia, hemorrhage and necrosis as well as ventricular subepicardial and
subendocardial petechiae may be evident (Bryans et al., 1997; Hartley and Dixon, 1979).
On histological examination, lung tissue from affected foals shows congestion, edema and
focal necrotizing bronchiolitis. Hyaline membrane formation may be present. Intranuclear
inclusion bodies may be found in bronchiolar epithelial cells and hepatocytes, but
generally may not be as clearly evident in organs of older foals (Hartley and Dixon, 1979;
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Leblanc, 1999; Savage, 1999). The liver may have foci of hepatocellular necrosis (Savage,
1999), while massive thymic parenchymal necrosis may be evident (Hartley and Dixon,
1979). EHV-1 in liver, spleen, and lung can often be detected by immunohistology and
electron microscopy (Jonsson et al., 1989).
Myeloencephalopathy
Diagnosis of EHV-1 associated central nervous system disease is more difficult.
Presumptive diagnosis of EHV-1 myeloencephalopathy can be made from the history.
Sudden onset and early stabilization of neurological signs are characteristic of EHV-1.
When there is a recent history of fever, abortion, or viral respiratory disease in the horse or
its herdmates, EHV-1 should be suspected (Wilson, 1997). Clinical specimens include
nasal swabs, whole blood, cerebrospinal fluid, acute and convalescent sera, brain, and
spinal cord from horses with central nervous system disease. Infection may be assumed if a
significant increase in specific antibody can be demonstrated between acute and
convalescent sera, but most horses with EHV-1 myeloencephalopathy do not show a fourfold rise in serum neutralizing titer and in some, there is even a decline(Wilson, 1997).
Antibodies to EHV-1 in the CSF are a variable finding (Wilson, 1997). Elevated protein
and CSF to serum albumin ratio reflect vasculitis and leakage into CSF (Wilson, 1997).
Xanthochromia and an elevated protein level in CSF are supportive evidence for EHV-1
(Hahn et al., 1999). The virus may be isolated from nasal swabs and buffy coat of the
blood from acutely affected horses, but the virus shedding has often ceased at the time of
onset of neurological signs. The virus is difficult to isolate from central nervous system
tissue post mortem (Timoney, 1992; Wilson, 1997). At necropsy, a brownish patchy
discoloration may be seen grossly in the brain and spinal cord. Histologically, vasculitis
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with ischemic and hemorrhagic infarction as well as perivascular edema and necrosis of
parenchyma are observed (Timoney, 1992).
Ocular Disease
On histological examination of ocular disease in foals, a mononuclear cell infiltrate
is present in the cerebral cortex, cerebellar choroid plexus and cervical dorsal root
ganglion. The optic nerve is demyelinated. Bilateral degeneration of the neurosensory
retina, retinal pigment epithelium and choroidal layers is evident in the eyes.

EHV-1 Treatment
Current Recommendations
EHV-1 infections are usually dealt with using management practices that limit
spread of the disease, providing symptomatic relief to infected horses, and treating
potential secondary bacterial infections with antibiotics. Current recommendations of
treatment of EHV-1 infections in horses include the use of steroids, non-steroidal antiinflammatory agents, and nucleoside analogs as well as some other compounds used to
treat EHV-1-associated neurological symptoms like paresis, paralysis, ataxia, distention of
the urinary bladder, stiffness of pelvis or ocular damage, but no specific treatment is
available.
Supportive Care
EHV-1 infected horses should be kept quiet and have adequate supportive care.
Stall rest in a well ventilated, dust-free environment is essential for the EHV-1 infected
horse showing respiratory signs. Antibiotics may be given prophylactically to prevent
secondary bacterial infections (van Maanen, 2002). More specific antibiotics are prescribed
to target any secondary infections that develop (Wilson, 1997). Supportive treatment for
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neonatal disease including fluid therapy, antibiotics, steroids and assisted ventilation are
minimally effective (Dixon et al., 1978).
Treatment of equine myeloencephalopathy is limited to supportive therapy and
management of patient comfort and secondary complications. Horses should be
encouraged to remain standing, and slings should be used to support moderately affected
horses that cannot stand on their own. Recumbent horses should be rolled every 2 to 4
hours to reduce the risk of myonecrosis and decubital ulcers. Intravenous fluids are
indicated in dehydrated patients. To maintain gastrointestinal system, laxatives or bran
mashes should be given, and manual evacuation of the bowel may be necessary to prevent
impaction and to maintain patient comfort. Some horses may need to be fed and watered
via a stomach tube or intravenously. Cystitis is a frequent complication, especially in
recumbent horses. Careful catheterization may be indicated, as well as treatment with
antibiotics. Urine scald can be prevented and managed with washing of the perineum and
application of repellent ointment, as well as wrapping the tail to keep it out of the way
(Wilson, 1997).
Corticosteroids
The treatment with corticosteroids is recommended because vasculitis, hemorrhage,
and edema are prominent early lesions of EHV-1 myeloencephalopathy and may have an
immune basis. However no objective data to document their efficacy is available, and their
use has to be weighed against the detrimental effects on immune function thus
exacerbating virus shedding as well as the possibility of inducing laminitis.
A short course glucocorticoid treatment with prednisolone acetate (1 to 2 mg/kg
q24hr) or dexamethasone (0.05 to 0.25 mg/kg q12hr for 2-3 days) is used to treat
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inflammatory conditions by blocking the release of arachidonic acid (Cassiani-Ingoni et
al., 2005). Experiments with HSV 1 in the past showed that the viral yield increased when
cells were treated with dexamethasone (Cassiani-Ingoni et al., 2005). The beneficial antiinflammatory effects of corticosteroids can be dramatic, but substantial complications may
ensue including immunosuppression, prolonged virus shedding, delayed healing, and
corticosteroid-associated laminitis.
Non-steroidal Anti-inflammatory Agents
Non-steroidal anti-inflammatory drugs (NSAIDs), such as phenylbutazone or
flunixin meglumine, are typically given to febrile horses to reduce the fever, thereby
encouraging horses to eat and drink (Allen et al., 2002b). Flunixin meglumine, a cyclooxygenase inhibitor, is a potent analgesic, antipyretic, and anti-inflammatory agent. It can
be used to treat EHV-1-induced vasculitis in the CNS at 1.1 mg/kg (Cassiani-Ingoni et al.,
2005). Dimethyl sulfoxide can be used to relieve typical IC, where symptoms including
pelvic pain, perineal pain, nocturnal urinary urgency, urinary frequency and constant
sensation of the urge to void.
Nucleoside Analogs in Treatment of EHV-1 infection
Dosing protocols for known antiviral drugs used to treat EHV infections are
currently based on extrapolation from well established dosage regiments used for treatment
of human infections with HSV-1 and VZV and have not proved to be effective (Huang Ja
et al., 2002). Data describing the pharmacokinetics, bioavailability, and safety of acyclovir
in horses are lacking.
Acyclovir, a synthetic purine nucleoside analog with viral DNA replication
inhibitory activity against several human herpesviruses, has been shown to exert an
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inhibitory effect on EHV-1 in vitro (Smith et al., 1983). Nucleoside analogues such as
acyclovir and pencyclovir have been used off label with variable effects in the treatment of
EHV-1 myeloencephalopathy. Several cases showing significant improvement when
treated with acyclovir were reported, but it is not known whether acyclovir actually
influenced the outcome in these cases (Friday et al., 2000; Murray et al., 1998). Treatment
of neurologic outbreaks with the acyclovir did not produce substantial benefits (CassianiIngoni et al., 2005).
EHV-1 and -3, HSV-1 and -2, and cercopithecine herpesvirus virus were all
sensitive in vitro to 9,((2-hydroxy-1-(hydroxymethyl)ethoxyl) methoxyl) guanine (BIOLF62), another nucleoside analogue, at concentrations of less than 0.55 micrograms/ml
(Cassiani-Ingoni et al., 2005).

Antivirals
The common classes of antiviral agents currently in overall use are nucleoside and
pyrophosphate analogues, direct non-nucleotide DNA polymerase or reverse transcriptase
inhibitors, and endogenous cytokines, while countless other classes are being investigated.
Newest class of antiviral agents was developed to combat HIV-1 infections and
includes such compounds as Amantidine and Rimantidine, which inhibit the M2 protein of
the virus to decrease hydrogen ion influx through a specific H+ ion channel, inhibiting viral
uncoating during entry and coating process at egress. Currently available fusion inhibitors
such as Enfuviritide and T1249 were also developed against HIV-1. Amprenavir is a
sulfonamide compound that was introduce in the market as an HIV protease inhibitor.
Despite the success of this drug, it has some shortcomings including gastrointestinal side
effects and long term metabolic disturbances (Hanlon et al., 2004; Miller et al., 2004).
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Current Antiherpetics
Nucleoside analogues such as acyclovir and ganciclovir have been the
mainstay of therapy for alphaherpesviruses, such as HSV, VZV, and CMV infections (see
Table I-8). Active compounds currently available for the treatment of herpes virus
infections include the nucleoside analogues: acyclovir (Zovirax, GlaxoSmithKline,
Middlesex, UK) and its valyl-ester prodrug valacyclovir (valtrex, GlaxoSmithKline,
Middlesex, UK), the valyl-ester prodrug of pencyclovir - famciclovir (famvir, Novartis,
New York, NY), penciclovir, vidarabine, and ganciclovir (cytovene, Hoffmann LaRoche)
and its prodrug valganciclovir (valcyte, Hoffmann LaRoche, Nutley, NJ), the acyclic
nucleoside phosphate (ANP) derivative cidofovir (vistide, Gilead Sciences, Boulder, CO),
the pyrophosphate analogue foscarnet (foscavir, Astra-Zeneca, Boston, MS) as well as the
CMV antisense molecule fomivirsen (vitravene, Novartis, New York, NY). More
specifically, antiviral agents currently lisensed for the treatment of HSV and VZV
infections include acyclovir, valacyclovir, famciclovir, penciclovir, foscarnet. For CMV
infections: ganciclovir, valganciclovir, cidofovir, foscarnet, and fomivirsen. Except for the
CMV antisense molecule, all compounds terminate viral DNA synthesis by inhibiting the
viral DNA polymerase (Table I-8).
While some of these antiviral therapies are considered safe and efficacious
(acyclovir, penciclovir), some have toxicities associated with them (ganciclovir and
foscarnet). Several of the currently available therapies can result in mild to severe side
effects making the discovery of less toxic drugs desirable. Prolonged use of these
compounds in the clinical setting has led to the emergence of human viral resistance
against most of these drugs. Because nucleoside analogues share a similar mechanism of
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action, treatment options are limited once resistance develops. Efforts over the last decade
have focused on the identification and development of improved therapies including less
toxic compounds with novel mechanisms of action.
Acyclovir, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one, is a
white, crystalline powder with the molecular formula C8H11N5O3 and a molecular weight
of 225 (Figure I-14). Recently, acyclovir was shown to inhibit the wild-type HIV strain
infection at a 50% inhibitory concentration (IC50) of ~ 5 µM (McMahon et al., 2008).
Current published dosing of acyclovir for treatment of EHV-1 starts with the
loading dose of 27 mg/kg of acyclovir every 8 h for 2 days, followed by a maintenance
dose of 18 mg/kg every 12 h, will maintain effective serum acyclovir concentrations (L. K.
Maxwell, 2008). Small interfering RNA (siRNA) designed against ORF of gB and originbinding viral helicase resulted in reduction of viral replication in the murine model of
respiratory disease (Fulton et al., 2009).
Table I-8. Antiviral compounds against alphaherpesviruses.
Compound

Trade Name

Chemistry

2nd generation

foscarnet

pyrophosphate analogue

cidofovir

acyclic nucleoside phosphonate
derivative

acyclovir
valacyclovir
famciclovir

ganciclovir
valganciclovir
cidofovir
foscarnet
fomivirsen

Zovirax, GlazoSmithKline
valtrex, GlaxoSmithKline
famvir, Novartis
penciclovir
Valtrex/Zelitrex
Denavir
Abreva
vidarabine
cytovene, Hoffmann LaRoche
valcyte, Hoffmann LaRoche
vistide, Gilead Sciences
foscavir, Astra-Zeneca
vitravene, Novartis
Cytovene, Valcyte

valyl-ester prodrug
valyl-ester prodrug of penciclovir

ganciclovir prodrug
acyclic nucleoside phosphate (ANP)
derivative
pyrophosphate analogue
CMV antisense molecule
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Clinical
Application
HSV, VZV,
CMV
CMV
HSV, VZV
HSV, VZV
HSV, VZV
HSV, VZV
HSV, VZV
HSV, VZV
HSV, VZV
HSV, VZV
CMV
CMV

CMV
CMV

Figure I-14. Chemical structure of Acyclovir, 2-amino-1,9-dihydro-9-[(2hydroxyethoxy)methyl]-6H-purin-6-one.
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CHAPTER II. ANTIVIRAL SCREENING
INTRODUCTION
Hypothesis and Goals
The central hypothesis of the proposed investigations is that porphyrin compounds
can specifically inhibit membrane fusion phenomena required for virus entry and virus
spread. Such inhibition would be achieved via interactions with one or more viral
glycoproteins required for membrane fusion. It is expected that the antiviral activity can be
enhanced by further modification of the chemical structure of the porphyrin compounds.
Our immediate goal addressed in this chapter, was to identify a few relatively small
organic compounds that possess strong antiviral properties against EHV-1 infections.
Specifically, two classes of compounds were investigated: porphyrin and platinum
compounds. Representatives of these classes of compounds have been already found to
possess potent antiviral activities against human immunodeficiency virus (HIV), vaccinia,
and coronaviruses (Vzorov et al., 2003). The following chapter describes our approach to
define the molecular basis for their actions in cell culture experiments and to further
modify their chemical structure to enhance their antiviral potency.
It was envisioned that the proposed investigations will lead to the development of
antiviral strategies used as prophylactic treatment for successful combating EHV-1 acute
infections of horses.

Significance of EHV-1 Infections and Need for Therapeutic Options
The development of new antiviral or virucidal compounds for the prophylactic and
therapeutic treatment of EHV1 infection is necessary to avoid economic loss to the horse
industry. Louisiana ranks fifth nationwide in terms of economic impact on its horse
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industry, contributing over $2.45 billion to the state's economy (Deloitte-Consulting,
2005). As described previously, EHV-1 is enzootic in most equine populations. The
seroprevalence of EHV-1 has been increasing over the past decade, reaching
approximately 30% according to a recent survey (Gilkerson et al., 1999a). Clinical upper
respiratory tract disease (URTD), rhinopneumonitis, caused by EHV-1 infection of the
upper airway mucosal epithelium is an acute condition seen primarily in young horses.
Infection spreads rapidly within a population via aerosolized respiratory secretions or
virus-contaminated fomites. Although, the majority of respiratory infections run a
subclinical course, viremia occurring in primary and all recrudescing infections have a
great potential for clinically severe sequelae such as late term abortion, neonatal foal death,
neurological disorders (paresis/paralysis), myeloencephalopathy, ocular disease, or death
by peracute pulmonary vasculitis. Diagnosis cannot be made on the basis of presenting
clinical signs alone and requires laboratory confirmation.
Current EHV-1 vaccines help to curtail the respiratory disease and abortion, but are
ineffective against the neurological form of infection. Horses become seriously ill despite
regular vaccinations in very short intervals. In devastating recent outbreaks, an unusually
high number of horses exhibited the neurological form of the disease. This is alarming
because this form of EHV-1 infection used to be sporadic and contained to individual
animals of an affected herd. Better treatment options are in high demand. Currently,
several compounds have been used to address EHV-1-associated neurological symptoms
like paresis, paralysis, ataxia, distention of the urinary bladder, stiffness of pelvis or ocular
damage, but no specific treatment is available. Dosing protocols for known antiviral drugs
used to treat EHV infections are based on extrapolation from well established dosage
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regiments used for treatment of human infections with HSV-1 and VZV. Vaccine
ineffectiveness to curtain neurologic manifestation of the infection or virus spread through
the population, as well as limited therapeutic options, make the development of vaccine
and other prophylactic strategies, as well as options for antiviral treatments of affected
horses necessary.

Literature Review of Porphyrins
Classes of Potential Microbicides
Porphyrins are a group of naturally occurring and intensely colored compounds,
whose name is drawn from the Greek word porphura, a word for purple (Anderson, 1999;
Milgrom, 1997). Porphyrins were originally under consideration as topical microbicide,
specifically for intravaginal application for HIV prophylactic. There are various groups of
potential microbicides (see Table II-1): polyanionic molecules, surfactants, various natural
products, peptides, heterocycles, and various virucidal agents. The specific microbicides
exemplifying each group are those that are best described, since they have been evaluated
for their potent anti-HIV activity.
The first generation antiviral/microbicides candidates were surfactants, with most
notable of these products, nonoxynol-9 (N-9). It has been shown to be ineffective in
preventing HIV, or even harmful (Roddy et al., 1993). The second generation microbicides
were polymers. Having more focused spectrum of activity, they interfered with viral
attachment to host cells. Several efficacy trials with different polymers, such as PRO 2000,
Carraguard, Cellulose Sulfate, and Dextrin-2-Sulfate, have been underway. Several other
entry inhibitors are currently in pre-clinical stages of development. The latest generation of
microbicides targets attachment, a critical step of the viral life cycle, during which the
99

virus binds to the receptors on the cell surface. The future of the anti-HIV microbicide
development would likely focus on attachment and fusion inhibitors or co-receptor
blockers. The main consideration in such microbicide or any antiviral design, is the level
of toxicity at therapeutic doses, potential for rapid establishment of resistant isolates, as
well as the expense of production using currently available technology.
Table II-1. Examples of potential microbicides evaluated for anti-viral activity.
Group
Polyanionic
molecules
Buffers
Surfactants
Entry blockers
Fusion inhibitors
Natural products
Peptides
Proteins
Heterocycles
Virucidal agents
Antiretroviral agents

Potential Microbicides
napthalene sulfonates, sulfated polysaccharides, polycarboxylates
and polyoxometalates
engineered lactobacillus, hydrogen peroxide/peroxidases,
Buffergel
N-9, Benzalkonium chloride, C31G-Savvy, Chlorhexidine zinc
gel, detergents
Carraguard/PG515, PRO2000 gel, Emmelle/Dextrin-2-Sulfate
CCR5 inhibitors, soluble CD4
tannins, plant lectins, betulinic acid derivatives and macrolides
natural and synthetic surface active agents, CPFs, T20, T21 and
lexitropsins
negatively charged albumins and cyanovirin-N
bicyclams, monensins, porphyrins, diaminoacridones and
phenazines
azodicarbonamide
non-nucleoside RT inhibitors, inhibitors of post-fusion
replication, nucleoside RT inhibitors (e.g. Tenofovir), NNR-TIs
(UC-781), protease inhibitors

Structure of Porphyrins
Tetrapyrrole is a term referred to a member of class of compounds whose
molecules have four rings of the pyrrole type (C4H5N), generally linked together on
opposite sides by single-atom bridges, usually the four methine (=C-) bridges (Figure II-1).
The common arrangements of the four rings for which this name is used are macrocyclic,
as in the porphyrins and linear, as in the bile pigments (Figure II-2). The famous members
of this family include bilirubin, chlorophylls, cytochrome, and heme as part of
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hemoglobin. Natural tetrapyrroles are critical for biological processes of energy and
electron transfer like photosynthesis or in the respiratory chain. Synthetic tetrapyrroles,
like phtalocyanines become more important not only as colors, but also as photoactive
compounds in photovoltaic, photomedicine, molecular electronics and other fields.
3

4

5

6

7

2

8

NH

1
20

N

21

22

24

23

N

19

9
10

HN

11

18

12
17

16

15

14

13

Figure II-1. The macrocyclic tetrapyrrolic ring system named porphyrin.

Bilirubin

Chlorophyll

Cytochrome P450

Heme

Figure II-2. Examples of natural tetrapyrroles. These critical to life molecules play
important biological roles. They are natural pigments containing four pyrrole rings joined
by one carbon each into a macrocyclic tetrapyrrole.
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Current Use of Porphyrins
Porphyrins are in use as photodynamically activated agents for cancer, psoriasis,
and macular degeneration. Porphyrins in photodynamic therapy or porphyrin based
detection treatment (PDT) are used as tumor localized photosensitizer (chelated metal
without a central metal or with a diamagnetic central metal), which reacts with molecular
oxygen and other substrates to generate highly cytotoxic species that destroy tumor tissue.
Photosensitizer are molecules, which, when excited by light energy, can utilize this
energy to induce photochemical reactions to produce lethal toxic agents. In a cellular
environment within the immediate area of light illumination, these agents (singlet oxygen
(1O2), hydroxyl radicals (•OH), and superoxide (O2−) ions) can interact with cellular
components including unsaturated lipids, amino acid residues, and nucleic acids; and
ultimately, result in cell death and tissue destruction (Detty et al., 2004; Ian J. Macdonald,
2001).

Structure-Activity Relationship of Porphyrins
Synthetic porphyrins are most readily synthesized from pyrrole and benzaldehyde
derivatives and constitute two main groups, the metallo-TPPS4 (sulfonated tetraphenyl
porphyrin) derivatives (Figure II-3) and phthalocyanines (sulfonated tetra-arylporphyrins)
(Figure II-4).
Substantial work performed by Dr. Marzilli of the LSU Department of Chemistry
and his collaborators at Emory University, Atlanta, GA has shown that specific porphyrinbased compounds exhibited strong and specific antiviral activities against different viruses
such as HIV and vaccinia (Figure II-5). In our laboratory, different groups of antiviral
compounds have been tested against Respiratory Bovine Coronavirus (RBCoV) infection.
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Figure II-3. Structures of a synthetic 5,10,15,20-Tetraphenylporphyrin, TPP,
C44H30N4 .
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Figure II-4. Structures of phthalocyanine, tetrabenzotetraazaporphyrin.
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Figure II-5. Structures of synthetic porphyrins which were effective against HIV.
Sulfonated, halogenated tetraaryl porphyrins and sulfonated tetraaryl porphyrins with large
or electron-donating substituents like tetranaphtyl porphyrins and tetraanthracenyl
porphyrins were the most efficient compounds against HIV (Dixon et al., 2005).
Importantly, some of these compounds have showed exceptional antiviral properties
(Vzorov et al., 2003). The molecular basis for these antiviral activities and their action
against herpesviruses are not known and is the subject of the proposed investigations.
Virucidal as well as antiviral activities can be found in “natural” and “synthetic”
porphyrins. Both classes exist as “free base” form without any central metal or as “metalloporphyrin” with different metal ions in the centre. A number of studies have investigated
the detailed structure–activity relationships of porphyrins (Dixon et al., 2005; Vzorov et
al., 2002). Porphyrins were originally under consideration as topical microbicides. They
were later shown to inhibit cell fusion induced by the HIV-1 Env protein and to block
binding of gp120 to the CD4 receptor. Active over a range of pH values, while having no
detectable activity against normal bacterial flora, the compounds have been shown to
inhibit transmission of cell-associated HIV and inactivate a broad range of isolates. None
of the tested natural compounds were able to inhibit an HIV infection for more than 80%
(Vzorov et al., 2002).
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Metallated tetrapyrroles are present in most organisms and participate in essential
biochemical processes that include photosynthesis, oxygen transport, drug metabolism,
transcriptional regulation, nitric oxide synthesis, and oxidative phosphorylation. In nature,
metallation of tetrapyrroles is catalyzed by a group of enzymes named chelatases. Heme is
an iron porphyrin coordination complex. Metallation in the laboratory can be achieved by
heating with Fe(II)Cl2x4H2O in the presence of nitrogen air (Marzilli, 2004 Baton Rouge,
LA, May 2004). Addition of naphthalene group (C10H8) extends the porphyrin structure.
These compounds have two additional benzene rings attached on the periphery of the
porphyrin structure (for example, TNap1P and TNap2P in Figure II-5).
Overall, for coronavirus, HIV and vaccinia, the most effective compounds were a
combination of porphyrins with sulfonate groups which are associated with antiviral
activity and low toxicity (Dixon et al., 2005). With sulfonation using chlorosulfonic acid,
the chlorosulfonyl compounds can be converted into derivatives with free sulfonic acid, a
sulfonamide or a sulfonate ester (Rocha Gonsalves et al., 1996; Sobral et al., 2002).
Sulphonation significantly increases solubility of porphyrin compounds in polar solvents
including water, circumventing the need for alternative delivery vehicles (Ali and van Lier,
1999; Detty et al., 2004; Nyman and Hynninen, 2004; Phillips, 1995).

Properties of Porphyrins Favorable as Therapeutic Compound
The different attributes of porphyrins such as independence of pH changes, stability
against different redox situations, affinity for serum proteins, favorable pharmacokinetic
properties, and no photoactivity renders them attractive candidates as antiviral or virucidal
compounds against EHV-1 infections, especially against the neurological form of the viral
infection. Most of them are non-toxic, inexpensive, and form stable complexes with a
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variety of metal ions (chelate). The time required for complete elimination of porphyrins
from biological tissues is reported to be about a week and most porphyrins are known to be
non-toxic. These compounds may also be modified to increase their half-life in blood.

Porphyrins Mechanism of Antiviral Action
The mechanisms of action and the stage in the viral life cycle at which the
porphyrins inhibit the virus, is not well understood yet. In case of HIV infection, the
antiviral effect may be due, at least in part, to inhibition of the reverse transcriptase.
Metalloporphyrins as well as natural porphyrin class showed significant inhibition of RT
activity. A second way of action may be inhibition of the HIV protease. Furthermore,
natural porphyrins seem to inhibit HIV virus entry mediated by the Env glycoprotein
interaction with its cellular receptors CD4+, CCR2 (Vzorov et al., 2003).

Stages of the EHV-1 Life-cycle as Targets for Porphyrin Therapy
Cell Tropism and Spread
Natural infection with EHV-1 occurs by inhalation or ingestion, after which the
virus attaches to, and rapidly replicates in, cells of the nasopharyngeal epithelium and
associated lymphoreticular tissues, causing necrosis, exudation, and infiltration of
phagocytic cells. Bronchial and pulmonary tissues also become infected, particularly in
foals, predisposing them to secondary bacterial pneumonia.
Migration of virus-infected phagocytes into the circulation results in a T
lymphocyte associated viremia. T-lymphocytes are the most susceptible of the peripheral
blood mononuclear cells (PBMC) and carry EHV-1 to distal organs (Scott et al., 1983).
Viremia is associated with, T-cell lymphopenia and appearance of blastic cells (McCulloch
et al., 1993) and may occur in the presence of virus-neutralizing antibodies (Doll and
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Bryans, 1963; Mumford et al., 1987). For 9–14 days, starting from 4–6 days post EHV-1
infection, an extensive cell-associated viremia is detectable (Gibson et al., 1992). The
ability of EHV-1 to spread from cell-to-cell without an extracellular phase, via virus
mediated cell-to-cell fusion, enables it to avoid inactivation by circulating neutralizing
antibody and permits dissemination to other tissues.

Virus Entry and Neutralizing Antibodies
Recent developments in molecular studies of HSV-1 entry, maturation, and spread
have contributed to deeper understanding of EHV-1 life cycle and pathogenesis. Herpes
simplex virions have evolved mechanisms to deal with multiple membrane barriers during
virus-entry and cellular egress through the use of multiple glycoproteins (gB, gC, gD, gE,
gI, gJ, gH, gK, gL, gM) and other virus-specified proteins. Initially, virions attach to
ubiquitous glycosaminoglycans, e.g., heparan sulfate moieties on cell surfaces via
glycoproteins gC and gB. Subsequently, viral glycoprotein gD interacts with specific
cellular receptors embedded in plasma membranes initiating the fusion of viral and cellular
membranes. These receptors include members of the immunoglobulin superfamily (nectin1, nectin-2, and CD155) and HveA (or HVEM), a member of the tumor necrosis factor
(TNF) superfamily (Campadelli-Fiume et al., 2000; Whitbeck et al., 1997). Viral
glycoproteins gB , gH and gL are directly involved in fusion of the viral envelope with
plasma membranes (Hagglund et al., 2002). Generally, all herpesviruses have evolved
mechanisms to facilitate virus-entry into cells through the use of multiple glycoproteins
embedded within their viral envelope. The glycoproteins are efficient primary targets of
virus-specific neutralizing antibody, development of which is coincident with resolution of
clinical signs and resistance to homologous reinfection for 3 to 4 month. Viral
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glycoproteins are also key determinants of membrane-associated events occurring during
virion morphogenesis and egress from infected cells, where cell-to-cell transmission of
herpesviruses occurs either by release of virions to extracellular spaces or through virusinduced cell-to-cell fusion.

Latency
Trigeminal ganglia, circulating T lymphocytes and lymphoid tissues draining the
respiratory tract, are the sites for establishment and maintenance of the lifelong state of
latency characteristic of all herpesviruses. The cycle of a persistent latent infection with
intermittent reactivation and shedding is thought to keep EHV circulating within the
equine population. In latently infected animals, reoccurrence of viremia and shedding of
the virus in nasal secretions of horses has been produced by immune suppression through
the administration of corticosteroids (Slater et al., 1994).

SPECIFIC OBJECTIVES
This chapter describes the initial experiments conducted with large number of
porphyrin, phthalocyanine, and platinum compounds for preliminary determination of their
potential antiviral and cytotoxic effects. The tests were designed to screen the available
compounds for their inhibition of free virus as well as interference with virus entry and
production. A number of leading compounds were then selected based on their in vitro
efficacy (EC50, 50% effective concentration), toxicity to the cells (CC50, cytotoxic
concentration), cell localization, and therapeutic index (TI=CC50/EC50). The chemical
structures of the selected substances were then then modified by the collaborating
laboratory of Dr. Marzilli, and the resulting change in quantity of the EHV-1 antiviral
activity and cytotoxicity was determined.
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EXPERIMENTAL DESIGN
During lytic replication, EHV-1 destroys the host cells that it infects, observed as
rounding of the cells, multinucleated giant cell formation (syncytia), and presence of
acidophilic inclusions. The antiviral activity of potential therapeutic agents against EHV-1
can be determined by evaluating the inhibition of this virus-induced cell killing, or
cytopathic effect (CPE).
Initially, experiments to determine cytotoxicity of the different compounds to the
rabbit kidney cells, RK13, were performed. RK13 cells were chosen, since it is a standard
cell line used for EHV-1 propagation, research, and diagnosis. Based on preliminary data
from Dr. Marzilli’s laboratory and our studies with coronavirus and vaccinia, the baseline
concentration of antiviral in cell culture media was chosen at 50µg/ml. For those
compounds that were found to be cytotoxic at this concentration, two-fold dilutions were
performed to determine optimal concentration that does not exhibit an obvious cytopathic
effect on the cells. Second, a collection of up to a 100 antiviral drugs was tested in the
EHV-1 cytopathic effect inhibition assay. The set of drugs tested included platinum,
tetraphenylporphine, sulfonated and metallo-porphyrin compounds and others. The initial
screen was followed by a plaque reduction assay to determine the 50% effective
concentration (EC50) of compounds showing positive results.
Following primary and secondary screenings, subsequent chemical modifications
of leading compounds was performed by the Dr. Marzilli’s group at the LSU Chemistry
Department to ascertain whether antiviral properties were improved or diminished, while
cytotoxicity avoided.
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MATERIALS AND METHODS
Cells
RK13 cells, rabbit kidney epithelial cells, were obtained from American Type
Culture Collection (ATCC CCL-37, Rockville, MD). Cells were propagated and
maintained in Dulbecco's Modified Eagles Medium (DMEM; Sigma Chemical Co., St.
Louis, MI) containing sodium bicarbonate, 15 mM Hepes, and supplemented with 7% heat
inactivated fetal bovine serum (FBS). The equine dermal cells, ED (ATCC CCL-57),
equine fetal tracheal cells, EFTr (Primary cell line, field strain provided by Dr. Corstvet,
LSU SVM, Baton Rouge, LA), and Vero (African Green Monkey Kidney Cells, ATCC
CCL-81) were maintained in Dulbecco modified Eagle’s minimum essential medium
(DMEM) supplemented with 15 mM Hepes, and 7% fetal bovine serum (FBS) and
incubated at 37°C, 5% CO2.

Viruses
The NY1, NY2, VA, and RacL11∆gp2/EGFP viruses were kindly provided as
ethanol precipitated DNA by Dr. Osterrieder of the Cornell University School of
Veterinary Medicine, Ithaca, NY. Neurologic field Isolates, NY1 (New York) and NY2,
were collected a few years apart, from the animals of the same herd. VA (Virginia) isolate
was obtained from the brain tissue of a horse with clinical symptoms of encephalitis. To
establish infectious virus stocks, viral DNA was transfected into RK13 cells using
SuperFect Transfection Reagent (Cat. No. 301305, Qiagen Inc., Valencia, CA) according
to the manufacturer’s instructions. The virus strain Ab4, parental strain of
RacL11∆gp2/EGFP recombinant virus, was isolated in the late 1950s from an aborted foal
and exhibits high virulence both in the natural host and in laboratory animals, such as the
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Syrian hamster and the mouse. The EHV-1 Ab4 genome has been cloned into bacterial
artificial chromosomes (BAC), which facilitated the construction of mutant viruses
constitutively expressing the green fluorescence protein (GFP) under the human
cytomegalovirus immediate early promoter (HCMV-IE). Specifically, a portion of an F
plasmid and an EGFP expression cassette HCMV-IE promoter were substituted for gene
71 encoding glycoprotein gp2 to create a RacL11∆gp2/EGFP recombinant virus. Deletion
of the gp2 glycoprotein does not appreciably affect virus entry and virus replication, while
a slight reduction (5%) in plaque size is observed (Neubauer et al., 2002).

Antiviral Compounds
About a hundred different inorganic and organic compounds, either commercially
available or synthesized by the collaborating laboratory of Dr. Marzilli, LSU Chemistry
Department were kindly provided by Dr. Marzilli (Louisiana State University, Baton
Rouge, LA) and stored at 3-5°C in containers not permissive to light. Due to patent
considerations, some of the tested compounds are referred to as they were named upon
synthesis at the laboratory of Dr. Marzilli and not by the corresponding nomenclature of
porphyrin chemistry (Moss, 1988). The chemical nomenclature of porphyrin and porphyrin
derivatives and the abbreviations used are as follows: meso-tetraphenylporphirine (TPP);
5,10,15,20-tetrakisphenylporphyrin (H2TPP); and 5,10,15,20-(4-chlorosulfonylphenyl)
porphyrin (H2TPPS4). An “S” at the end of the abbreviation indicates that the parent
porphyrin was sulfonated and the derivatives are mixtures with variable numbers and/or
positions of the sulfonates on the ring. Cu(II)-5,10,15,20-tetrakis(4-[p-sulfobenzyl]
sulfoamidonylphenyl) porphyrin (Cu(II)TPPS4) is a sulfonated tetraphenylporphyrin with
a copper moiety/chelate at the meso position, while Fe(III)-5,10,15,20-tetrakis(4-[p111

sulfobenzyl] sulfoamidonylphenyl) porphyrin (Fe(III)TPPS4) is a sulfonated
tetraphenylporphyrin with an iron moiety/chelate, and for simplicity, will be referred to as
metalloporphyrins in this paper. Distilled water was used as solvent to prepare 2 mg/ml
stock solution for each test chemical. Several compounds were provided dissolved in
dimethyl sulfoxide (DMSO, (CH3)2SO) as solvent. DMSO is miscible with water and prior
to their use in assays, solutions of porphyrin compounds were diluted in excess of 100-fold
in water. Therefore, DMSO was not expected to influence the outcome of the assays via its
function to enhance membrane penetration and transport. Preparation of solutions and all
experiments were done under red light to prevent chemicals degradation or phototoxicity
upon exposure to light. ChemDraw Pro 11.0 (CambridgeSoft Corporation, Cambridge,
MS) program was used to present chemical structures of the compounds. All stock
solutions of compounds were in the range of pH 8.5 to 9.

Initial Screening Assay: Antiviral Effect on Free Virus
The initial screen of antiviral compounds was a cell-based assay with endpoint
detection performed using visual inspection and calculation of ratio of the number of
infected cells (EGFP fluorescent cells) counted by FACS to that of untreated control
(Figure II-6). RK13 cells were plated in triplicates in 24-well tissue culture plates (Greiner,
Frickenhausen, Germany), at a density of 2 x 105 cells per well and incubated overnight in
a humidified 5% CO2-air at 37°C. At 80% confluency, cell monolayers were infected with
EHV-1 RacL11∆gp2/EGFP at a multiplicity of infection of 10 and 0.1 PFU/cell in DMEM
25 mM Hepes medium. Prior to infection, virus was incubated with 50 µg/ml
concentrations of the compounds for 30 min at 37°C. Virus was allowed to enter the cells
during one hour incubation at 37°C. Then, EHV-1 infected cell monolayers were washed
112

with phosphate-buffered saline (PBS) to remove residual drug and the virus that has not
entered, overlaid with fresh 2% FBS DMEM, and incubated at 37°C for 8 h, at which time
the cells were harvested, washed and subjected to FACS analysis to determine the percent
of infected cells via GFP fluorescence. Acyclovir was used as control antiviral, applied at a
concentration 50, 25 and 5 µg/ml. Cells infected with viruses at the same multiplicity of
infection (M.O.I.) of 10 and 0.1 PFU/cell and without adding any of the compounds served
as a control of a 100% infection. Those compounds that show more than 50% reduction in
EGFP fluorescence at the M.O.I. of 10 were selected for further testing.

Cytotoxicity Assays and 50% Cytotoxic Concentration
Current assays to monitor the viability of cells include vital dye uptake, tritiated
thymidine uptake, and tetrazolium salts (e.g. MTT, WST-1). We used the following assays
to determine compound cytotoxicity: (i) Cytopathic effects produced in RK13 cells were
determined by daily visual inspection and qualitative assessment of cells exposed to serial
dilutions of the candidate microbicides; (ii) The effects of the compounds exerted during
two population doublings of RK13, ED, and EFTr cells determined by staining the cells
with trypan blue and visually counting the cells that incorporated the dye. Briefly, serial 2
to 10-fold dilutions of the compounds, 0.1 to 100 µg/ml, were added to 20%, 40%, 60%, or
80% confluent monolayer of RK13, ED, EFTr or Vero cells, without viral challenge. Then,
plates were left at 37°C and 5% CO2 for 3 days and examined for toxicity effects by using
trypan blue exclusion test. Alternatively, the treated cells were incubated under normal
growth condition for 48 hours and then, stained with neutral red containing medium to
access cell viability. The cells were subsequently washed, the dye was extracted in each
well, and the absorbance was read using a spectrophotometer. The 50% Cytotoxic
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Concentrations (CC50) were calculated. Therapeutic Index (TI) values were calculated as
the ratio of 50% cytotoxic concentration to %50 Inhibitory Concentration of each
compound (TI=CC50/IC50). Compounds were scored as active if TI > 10, moderate if TI >
1.5 < 10, inactive if TI < 1.5.

CMVpr GFP

Signal Detected
Viral genome

Virus
GFP
EHVEHV-1

+40C

+370C

X
Compound
inhibits free virus

Figure II-6. Diagram of initial antiviral screening assay.

Figure II-7. Diagram of the modified screening assay.
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Cell

Confocal Microscopy
For laser scanning confocal-microscopy experiments, RK13 cells were cultured in
eight-well chamber slides (Lab-Tek II; Nalge Nunc International, Naperville, Illinois).
Twenty-four hours after being seeded, the cells were EHV-1 or mock infected and further
incubated in the presence or absence of the antiviral compounds. At various times post
infection, the cells were fixed with paraformaldehyde and permeabilized with 0.5% Triton
X-100 in order to maintain the integrity of cellular structures. For cell surface biotinylation,
prior to fixation cells were washed with TBS-Ca/Mg and incubated for 15 minutes at RT in
EZ-Link Sulfo-NHS-LC Biotin cell impermeable biotinylation reagent (Pierce Chemical,
Thermo Fisher Scientific Inc., Rockford, Illinois), which reacts with primary amines on
cell surface proteins. Cells were then washed with TBS and fixed with electron microscopy
grade 3% paraformaldehyde (Electron Microscopy Sciences, Fort Washington,
Pennsylvania) for 15 minutes, washed twice with PBS-50 mM glycine, and permeabilized
with 1.0% Triton X-100. For cell surface labeling, biotinylated cells were reacted with
1:1000 diluted Alexafluor 647 conjugated streptavidin for 20 minutes. For Golgi and ER
organelle labeling, cells were incubated with 1:750 dilution of Alexafluor 488 conjugated
lectins GSII and concanavilin A, respectively. TGN was identified with a donkey antiTGN46 primary antibody and an Alexafluor 488 conjugated sheep anti-donkey secondary
antibody. Specific immunofluorescence was examined using a Leica TCS SP2 laser
scanning confocal microscope (Leica Microsystems Inc., Bannockburn, IL) fitted with a
CS APO 63x Leica objective (1.4 numerical aperture). Individual optical sections in the zaxis, averaged 6 times, were collected at set zoom in series in the different channels at
1024 x 1024 pixel resolution. Images were compiled and rendered in Adobe Photoshop.
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Modified Screening Assay: Effect on Virus Entry and Replication
To analyze whether antiviral compounds affected viral particles prior to and at
entry steps of the infection, the virus EHV-1 RacL11∆gp2/EGFP was incubated with the
compounds for 30 min at room temperature and then added to the cells (see Figure II-7).
Then, after the incubation time of 1.5 hours at 4°C and another hour at 37°C the wells were
washed and fresh DMEM 25 mM Hepes medium was added. To determine if the
antivirals act at the level of binding, penetration, or post-entry, the antiviral compounds
were added to the infected cell monolayers for 10 minutes and then, removed by a wash,
either during the 4°C period, at the time that the cells were transferred to 37°C, or
immediately after the 1 hr incubation at 37°C respectively. High resolution pictures of the
EGFP fluorescent virus infected cells were taken 12 hours post infection and the numbers
of infected cells were counted as percent of control, number of infected cells without the
antiviral compounds.

Cytopathic Effect Inhibition Assay and 50% Inhibitory Concentration
To determine the efficacy of antiviral compounds, a cell-based assay utilizing
cytopathic effect inhibition (CPE) or reduction in the number of viral plaques was set up.
The basic assay involved infection of RK13 cells as described above, however
neurological isolates (NY1, NY2, and VA) were tested in the presence of various
concentrations of test compounds in addition to EHV-1 RacL11 virus. Cells were seeded at
a density of 2 x 10e5 cells per well and grown in triplicate wells in 24-well plates
overnight. Each drug was added at least eight different concentrations within 0.1 to 30
µg/ml range of concentrations, at the time of the infection and maintained until completion

of the assay.
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EHV-1 (0.1 to 5 PFU/cell) was exposed to serial dilutions (0.1-30 µg/ml) of the
candidate microbicides for 30 min at 37°C. After incubation for 1 h at 37°C, the virus
inoculum was aspirated, and a maintenance medium overlaid containing 1%
methylcellulose and the appropriate compound concentration added. The plates were
incubated at 37°C in 5%CO2 for 2-3 days and observed daily for CPE. The end point
titration was determined as the drug dilution that inhibited 100% of the CPE in triplicate
wells. The plates were fixed with 5% formaldehyde and stained with crystal violet. The
viral titer in the presence of each concentration of drug was determined by counting the
plaques. The ability of the compounds to inhibit EHV-induced cell killing was determined
as reduction in plaque number and diameter. Median inhibitory concentration or the IC50
(or EC50, 50% effective concentration) calculated as the concentration required for 50%
inhibition. Reported IC50 values are the average and standard deviation of three separate
determinations per experiment, with each experiment repeated three times. The IC95
values were extrapolated via polynomial of order three.

Image Analysis and Quantitation
For most experiments, high resolution pictures of the fluorescent virus infected
cells were taken under fluorescent microscope magnification of x40 at 12 hours post
infection and the numbers of infected cells were counted as percent of control. Image
analysis was done using the Leica microscopy software (Leica Microsystems Inc.,
Bannockburn, Illinois). Image masks of fluorophore were generated from the image
fluorogram data by defining the specific regions of interest with a bounding box. To
determine an percentage of the surviving virus, pixel enumeration and intensity statistics
within the Leica software package was applied to a series of individual sections.
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RESULTS
Initial Screening of Antiviral Compounds for Inhibition of EHV-1
Infection
Using a recombinant, BAC progeny EHV-1 strain, RacL11-∆gp2-GFP, as a model
target, we conducted antiviral activity testing of up to 100 different inorganic compounds
synthesized by the collaborating laboratory of Dr. Marzilli of Louisiana State University
(LSU) Chemistry Department, Baton Rouge, LA. RacL11 encodes a portion of the F
plasmid and an EGFP expression cassette under the human cytomegalovirus immediate
early promoter (HCMV-IE) that was substituted for EHV-1 non-essential gene 71
encoding glycoprotein gp2 (Neubauer et al., 2002).
The screening assays were used to estimate the antiviral and cytotoxic effects of the
compounds and to identify lead candidate antiviral compounds on the basis of their in vitro
efficacy and toxicity. Tests were done as cell-based assays with end-point detection
performed using visual inspection, Leica image analysis software and FACS detection of
percent infected cells showing green fluorescence from EGFP gene encoded by the
recombinant EHV-1. The chemical structure of the compounds used in initial screening
was undisclosed to the investigators to avoid bias in selecting compounds as well as due to
patent and other intellectual property issues. Only compounds selected for further testing
were matched to corresponding structural formula, otherwise the compounds were referred
to as they were numbered upon synthesis at the laboratory of Dr. Marzilli (Louisiana State
University, Baton Rouge, Louisiana).
Initial experiments showed that many of the compounds had potent virucidal
activity against the virus, since exposure to virus-stocks for as little as few minutes
inactivated more than 99% of the virus (results not shown). These compounds were
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selected and further tested for their effect on virus during replication stage of infection.
The results of a representative experiment are shown in Figure II-8. Infected cells were
treated with antiviral compounds once the virus has already entered the cell: virus envelope
and cellular membrane were fused and the capsid released into the cytoplasm.
Treatment with compound LGmP 250 (sulfonated tetraphenoxyphenyl porphyrin)
and LGmP 73’((3-Cl)4-SO3 tetraphenyl porphyrin) resulted in about 90 and 70%
inhibition of the viral infection respectively, while LGmP 73, 74, and 249 had practically
no effect (Figure II-8). Those compounds that when used post entry showed more than
40% reduction in virus infection at the MOI of 10 were selected for further testing and are

Virus Survival, % of Control

shown in Table II-2.
100
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40
30
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0
LGmP LGmP LGmP LGmP LGmP LGmP LGmP LGmP LGmP
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49'
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73'
74
74'
96
249
250
25 ug/ml Antiviral Added Post Entry

Figure II-8. Blinded initial screening of the antiviral compounds. Inhibitory effect of
photodynamic compounds on post entry events of virus infection resulted from
photoinactivation of EHV-1 and decreased cell growth due to cytotoxicity of the
photodynamic effects (49, 49’, 249, and 250) and chloro groups (73’, 74, and 74’).
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Table II-2. A selection of the compounds tested.
Compounds
in
LGmP 17
LGmP 37
LGmP 38
LGmP 39
LGmP 44
LGmP 45
LGmP 46
LGmP 47
LGmP 49
LGmP 69
LGmP 71
LGmP 73
LGmP 74
LGmP 96
LGmP 106
LGmP 128
LGmP 129
LGmP 149
LGmP 176
LGmP 177
LGmP 179
LGmP 179b
LGmP 188
LGmP 196
LGmP 199
LGmP 200c
LGmP 205a
LGmP 210a
LGmP 212a
LGmP 213a
LGmP 226
LGmP 241
LGmP 246
LGmP 248
LGmP 249
LGmP 250
LGmP 252
LGmP 273
LGmP 275
LGmP 276
LGmP 277
LGmP 278
LGmP 279
LGmP 280
LGmP 282
LGmP 284

Solvent
H2O or
DMSO
H2O
H2O

Class of Compound

Sulfonate/
Metallo group

H2TPPS4

M-; S+

H2O
H2O
H2 O
H2O
H2O
H2O
H2O

Cu(II)-tetrasulfonated phenyl porphyrin
2-fluoro-4-sulfo porphyrin
4 chloro-3-sulfo porphyrin
2,6-difluoro-tetrasulfonated phenyl
(4-F)3-sulfo- tetraphenyl porphyrin

Cu; S+
M-; S+
M-; S+
M-; S+

H2O
H2O
H2O
H2O

3-fluoro-4-sulfonato porphyrin
chloro

H2O
DMSO
DMSO
DMSO

insoluble

DMSO
H2O

Cis-Platinum, Pt(NH3)2Cl2

MM-; S+

(2-F)3-sulfo-tetraphenyl porphyrin

M-; S+
MM-

Phthalocyanine

FFF+
F+
F+
F+
F+
F+
FF+
F+
F+
FFF-
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>100

FF+
FF+
FFFFFF-

Platinum
Platinum
Porphyrin
Platinum

H2O
H2O

Porphyrin
Fe (III)-tetrasulfonated phenyl porphyrin

H2O
H2 O
H2O

Metalloporphyrin
tetra-(phenoxyphenyl sulfonated
Cu(II) tetra OCH3SO3 phenylporphyrin
Italian lab
Novel photodynamic porphyrin, H2TPPS8
Novel Cu H2TPPS8
Italian lab
Italian lab
Novel, Naphthalene H2TPPS8
Novel Cu, naphthalene H2TPPS8
Novel Cu, fluoride H2TPPS8
Novel photodynamic naphthalene

H2O
H2O
H2O
H2 O

F-

F-

H2O
H2 O
DMSO
DMSO
DMSO
DMSO

H2O
H2O
insol

Fluorescence/ Cytotoxicity Inhibition of
Photodynamic
CC50 Free Virus, %
25 µg/ml
properties
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M+; S+
M+
M-; S+
M+; S+
M-; S+
M+; S+
M+
MMM+; S+
M+; S+
M-

FFFF+
FF+
F+
F-

F+
FFF+

>100

>100
>30
>100
>30
>30
>30
>30
>100
>100
>30

98
90
95
95
100
100
50
90
5
100
100
20
95
0
0
0
100
0
40
82
0
98
0
82
0
10
0
10
0
100
70
95
65
100
100
100
100
100
100
100
100
100

Cytotoxic Effects of Antiviral Compounds
Cytotoxicity tests were conducted for each individual compound. Different
concentrations of the compound were added to rabbit kidney cells, RK13, equine dermal
cells, ED, equine fetal tracheal cells, EFTr, and African green monkey kidney cells, Vero,
at 20 , 40, 60, or 80% confluency to reach concentrations of 100 µg/ml, 50 µg/ml, 30
µg/ml, 25 µg/ml, 15 µg/ml, 10 µg/ml, 5 µg/ml, and 1 µg/ml in the culture medium. Cells

were examined after 12 hr, 24 hr and 36 hr post infection. The observed cytotoxic effects
included rounding and shrinking, vacuolization, membrane blebbing/budding, loss of
confluency, reduction of growth rate, nuclear damage, and cellular debris. Examples of
cytotoxic effects observed are shown in Figure II-9. The results were recorded and used to
select compounds without significant cytotoxic effect. Cytotoxicity of compounds was
directly related to their fluorescence and therefore photoactivity.
Tetrapyrrole compounds with chloro group, such as LGmP 45 ((4-Cl)3-SO3
tetraphenyl porphyrin), LGmP 73’((3-Cl)4-SO3 tetraphenyl porphyrin), LGmP 74, LGmP
74’ and others were proven to be cytotoxic even if assayed in the absence of light (results
not shown). The chloro group was the only common feature of these compounds and was
assumed to have contributed to the cytotoxic effect. Therefore, LGmP 73’ was ruled out as
a potential antiviral.

Untreated healthy cells

Apoptosis

Reduced growth rate

Cellular debris

Figure II-9. Cytotoxic effects of antivirals as observed on phase-contrast microscopy.
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Photoactivation
A flaw of the initial screening approach was that many of the compounds were
photodynamic as seen by their red fluorescence when examined under fluorescent
microscope (Figure II-10), and therefore, inactivated virus and damaged the cells via light
activated production of reactive oxygen species (ROS). As an example, 0.2 µg/ml LGmP
46 inhibited virus by 90% upon exposure to visible and UV spectrum, and only 50% in the
dark (Figure II-11). Thus, the exceptionally good antiviral properties all fluorescent
compounds were most likely due to photoactivity against EHV-1.
As mentioned previously, the fluorescent compounds were also cytotoxic at
concentrations inhibitory to virus infection, resulting in decreased rates of cell growth.
Photoinactivation of viruses by diamagnetic porphyrins have been studied previously
(Horowitz et al., 1992). The light-activated compounds react with molecular oxygen to
produce reactive oxygen species and radicals; in a biological environment these toxic
species (singlet oxygen (1O2), hydroxyl radicals (•OH), and superoxide (O2−) ions) interact
with unsaturated lipids; amino acid residues; and nucleic acids causing biochemical
disruption to the cell(Detty et al., 2004; Ian J. Macdonald, 2001). If the homeostasis of the
cell is altered significantly, then the cell enters apoptosis. Therefore, all subsequent
experiments with photodynamic compounds were conducted in dark room conditions to
minimize the photoinactivation effect and to evaluate other mechanism of their antiviral
function.

Cellular Distribution, Cytotoxicity, and Stability of Antiviral Compounds
We capitalized on the fluorescent property of the porphyrins to evaluate their
cellular localization during our preliminary investigations of the cytotoxic effects on RK13
122

Figure II-10. Illustration of GFP-expressing virus infected cells in the presence of
photoactive porphyrin. Cells exhibit green fluorescence and syncytia formation
characteristic of recombinant GFP-expressing EHV-1 RacL11 infection in the presence of
0.2 µg/ml photodynamic antiviral compound LGmP 37, H2TPPS4 (red fluorescence),
examined under fluorescent microscope at x100 magnification.

Figure II-11. Inhibition of viral infection by photoactive antiviral compound in the
presence and absence of visible and UV spectrum. Prior to infection of RK13 cells,
EHV-1 RacL11/EGFP virus was incubated with indicated concentration of LGmP 46 in
the absence (gray bars) or presence (black bars) of visible and UV exposure.
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cells (Figure II-12, A and B). Compounds were observed to rapidly enter the cytoplasm of
both EHV-1 RacL11 and mock infected cells and remain within cytoplasm potentially as
either aggregates or as content of endoplasmic vesicles.
If compounds were added to the cells post infection, they were also seen to
concentrate in the nucleus, most likely due to EHV-1 induced modification of cell
architecture. If the compounds were preincubated with a virus prior to virus infection, no
nuclear staining was observed, as no infection was detected due to complete inhibition of
the infection by the compounds.
Confocal microscopy was considered to obtain more detailed information about the
internalization and intracellular localization of compounds (Figure II-12, C-E). However,
non-photoactive/non-fluorescent compounds could not be evaluated since there is no
available marker to localize them to the organelles. The pattern of distribution of
photoactive compounds is suspected to be due to the onset of apoptotic changes in the cell.
To evaluate stability of antiviral compound upon storage, the activity of several
compounds was retested after three weeks of refrigeration. Most compounds showed
significant stability or an increase in antiviral activity (Figure II-13), potentially due to
evaporation, while other compounds were unstable in storage (results not shown) and were
eliminated from further investigations.

Modified Screening of Antiviral Compounds Based on Their Activity on
EHV-1 Attachment, Fusion and Post-entry Events
A new set of compounds was synthesized, containing various metals in the meso
position. Presence of the metal group was expected to decrease or fully abolish
photoactivity of these compounds, and therefore, diminish their cytotoxicity. Compounds
selected based on initial screening and ruling out cytotoxic compounds and those newly
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C

D

E

Figure II-12. Differential cellular localization of antiviral compounds within cellular
compartments. RK13 cells infected (A) and mock infected (B) with GFP fluorescent
RacL11 virus were subjected to antiviral treatment for the duration of infection (12 hours),
starting at one hour post infection at a concentration of 20 µg/ml in cell culture media.
Porphyrin-based antiviral compound is seen exhibiting red fluorescence under UV
exposure. Arrows denote nucleus, arrow head indicates cytoplasmic vacuolization.
Porphyrin compound is seen as red fluorescence. Green fluorescence is the GFP
expression from the recombinant EHV-1 genome. C, D, E) Laser scanning confocalmicroscopy images showing individually stained ER, Golgi and surface cellular
compartmentsof RK13 cells, respectively.

Figure II-13. Effect of storage on antiviral activity of Fe(III)TPPS4. Increase in
antiviral activity of Fe(III)TPPS4, potentially due to evaporation of the solvent, was seen
after refrigerated storage for 3 weeks.
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synthesized, were tested for their ability to interfere with EHV-1 infection. Since most of
the selected compounds efficiently inactivated the free virus, to better differentiate their
antiviral properties and to determine at what stages of viral infection they might exert their
antiviral properties, a time course assays were conducted. RK13 cells were precooled to
4°C, and each well inoculated with EHV-1 RacL11∆gp2/ EGFP virus, and the infected
cells were incubated for 1 hour at 4°C to allow virus binding. Washing the cells at this
time, removed any unattached virus. The shift to 37°C at this step allowed virus
penetration into the cells.
To evaluate effect of antiviral compounds on attached virus, following a 1 hour
attachment at 4°C, the antiviral compounds were added, cells were incubated for 10 more
minutes at 4°C, washed and transferred to 37°C to allow virus entry. To evaluate effect of
antiviral compounds on fusion step of virus entry, antiviral was added post 1 hr at 4°C
and the cells immediately transferred to 37°C for 10 min, then washed, and transferred to
37°C to continue infectious cycle. To evaluate effect of the antiviral compounds on post
entry events, antiviral was added for 10 min at the step after the virus has entered the cells
(post 1 hr at 4°C and additional 1hr at 37°C). At 12 hours post infection, numbers of
infected cells were counted and are shown in as percent of untreated control, a number of
infected cells without the antiviral compounds. The extent of inhibition of infection was
determined from the percent of virus that survived.
The results of antiviral effect on attachment, fusion and post entry were taken
together to select most active compounds for further studies (Figure II-14, A-B). Most
compounds had minimal effect on post entry events, inhibiting the virus survival at most
by 45%. LGmP 73’ inhibited post entry events by 70%, however had minimal effect on
126

attachment and fusion. Treatment of attached virus or virus undergoing fusion event with
LGmp 39, 46, 179b, 210a, 213a, or 246 compounds, reduced virus survival by 50% or
more. LGmP 39, 46, 179b and 246 reduced virus survival by 75% or more, when these
compounds were added during onset of fusion.
The chemical structures of the selected most active compounds were one nonmetallated sulfonated porphyrins LGmP 46 (2,6-difluoro-tetrasulfonated phenyl
porphyrin), two metallated sulfonated porphyrins, LGmP 39 (Cu(II)-tetrasulfonated phenyl
porphyrin) and LGmP 246 (Iron (III)-tetrasulfonated phenyl porphyrin), as well as three
platinum compounds LGmP 179b (Cis-Platinum, Pt(NH3)2Cl2), LGmP 210a, and LGmP
213a. Selected compounds were tested at higher concentration of 10µg/ml, for their effect
on free virus, attached virus, virus undergoing fusion, and virus that has entered the cell
(Figure II-15). Platinum compounds LGmP 210a and LGmP 213a showed only 40%
reduction in the free virus survival and post entry. Compounds, LGmP 39 (Cu(II)tetrasulfonated phenyl porphyrin) and LGmP 246 (Iron (III)-tetrasulfonated phenyl
porphyrin), have near identical effect on every stage of virus infection tested. These two
compounds have identical chemical structure with the exception of a different metal
chelate.

Leading Compounds and Synthesis of Derivatives
The leading compounds chosen for further investigations were LGmP 39, Cu (II)
tetrasulfonated phenylporphyrin, and LGmP 246, Fe (III) tetrasulfonated phenylporphyrin
(Figure II-16). Since platinum compounds had less effect on free virus, only porphyrin
compounds were chosen for further investigation. For the antiviral compounds of interest
and at specifically selected concentrations of the compounds, cell viability was determined
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Figure II-14. Modified antiviral screening assay based on the effects of antiviral
compound at 5 µg/ml on various steps of virus life cycle during GFP-expressing EHV1 RacL11 virus infection of RK13 cells. To determine if the antivirals act at the level of
binding, penetration, or post-entry, the antiviral compounds were added for 10 minutes
followed by a wash: either during the 4°C attachment period, at the time that the cells were
transferred to 37°C to allow fusion, or immediately after the 1 hr incubation at 37°C,
respectively. No drug was added to the control wells, however all washes were performed
as with other wells.
128

Figure II-15. The effect of antiviral compounds at various stages of viral infection.
RacL11∆gp2/EGFP infected RK 13 cells were exposed to the antivirals at 10 µg/ml at
different times post infection: 10 min at 4°C to test the compounds effect on the
attachment (white), 10 minutes when the cells were shifted to 37°C to test the compounds
effect on the fusion (light gray), after 1 hour at 37°C for 12 hours to test the drugs’ effect
on post-entry events (dark grey), and for the entire time of infection, including a 20
minutes virus preincubation with compounds (black). Pictures were taken under
fluorescence microscopy 12 hours post infection. Cells harvested, washed in PBS and
analyzed via FACs. Graphed are the % infected cells when the drug was applied at
different times of infection.
using metabolic rate assays, while cell proliferation was ascertained using cellular growth
curves (results not shown). LGmP 46 was an excellent antiviral compound, however due to
photoactivity was more cytotoxic, reaching 50% cytotoxic concentration (CC50) at 200
µg/ml. The CC50 of LGmP 37 (5,10,15,20-(4-chlorosulfonylphenyl)porphyrin), a parent

compound of LGmP 39 and LGmP 246, was only 50 µg/ml, however it was chosen for
further studies for comparative purposes. LGmP 37 is a non-metallated tetrasulfonated
phenylporphyrin. The 50% cytotoxic concentration of Cu (II) tetrasulfonated
phenylporphyrin (LGmP 39) was 450 μg/ml. The 50% cytotoxic concentration of Fe (III)
tetrasulfonated phenylporphyrin (LGmP 246) was 600 μg/ml.
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Multiple antiviral assays for selected compounds were conducted to using identical
conditions such as cell number, confluency of cell monolayer, incubation temperature, and
incubation time were followed throughout the performed experiments. These two selected
compounds were used to synthesize new compounds with further modified chemical
structure. Presence of the central metal was expected to retain low cytotoxicity properties
of compounds due to the absence of photoactivity. Sulfonation has been shown to yield
compounds that are more soluble in polar solvents, such as water, thus eliminating the use
of DMSO(Phillips, 1995), and to increase antiviral activity against HIV (Dixon et al.,
2005) and, as shown here, against EHV-1. Additional sulfonation was expected to yield
more active antiviral properties of the compounds.
New porphyrin compounds synthesized were LGmP 265, 276, 280, and 282. LGmP
276 has a higher level of sulfonation but otherwise identical to LGmP 39 (Figure II-17).
LGmP 275 is a photodynamic non-metallated equivalent of LGmP 276 (Figure II-18).
LGmP 280 was derived from LGmP 276 by addition of naphthalene groups, while LGmP
282 was derived from LGmP 276 by addition of fluoride.

Evaluation of Antiviral Properties of Novel Compounds
Newly synthesized compounds were tested for their ability to inhibit virus
infection. The result of antiviral assays showed little deviation in the antiviral properties of
the newly synthesized compounds from that of their parental set (Figure II-19). Decrease
of virus survival attributed to the effect of LGmP 275 was actually the result of decrease in
cell numbers, due to the cytotoxic effects of this photoactive compound. LGmP 37 was
much less effective at corresponding concentrations of antiviral compounds and reached
IC50 for free virus at about 15 µg/ml. Presence of central metal, Cu(II) or Fe(III), reduced
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Figure II-16. Chemical structure of leading compounds, metal chelates of 5,10,15,20(4-chlorosulfonylphenyl)porphyrin. M represents Cu(II) in LGmP 39 (C44H28CuN4, MW
676.28 ) and Fe(III) in LGmP 246 (C44H28FeN4). Position of SO3- at the center of benzene
ring indicates that the parent porphyrin compound, LGmP 37, was sulfonated and the
derivatives are mixtures with variable positions of the sulfonates on the ring.

Figure II-17. Chemical structure of newly synthesized compound, Cu(II) -5,10,15,20tetrakis(4’-[p-sulfonylbenzyl]sulfonylamidophenyl)porphyrin. Compound, named
LGmP 276, was derived by additional chlorosulfonation of LGmP 39, where M represents
Cu(II).
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Figure II-18. Chemical structure of newly synthesized compound, 5,10,15,20tetrakis(4’-[p-sulfonylbenzyl]sulfonylamidophenyl)porphyrin. Compound, named
LGmP 275, was derived by additional chrolosulfonation of LGmP 37 and is
photodynamic. Expanded view of hydrogens is shown.
IC50 to about 3 g/ml (LGmP 39 and LGmP 246). Higher levels of sulfonation and
additional naphthalene or fluoride moieties, as for compounds LGmP 276, 280, and 282,
did not improve IC50 (Figure II-20).
Further study of the newly synthesized compounds revealed that although at
concentrations effective to inactivate free virus in solution, virus that has attached to the
cell surfaces is not susceptible to the antivirals unless much higher concentrations were
used (Figure II-21). At concentrations above 100 g/ml, antivirals started to exhibit
increasing cytotoxic effects. No significant difference in ability to inactivate attached virus
was noted among the compounds studied.
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Figure II-19. Inhibition of EHV-1 RacL11/EGFP virus infection of RK13 cells at
various concentrations of antiviral compounds. The effect of antiviral treatment on free
virus was tested at a range of concentration for parental LGmP 39 compound, 5,10,15,20(4-chlorosulfonylphenyl)porphyrin), its Cu(II), LGmP 39, and Fe(III), LGmP 246, metal
chelates, as well as on the higher sulfonation LGMP 37 derivative, LGmP 275, and its
Cu(II) chelate, LGmP 276.

Figure II-20. Inhibition of EHV-1 RacL11/EGFP virus infection of RK13 cells at
various concentrations of new antiviral compounds. LGMP 276 (Cu(II)-5,10,15,20tetrakis(4’-[p-sulfonylbenzyl]sulfonylamidophenyl)porphyrin) and its naphthalene (LGmP
280) and fluoride (LGmP 282) derivatives.
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Figure II-21. Inhibition of virus attached to cellular membranes at high
concentrations of antiviral compounds. Following 1 hour at 4°C, EHV-1 RacL11/EGFP
virus infection of RK13 cells was treated for 10 min at 4°C with indicated concentrations
of new antiviral compounds, the cells were then washed and infection allowed to proceed.
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DISCUSSION
There is a pressing need for effective antiviral compounds to treat disseminated as
well as neurological forms of EHV-1 infections. Porphyrins have been shown to possess
strong antiviral properties against HIV and Vaccinia. Preliminary results in our laboratory
indicated antiviral activity of porphyrins against EHV-1 and Coronaviruses.
Out of the first set of tested compounds, most showed 99% inhibition of free virus
even at concentrations as low as 5 µg/ml. However, most of these compound exhibited
high level of cytotoxicity, which was attributed to their photodynamic properties, seen in
cell culture as high level of red fluorescence. Subsequently, all assays were performed in a
dark room environment. Experimental conditions such as confluency of RK13 cell
monolayer used for infections, number of infected cells, incubation temperatures and times
were maintained consistent.
For all compounds selected following the screening assays, exposure of the free
virus to the antiviral compounds prior to attachment, resulted in zero virus survival at 50
µg/ml or 25 µg/ml concentration of compounds in culture medium. At 5 µg/ml
concentration of antiviral compounds in culture medium overlaying the cells at the onset of
infection, 20% of the virus survived.
After repeating the experiment, we concluded that most of the antiviral properties
of photodynamic compounds seen initially were most likely due to photoinactivation of
EHV-1 (free radicals and singlet oxygen). Photoactivity of porphyrins is utilized in
palliative photodynamic therapy (PDT) of cancer. For antiviral activity, the important
consideration is that the agent is not phototoxic to the cells. In our investigations we were
interested in the potential of porphyrins for light-independent inhibition of virus infection
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and not a photodynamic mechanism. New compounds were synthesized with metals
incorporated into the meso position in an attempt to abolish photodynamic properties.
To further study the effect of porphyrins on the cells, we were interested in
determining the cellular compartments where porphyrins would localize. We were unable
to study localization of porphyrins inside the cellular compartments using confocal
microscopy, short of using analytical chemistry analysis of nucleus and cytoplasmic
fractions to identify localization. Photoactive porphyrins and metallated non-fluorescent
porphyrins have drastically different antiviral and cytotoxic properties, so we cannot
assume that their cellular uptake and localization would be identical. Metallated nonfluorescent porphyrins may or may not localize to the cytoplasm as do the photoactive
porphyrins.
Interesting to note that without the virus present, the fluorescent compounds
localized to the cytoplasm and within vacuoles and did not enter the nucleus, while in the
presence of infection porphyrins freely enter the nucleus and occupy the cytoplasm. Thus,
potentially, virus infection modifies the nuclear envelope rendering it permeable to the
porphyrin compounds.
Irrespective of localization of the fluorescent porphyrins, these compounds were
highly cytotoxic with or without the virus infection, and cytoplasmic distribution could be
due to initiation of apoptosis by the cell. Metallation of porphyrins abolished the
fluorescence, making them significantly less toxic to the cells. The photodynamic
compounds that contained chloro group remained cytotoxic, even in the absence of light
activation. An initial screening of almost 100 porphyrin and platinum compounds as well
as a detailed screening of 18 different compounds revealed that Cu (II) tetrasulfonated
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phenylporphyrin and Fe (III) tetrasulfonated phenylporphyrin possessed strong virucidal
and antiviral activities against EHV-1, inhibiting 100% of EHV-1 infectivity at a
concentration of 10 μg/ml and 15 μg/ml, respectively. The photoactive compound
H2TPPS4, a precursor/parental compound to the two metalloporphyrins, was used as
control in subsequent experiments. Antiviral compounds showed the most dramatic
inhibitory effect on free virus. Virus undergoing fusion was also significantly affected.
Much less inhibition of virus infection was seen with antiviral treatment of virus attached
to the cellular membranes or virus that has already entered into the cytoplasm.
The excellent antiviral activity and low toxicity of the selected porphyrin
compounds led to their selection for further evaluation against additional laboratory and
clinical virus strains, which were also inhibited effectively. The selected two compounds
were used to design new compounds of modified chemical structure. Additional
sulfonation of compounds did not lead to improvement in their antiviral properties against
free virus nor virus attached to cell surfaces. Addition of fluoride or naphthalene groups,
also did not improve antiviral properties. A more detailed analysis of chemical structures
in correlation to their antiviral or cytotoxic properties could not be conducted due to
proprietary limitations. Such analysis was left up to the researchers that developed and
patented the compounds and is not presented here. Porphyrin compounds were shown to
specifically inhibit free virus particles as well as membrane fusion phenomena required for
virus entry and virus spread, and the antiviral activity was enhanced by modification of the
chemical structure of the porphyrin compounds via primary sulfonation and metallation.
However, neither secondary sulfonation, nor the addition of naphthalene or fluoride
moieties, improved the effectiveness of compounds to inhibit EHV-1.
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CHAPTER III.
ANTIVIRAL ACTIVITY OF PORPHYRIN
COMPOUNDS AGAINST FUSION EVENTS OF EHV-1
INFECTIVITY AND SPREAD
INTRODUCTION
Motivation to Study EHV-1
Equine herpesvirus 1 (EHV-1), a member of Alphaherpesvirinae family, genus
Varicellovirus, is ubiquitous to the equine population worldwide, with seroprevalence
reaching up to 80% (Carvalho et al., 2000; Taouji et al., 2002). With 9.2 million horses in
the United States and horse industry contribution of $39 billion in direct economic impact
(Deloitte-Consulting, 2005), EHV-1 is responsible for economically detrimental diseases:
epizootic respiratory diseases in race horses and clinically serious diseases such as abortion
among mares at the late stage of gestation, perinatal mortality, as well as occasional
outbreaks of disseminated necrotizing myeloencephalitis. Of particular importance to the
management of EHV-1 infections, is the fact that these viruses establish latency, regardless
of natural or vaccine-induced immunity, and can recur in times of immune suppression.
Vaccination against EHV-1 reduces the severity of respiratory illness and occurrence of
abortion, but it does not prevent spread to newborn foals, the latent infection or the
neurological disease caused by the virus (Foote et al., 2004).

Current EHV-1 Treatment
EHV-1 infections are usually dealt with using management practices that limit
spread of the disease, providing supportive symptomatic relief to infected horses, treating
potential secondary bacterial infections with antibiotics. Because vasculitis, hemorrhage,
and edema are prominent early lesions of EHV-1 myeloencephalopathy (EHM) and may
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have an immune basis, controversial treatment with corticosteroids is often recommended
(Friday et al., 2000).

EHV-1 Antivirals
Multiple nucleoside analogue anti-viral agents show activity against EHV-1 in
vitro and in laboratory animals (de la Fuente et al., 1992; Rollinson and White, 1983;
Smith et al., 1983). Treatment of neurologic outbreaks with acyclovir (9-[2hydroxyethoxymethyl]guanine) (Schaeffer, 1982), a viral DNA replication inhibitor active
against several human herpesviruses, has been attempted in horses with a few reports of
reduced mortality in a study group of up to seven horses (Friday et al., 2000; Murray et al.,
1998). There is a lack of statistically significant data on increase of survival. Patent
restrictions have only recently been lifted from acyclovir and its use in treatment of EHV-1
is on the rise. Although acyclovir is a remarkably low toxicity drug, in an already
compromised equine patient with EHV-1 infection, nephrotoxicity, myelosuppression,
gastrointestinal disturbances and fetotoxicity can occur. In addition to toxicity issues,
resistance and cross-resistance is on the rise in human herpes patients. Acyclovir resistant
strains of HSV-1 are becoming more common and account for growing fraction of new
infections worldwide. Data describing the pharmacokinetics, bioavailability, and safety of
acyclovir in horses, is limited. Dosing protocols to treat EHV-1 infections are currently
based on extrapolation from well established dosage regiments used for treatment of
human infections with HSV-1 and VZV.

Rationale for Fusion Inhibitors
There is a need for EHV-1 antivirals that are less toxic than acyclovir and target
aspects of the herpes replicative cycle other than DNA replication. Therefore, development
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of new class of antiviral agents that prevent entry of herpes into cells is a promising
prospect for therapy. Characterizing the viral and host determinants that impact entry
inhibition sensitivity will provide information that can be used to guide the clinical
application.

Hypothesis
Herpes viruses infect cells by fusion of the viral envelope with the cellular
membranes and can spread from cell to cell via fusion of adjacent cells, mediated by viral
glycoproteins expressed on infected cell surfaces. While the majority of antiviral
compounds in use today interfere with function of viral genome replication enzyme,
several compounds have been described to interfere with virus infection at the stage of
virus penetration into the cell. The desirable antiviral compounds for in vivo use will
inhibit viral infectivity through interference with membrane fusion events critical to the
virus lifecycle.
The central hypothesis of the these investigations is that selected tetraporphyrinderived compounds can specifically inhibit membrane fusion phenomena required for virus
entry and virus spread through specific interactions with one or more viral glycoproteins
required for membrane fusion.

Objectives
The aim of the previous part of the study was to conduct screening tests to
determine preliminary virucidal and cytotoxic effects of the commercially available and
newly synthesized porphyrin compounds. A select group of compounds with virucidal
properties was analyzed by definitive tests in order to measure the observed effects and
identify potential antiviral substances. Further experiments were conducted to increase the
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information base relative to the mechanism of antiviral and cytotoxic effects, specifically,
to identify individual stages of virus lifecycle (attachment, virus to cell fusion, infectious
virus production, and cell-to-cell spread), which are affected by selected antiviral
compounds and to determine what specific viral and cellular components are affected by
the compounds.
Antiviral compounds were tested for their ability to interfere with EHV-1 infection
of rabbit kidney and equine cell culture during the entry and post entry events of the viral
life cycle in order to determine if antivirals act at the level of binding, penetration, or postentry. Specifically, selected porphyrin compounds were tested to determine whether they
selectively inhibit glycoproteins-mediated membrane fusion events of virus entry and virus
spread.

Porphyrins: Overview, Antiviral Properties and Synthesis
A number of attributes of porphyrins such as stability over the range of pH and
ionic strengths, favorable pharmacokinetic properties, low toxicity and cost, render them
attractive pharmaceutical candidates. Previous studies indicated that some porphyrins
inhibit the interaction between the human immunodeficiency virus (HIV-1, HIV-2)
envelope protein, gp120 and its receptors, by directly interacting with gp120 (Song et al.,
1997; Vzorov et al., 2002; Vzorov et al., 2003).
Synthetic porphyrins, namely the sulfonated derivatives of the
tetraphenylporphyrin, have also been shown to be active against HSV-1, HSV-2, and pox
virus (Vzorov et al., 2002; Vzorov et al., 2003). Sulfonamide (-SO2NH-) group occurs in
numerous biologically active compounds, including antimicrobial drugs, saluretics,
carbonic anhydrase inhibitors, insulin-releasing sulfonamides, antithyroid agents and a
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number of other agents with biological activities (Chen-Collins et al., 2003; Remko and
von der Lieth, 2004).
Iron containing porphyrins called hemes (Figure III-1, A) are the best known
natural porphyrins found in hemoglobins, myoglobins, peroxidase, catalase, bilirubin, and
cytochromes. Micromolar concentrations of synthetic metalloporphyrins have been shown
to have in vitro activity against human immunodeficiency (HIV) and vaccinia viruses
(Neurath et al., 1992). Both, natural and synthetic porphyrins exist without any central
metal, in a “free base” form (Figure III-1, D), or as metaloporphyrins with various metal
ions in the center (Figure III-1, B, C). While “free base” porphyrin derivatives are in daily
clinical use as photodynamic agents for cancer, it is critical for virucidal porphyrins to be
non-phototoxic and thus, non-cytotoxic. Introduction of a central metal compound
abolishes photodynamic properties, potentially reducing cytotoxicity. Virucidal as well as
antiviral activities can be attributed to either class of compounds.
A screen of different porphyrins and other compounds presented in the previous
chapter revealed that sulfonated metalloporphyrins, Cu (II) tetrasulfonated
phenylporphyrin and Fe (III) tetrasulfonated phenylporphyrin, possessed strong virucidal
and antiviral activities against as well as low cytotoxicity.

Fusion Process
Herpes simplex virus entry into cells requires four glycoproteins, gB, gD, gH, and
gL. Glycoprotein B forms a trimer (Heldwein et al., 2006) and gH establishes a
noncovalent complex with gL (Cairns et al., 2005; Hutchinson et al., 1992; Peng et al.,
1998). Virus-induced membrane fusion is subdivided into three sequential phases. During
Phase I, two membranes are brought into close proximity through viral glycoprotein
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binding of cellular receptors. In alphaherpesviruses, such as EHV-1, gC interacts with
heparan sulfate glycosaminoglycans (HSGAG) (Osterrieder, 1999), gB interacts with
HSGAG and paired immunoglobulin-like type 2 receptor (PILR) alpha (Roller et al.,
2008), and gD interacts with HveA and other receptors on cell surface (Spear et al., 2000).
Glycoprotein D is the only interaction required for Phase I. Binding of gD to one of its
receptors triggers conformational change that exposes the normally hidden receptor
binding residues of gD. This results in transient interaction between gD and gH/gL, where
gH/gL carries out Phase II hemifusion, followed by stable complex between gD and gB,
where gB completes Phase III full fusion. Specifically, Phase II involves the initiation of
lipid mixing between the two apposed membranes and is completed when the outer
membrane leaflets are mixed to form an intermediate called hemifusion. Phase III begins
when the inner membrane leaflets are mixed and continues the pore formation and
expansion until completion of the fusion process (Atanasiu et al., 2007; Subramanian and
Geraghty, 2007). Interestingly, Varicella Zoster Virus (VZV) fusion formation occurs upon
expression of the gH/gL complex alone. In contrast, Pseudorabies Virus (PRV) requires
expression of gH, gL and gB, while the Herpes Simplex Virus (HSV) types 1 and 2 require
the quartet of gH, gL, gB and gD. EHV-1 core fusion complex is not defined, but
suspected to parallel the HSV-1 model and include gH, gL, gB and gD.

MATERIALS AND METHODS
Cells
Rabbit kidney epithelial cells, RK13, were obtained from the American Type
Culture Collection (ATCC CCL-37, Rockville, MD). Cells were maintained in Dulbecco
modified Eagle’s minimum essential medium (DMEM) supplemented with 15 mM Hepes,
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and 7% fetal bovine serum (FBS) and incubated at 37°C, 5% CO2. Cell lines ED (Equine
Dermal, ATCC CCL-57), EFTr (Equine Fetal Trachea Cells, primary cell line, field strain
provided by Dr. Corstvet, LSU), Vero (African Green Monkey Kidney Cells, ATCC CCL81), and COS7 (African Green Monkey Kidney Cells , ATCC CRL-1651) were propagated
in DMEM with 15 mM Hepes and 7% FBS.

Viruses and Determination of Virus Titer
EHV-1 RacL11-∆gp2-GFP, NY-1, NY-2 and VA virus strains were kindly
provided by Dr. Osterrieder (Cornell University School of Veterinary Medicine, Ithaca,
NY). RacL11 encodes the F plasmid and an EGFP expression cassette under the human
cytomegalovirus immediate early promoter (HCMV-IE) that was substituted for EHV-1
non-essential gene 71 encoding glycoprotein gp2. Deletion of the gp2 glycoprotein does
not appreciably affect virus entry and virus replication, while a slight reduction (5%) in
plaque size is observed (Neubauer et al., 2002). The parental wild-type HSV-1 strain used
in this study, HSV-1 (KOS), was originally obtained from Dr. Priscilla A. Schaffer
(Harvard Medical School, Boston, MS). HSV-1 KOS-EGFP was provided by Dr. Prashant
Desai (The John Hopkins University, Baltimore, MD). Virus stocks of EHV-1 and HSV-1
were grown on RK-13 and Vero cells respectively. To determine the number of infectious
virus particles, the virus stocks were subjected to 3 cycles of freezing and thawing to
release virus from the cells or were sonicated. To infect the RK13 cells in triplicate wells,
the virus suspension was diluted tenfold across wells of the 24-well plate, starting at 20 uL
of virus stock and 180 uL of media. After 1 h of adsorption at 37°C in DMEM
supplemented with 25 mM Hepes, methylcellulose overlay medium (DMEM containing
1.5% methylcellulose and 2% FBS) was added to the infected cell monolayers. The plates
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were incubated at 37°C for several days and then fixed with methanol. The cell monolayers
were stained with 0.1% crystal violet, plaques were counted for each dilution, and the
number of virus particles in the original virus stock estimated.

Porphyrin Antiviral Compounds
According to the chemical nomenclature of porphyrin and porphyrin derivatives,
compounds are designated as follows: meso-tetraphenylporphirine (TPP); 5,10,15,20tetrakisphenylporphyrin (H2TPP); and 5,10,15,20-(4-chlorosulfonylphenyl)porphyrin
(H2TPPS4). An “S” at the end of the abbreviation indicates that the parent porphyrin was
sulfonated and the derivatives are mixtures with variable numbers and/or positions of the
sulfonates on the ring. Cu(II)-5,10,15,20-tetrakis(4-[p-sulfobenzyl]sulfoamidonylphenyl)
porphyrin (Cu(II)TPPS4) is a sulfonated tetraphenylporphyrin with a copper
moiety/chelate at the meso position, while Fe(III)-5,10,15,20-tetrakis(4-[p-sulfobenzyl]
sulfoamidonylphenyl) porphyrin (Fe(III)TPPS4) is a sulfonated tetraphenylporphyrin with
an iron moiety/chelate, and for simplicity, will be referred to in this paper as
metalloporphyrins (Liébecq, 1992). Compounds were either commercially available
(Kadish et al., 2003) or synthesized from compounds obtained from Sigma-Aldrich Corp.
(St.Louis, MO) by the collaborating laboratory of Dr. Luidgi Marzilli (Chemistry
Department, Louisiana State University, Baton Rouge, LA). Distilled water was used as
solvent for each test chemical. Preparation of solutions and all experiments were done
under red light to prevent chemicals degradation or phototoxicity upon exposure to light.
All compounds were stored at 3-5°C in containers not permissive to light. ChemDraw Pro
11.0 (CambridgeSoft Corporation, Cambridge, MA) program was used to present chemical
structures of the compounds.
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Determination of 50% Inhibitory Concentration of Antiviral Compounds
EHV-1 strain RacL11 at 2x10e5 PFU was incubated with indicated concentrations
from 0 to 20 µg/ml of porphyrin in media for 20 min at 37°C, then was used to infect
RK13 cells for 1 hour at 4°C, following which the media was replaced with fresh
containing the same concentrations of antiviral compounds, and the infection was allowed
to proceed at 37°C for 2 days. Virus titers were determined by endpoint titration of virus
stocks on RK13 cells (Cassiani-Ingoni et al., 2005). The effect of porphyrins at various
concentrations was determined as the ratio of virus surviving the treatment with
metalloporphyrins to the untreated control.

Neutral Red Uptake Cytotoxicity Assay
The procedure used to determine cell viability via spectrophotometric assay was
essentially as described by Ellen Berenfreund and James Borrero of Rockefeller University
(Borenfreund and Puerner, 1985). Tissue culture grade Neutral Red (NR) dye was
purchased from SIGMA (Cat. No. 289) in a liquid form at 3.3 mg/ml. Fresh stock solution
and Neutral Red Medium was prepared within 30 minutes of each experiment. Cells were
seeded in 96-well tissue culture plates. Antiviral compounds were serially diluted to eight
different concentrations in the range from 2,500 mg/ml to 1 mg/ml, and added to overlay
the 50% confluent cell monolayers. The treated cells were incubated under normal growth
condition for 48 hours and then, stained with neutral red containing medium to access cell
viability. The cells were subsequently washed, the dye was extracted in each well, and the
absorbance was read using a spectrophotometer. The 50% cytotoxic concentration (CC50)
was calculated.
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Antiviral Effect on Kinetics of Infectious Virus Production
Analysis of one-step growth kinetics of total infectious virus was as described
previously (Mettenleiter, 1989 ). Briefly, approximately 8 x 105 cells of the RK13 cell
monolayers were infected with RacL11-∆gp2-GFP at MOI of 5 or MOI of 0.1. Virus
adsorbed to cell surfaces at 4°C for 1 h. Thereafter, prewarmed media was added, and virus
was allowed to penetrate the cells for 2 h at 37°C. Any remaining extracellular virus was
inactivated by low-pH treatment (0.1 M glycine, pH 3.0). Cells were rinsed and overlaid
with DMEM supplemented with 2% FBS with or without Cu(II) TPPS4 or Fe(III)TPPS4
antivirals. Cells and supernatants were harvested immediately thereafter (4 h) or after 6-, 8, 10-, 12-, 20- or 32-hours post infection and frozen. The samples were then subjected to 3
cycles of freezing and thawing to release virus from the cells and virus titers were
determined by endpoint titration of virus stocks on RK13 cells.

Antiviral Effect on Kinetics of Virus Entry
All antiviral compounds were tested for their ability to interfere with EHV-1
infection during virus entry and infectious virus production. The RacL11-∆gp2-GFP virus
was preincubated with or without each compound for 20 minutes at room temperature, and
then, the treated virus stock was used to infect cells for 1 hour at 4°C to allow virus
binding. Subsequently, infected cells were incubated for 2 hours at 37°C to allow virus
penetration, washed with PBS, and overlaid with fresh DMEM with 25 mM Hepes.
Alternatively, infected cells were exposed for 10 minutes to the antiviral compounds added
at various times post-infection, as follows: 1) immediately following the 1 hr attachment at
4°C; 2) at the time that the cells were transferred from 4°C to 37°C; and 3) after the 1 hr
incubation at 37°C to determine the relative antiviral efficacy of each compound at the
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binding, penetration, or post-entry lifecycle steps, respectively. The relative inhibition of
viral infection was determined at 12 hour post infection, based on the percent reduction in
the number of cells emitting fluorescence and thus infected, as determined either via FACS
or direct cell counts. Alternatively, cells were inspected under fluorescent microscope at 48
hours post infection.

Evaluation of Antiviral Effect on Virus Spread
The antiviral effect on cell to cell spread and virus-induced cell fusion was
determined via comparison of plaque size and the extend of multinucleation of EHV-1
RAcL11 infected RK13 (rabbit kidney) cell monolayers treated with Cu(II)TPPS4 or Fe
(III) TPPS4 or neither (Muggeridge, 2000; Turner et al., 1998). Virus was adsorbed to cell
monolayers for 1 hour at 4°C. Thereafter, prewarmed media was added, and virus was
allowed to penetrate the cells for 2 h at 37°C. Cells were then rinsed and overlaid with
methylcellulose overlay medium (DMEM containing 1.5% methylcellulose and 2% FBS)
containing the indicated amount of antiviral. At 72 hpi, the number of infected cells per
viral plaque as well as the number of nuclei per polykaryocytes and frequency of their
occurrence within the plaque were counted microscopically using Leica software in two
independent assays. Polykaryocytes were defined as cells containing more than one
nucleus. Average values and standard deviation were then calculated.

Construction of Plasmids Expressing EHV-1 Glycoproteins
The glycoprotein genes amplified from the EHV-1 genomes were cloned in the
pcDNA™3.1 vector (Cat. No. V795-20, Invitrogen Corporation, Carlsbad, CA), under the
control of the Cytomegalovirus (CMV) early promoter, as detailed elsewhere. This vector
is suitable for constitutive expression in mammalian cells.
148

Assay for Virus-Free Cell-to-Cell Fusion
Rabbit kidney (RK13) cells were seeded at approximately 8 × 105 cells per well in
six-well culture dishes. Transfections were performed with SuperFect Transfection
Reagent (Cat. No. 301305, Qiagen Inc., Valencia, CA) with 2 µg of each glycoproteinencoding plasmid. The amount of DNA was equalized by adding appropriate amounts of
pcDNA™3.1 /V5-His-TOPO® vector (Cat. No. K4800-40, Invitrogen Corporation,
Carlsbad, CA). DNA was mixed in 150 µl of MEM without serum, and 10 µl of SuperFect
Transfection Reagent was added and mixed. After 10 min of incubation at room
temperature, 830 µl of medium containing 10% fetal calf serum was added, and the
transfection mixture was dispersed in duplicate wells onto the cell monolayer. Cells were
incubated at 37°C for 4 hours when transfection mixture was replaced by medium with
10% fetal calf serum. Cells were further incubated at 37°C for 9 to 24 hours as indicated,
then fixed with 80% ethanol, incubated with a monoclonal antibody (MAb) directed
against V5, and scored for syncytium formation. Nuclei in 100 polykaryocytes per assay
were counted microscopically using Leica software in two independent assays.
Polykaryocytes were defined as cells containing more than one nucleus. Average values
and standard deviation were then calculated (Muggeridge, 2000),(Turner et al., 1998).

Polyethylene Glycol Reversal Experiments
EHV-1 RAcL11 at an MOI of 1 was diluted in PBS with or without 100 µg/ml of
heparin sodium salt or 5 µg/ml of porphyrin. RK13, CHO-K1, EFTr cells were inoculated
with virus suspension. Virus was adsorbed to cell monolayers for 1 h at 4°C and shifted to
37°C for an additional hour. Viral inoculum was then removed and cells washed with PBS,
citrate buffer (135 mM NaCl, 10 mM KCl, 40 mM citric acid [pH 3.0]), or
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overlaid for 30-60 s with PEG50 (50% PEG 6000-8000 in MEM or PBS wt/vol) wt/wt.
PEG50 was removed by consecutive addition of PBS to make a 1:2 and 1:4 dilution of
PEG50 in a well. Cells not exposed to PEG were treated similarly in PBS without PEG.
Wells were carefully washed three times in PBS or DMEM supplemented with 5% fetal
calf serum, overlaid with methylcellulose medium or DMEM containing 8% FBS and
incubated further for 2 days at 37°C. The cell monolayers were stained with 0.1% crystal
violet and plaques were counted. To determine virus yields after PEG treatment, cells were
incubated in DMEM and harvested at 10 h postinfection.

Statistics
The results of the experiments were graphed and statistically analyzed using
SigmaPlot (SYSTAT Software Inc., San Jose, CA) and other applicable software.

RESULTS
Chemical Structure
Porphyrins are readily synthesized from pyrrole and aromatic aldehyde derivatives
and can be modified into sulfonamide and metal complex derivatives by using the process
of chlorosulfonation (Gonsalves et al., 1996). The basic compound is TPP, mesotetraphenylporphyrine (Figure III-1, D). A 5,10,15,20 (4’-sulfonphenyl) porphyrin or
H2TPPS4 was obtained by chlorosulfonation of 5,10,15,20-tetrakisphenylporphyrin
(H2TPP) to 5,10,15,20-(4-chrorosulfonylphenyl) porphyrin, which was then hydrolyzed to
its water soluble by-product H2TPPS4 (L. Marzilli, LSU, Baton Rouge, LA, May 2004). In
most cases, the product of the synthesis is a mixture of compounds, tetraphenyl porphyrin
derivatives, containing variable numbers of sulfonates and/or positions of the sulfonates on
the ring. Compounds are negatively charged and water soluble. EHV-1 inhibitors, Cu(II)
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tetrasulfonated phenylporphyrin and Fe(III) tetrasulfonated phenylporphyrin were
synthesized via metallation of water-soluble porphyrin (Figure III-2) , H2TPPS4 with
Cu(II) or Fe(II) oxide (Figure III-1, B and C), dichloride and tetrachlorde. Fe(III) or Cu(II)
chelates were inserted into H2TPPS4 by metallation process. H2TPPS4 heated with
Fe(II)Cl2x4H2O in the presence of nitrogen for 30 min, then stirred in air, cooled and
evaporated. Then dissolved in water and excess of iron removed (L. Marzilli, LSU, Baton
Rouge, LA, May 2004). The molecular mass of Cu(II) tetrasulfonated phenylporphyrin is
1134 g/mol and that of Fe(III) tetrasulfonated phenylporphyrin is 1126 g/mol, considering
the chemical structures of C48H24O12 N4Na4S4Cu1 and C48H24O12 N4Na4S4Fe1 formula
respectively.

Concentration of Antiviral Required to Inhibit Virus Infection
Rabbit kidney (RK-13) cells were the cells of choice to conduct the experiments,
since these cells are primarily used to study the equine herpesviruses and are the
recommended cell type in laboratory diagnosis of field infections by virus neutralization
assays. The virus was subjected to the porphyrins in solution prior to infection and
throughout the infectious life-cycle, at 0 to 20 µg/ml concentration of porphyrin in media
(Figure III-3). The effect was cumulative including that contribution from antiviral effect
on free virus as well as attachment, fusion and post entry events of the virus life cycle.
Once virus had attached to the cell surfaces, the cells were thoroughly rinsed to
remove virus that may have remained unattached. The media was then replaced with fresh
media containing the respective concentrations of the antiviral compounds and the
infection was allowed to proceed. The effect of porphyrins at various concentrations was
determined as the ratio of the virus surviving the treatment with porphyrins to the untreated
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Figure III-1. Chemical structures of common porphyrin, heme[Fe(II)
protoporphyrin-IX complex] (A), and tetrasulfonated phenyl metaloporphyrins used
in this study, Fe (III)TPPS4 (B), Cu(II)TPPS4 (C), and H2TPPS4 (D). Porphyrins have
aromatic groups at the meso position. H2TPPS4 has hydrogen substituents on the pyrrole
rings, while the central nitrogens have NH. Cu(II) tetrasulfonated phenylporphyrin
(Cu(II)TPPS4) and Fe(III) tetrasulfonated phenylporphyrin (Fe(III)TPPS4) were
synthesized via metallation of water-soluble porphyrin, H2TPPS4, with Cu(II) or Fe(II)
oxide.
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Figure III-2. Metallation of H2TPPS4 Porphyrin. The chemical reaction of addition of
metal ( M = Cu or Fe) to the meso position of the water-soluble tetraporphyrin.

control infection. Metalloporphyrins, Cu(II)TPPS4 and Fe(PPP)TPPS4, inactivated all
virus particles at the concentrations as low as 10 μg/ml.
At metalloporphyrin concentrations of around 2.5 μg/ml or less, virus survival was
reduced only by 15 % or less. At concentration of 2.5 - 5 μg/ml the virus survival had
dramatically decreased. Both metalloporphyrins followed a similar porphyrin
concentration to virus survival curve, although they contain different metals at their meso
position. The parental compound, TPPS4 had minimal effect on the virus at concentrations
up to 7.5 μg/ml, while virus survival dropped linearly from 100 % to 30%, when the
concentration was raised to 20 μg/ml. Addition of the metal at the meso position has
significantly increased antiviral function of sulfonated tetraporphyrin compound on virus
infection, irrespective of the metal compound added. Based on the result of these
experiments, most of the subsequent studies were conducted at minimum effective dose of
20 μg/ml. At 20 μg/ml the molar concentration of each compound is around 18 μM. By
comparison at 20 g/ml of acyclovir the molar concentration of acyclovir is 80 μM, while
2 g/ml is 8 μM.
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Figure III-3. Inhibitory concentration of antiviral compounds on virus infection.
2x10e5 PFU of EHV-1 strain RacL11 was incubated with indicated concentrations of
compounds for 20 min at 37°C, then used to infect RK13 cells for 1 hour at RT, following
which the media was replaced with fresh containing the same compound concentrations,
and the infection was allowed to proceed at 37°C for 2 days, when plaques were counted.
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Cytotoxic Effects of the Antiviral Compounds
To establish that the compounds have antiviral activity at the concentrations that
can be achieved without inducing toxic effects to the cells, cytotoxic effects of the
compounds as well as cell viability and proliferation were evaluated by using Neutral red
uptake assay. The results were then confirmed by trypan blue dye exclusion cell viability
assay and propidium iodide apoptosis assay. Neutral red uptake assay is based on the
ability of viable cells to incorporate and bind the supravital dye, neutral red. Neutral red is
a weak cationic dye that readily penetrates cell membranes by non-ionic diffusion and
accumulates intracellularly in lysosomes/endosomes. Microtitration plate cultures were
exposed to range of drug concentrations during the log phase of growth and viability was
determined. Alterations of the cell surface or the lysosomal membrane due to the toxic
effects of porphyrins would lead to lysosomal fragility, decreasing uptake and binding of
neutral red dye. Spectrophotometry was used to quantitate the amount of neutral red
uptake.
The assay was used to determine cytotoxic concentration of the compound that
reduced cell viability to 50% and 100%, CC50 and CC100, respectively. Inhibitory
concentration 50, IC50, is the concentration of a compound required to inhibit the effect of
the virus in vitro by 50% of the control value. The relative effectiveness of the compound
to inhibit viral infection compared to inducing cell death is defined as the therapeutic index
(USDHHS, 2005). Therapeutic index, TI, is CC50/IC50 or the ratio of the amount of the
compound that causes toxic effects to the amounts needed for therapy. A narrow
therapeutic range and thus smaller TI is less desirable, since even a small increase in the
amount of drug may lead to toxicity.
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Metallopophyrins reached cytotoxic dose lethal to all the cells at 1.25 mg/ml and
median cytotoxic concentration of 0.6 mg/ml and 0.45 mg/ml for Fe(III)TPPS4 and
Cu(II)TPPS4 respectively. Inhibitory concentrations of the compounds were obtained from
three sets of independent experiments such as shown in Figure III-3. Metalloporphyrins
reached 50% inhibitory concentration at around 3-3.5 µg/ml, while their parental strain
reached IC50 at the 4-fold higher concentration. Therapeutic indexes (TI) were computed
as the ratio between CC50 and IC50 (Table III-1). Iron metalloporphyrin had a higher twofold higher TI than its copper counterpart. The parental strain had extremely narrow
therapeutic range, as expected due to it phototoxic properties in the absence of the central
metal. Compounds with higher TI are better candidates as antiviral medication, due to
safety considerations. By comparison, the EC50 of acyclovir against HSV-1 virus infection
of MDBK cells was reported as 2.88 µg/ml and CC50 of 9.12x10e, resulting in a TI of
3.16x10e4 and one of the safest medications available (Bean, 1992; Clercq, 1995; Wiltink
and Janknegt, 1991).
Table III-1. Quantitation of cytotoxic concentrations and therapeutic indexes of
antiviral compounds. Cytotoxicity is expressed as concentration-dependent reduction
of the uptake of the Neutral Red dye evaluating both cell integrity and growth
inhibition.
Chemical denomination
Fe (III) tetrasulfonated phenylporphyrin
Cu (II) tetrasulfonated phenylporphyrin
Tetraphenoxyphenyl sulfonate porphyrin

CC100
μg/ml
~1250
~1250
~625

CC50
μg/ml
~600
~450
~50

IC50
μg/ml
3.0
3.5
13

TI
200
118
4

Antiviral Effects of Porphyrins: Reduction of Infectious Virus
Production
RK13 cell monolayers were infected with RacL11-∆gp2-GFP at MOI of 5 (Figure
III-4) or MOI of 0.1 (Figure III-5). Three hours into infection, once the virus has attached
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and entered the cell initiating replication, porphyrin compounds were added to the media
overlaying the cell. One hour later and at specified intervals thereafter, supernatants of
infected cells and the infected cells were collected and total infectious virus yield
determined by plaque assay.
The exponential phase of the virus growth from 4 to 20 hours post adsorption, was
graphed on a logarithmic versus linear scale, and therefore, follows a linear pattern. The
relative growth rate (RGR) in the presence of either compounds or in their absence
remained the same, as indicated by similarity of slope (dy/dx) of all three functions.
Decreasing growth rate after 20 hours post adsorption is evident by the leveling of the
slope over time.
The kinetics of virus growth is depicted as virus titers determined as the sum of the
extracellular free virus in the supernatants and the intracellular infectious virus. The

Figure III-4. Inhibitory effects of metalloporphyrins on virus replication at high
MOI. Monolayers of RK13 cells were infected with EHV-1 RacL11 at an MOI of 5. At 4
hours post infection the cells were treated with antivirals. At indicated times post infection,
cells and supernatant were harvested, and the total infectious virus production was
measured by plaque assay. Viral titers as mean PFU/ml at each time point are shown in a
logarithmic vs. linear scale. The error bars represent the average of three independent
experiments.
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intracellular and extracellular titers of EHV-1 are generally about equal at each time point
(Schimmer and Neubauer, 2003). The viral titers of treated versus untreated virus were
decreased by approximately two logs throughout infection. For example, at 12 hpi, the
untreated virus titer was 3x10e6 PFU/ml, while porphyrin treated virus titer was 1x10e4
PFU/ml. Such large difference in virus yield cannot be explained by the porphyrin
inactivation of the extracellular fraction alone. From previous experiments (Figure III-3), it
is expected that the extracellular fraction of the treated viruses is not infectious, since free
virus is easily inactivated by the porphyrins at this concentration. However, to definitively
prove porphyrin effect on intracellular fraction of infectious virus, the experiment should
be conducted with virus titers determined for intracellular and extracellular fraction
individually.

Figure III-5. Inhibitory effects on virus replication as shown by reduction at low
MOI. Monolayers of RK13 cells were infected with EHV-1 RacL11 at an MOI of 0.1. At
4 hours post infection the cells were treated with antivirals. At indicated times post
infection, cells and supernatant were harvested, and the total infectious virus measured by
plaque assay. Viral titers as mean PFU/ml at each time point are shown in a logarithmic vs.
linear scale. The error bars represent the average of three independent experiments.
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Figure III-6. Antiviral effects at 48 hpi on RK13 cells infection with RacL11 virus at
MOI 5i. A). Cells were pretreated with compound for at 37°C 1 hour before infection. B).
Untreated cells. C).Virus pretreated with compound for 1 hr at 4°C before infection. D).
Cells were infected in the presence of the compound for 1 hour at 4°C to allow virus to
attach. E). Following 1hr at 4°C, infected cells were overlaid with antiviral media and
incubated for 1hr at 4°C. F). Following 1hr at 4°C, infected cells were overlaid with
antiviral media and incubated for 1hr at 37°C. G). Antiviral compounds were added at 2
hpi following 1 hr at 4°C and 1 hr at 37°C. H). Acyclovir treatment.
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Qualitative Assessment of Antiviral Effect during Early Stages of Viral
Infection at MOI 5
Infected cells were exposed for 10 minutes to the antiviral compounds added at
various times post-infection, immediately following attachment, once attached, as well as
during and post fusion to determine the relative antiviral efficacy of each compound at the
binding, penetration, or post-entry infectious life cycle (Figure III-6). The RK13 cells were
subjected to the Cu(II)TPPS4 or Fe(III)TPPS4 antivirals in the media for 1 hour, and then,
washed thoroughly to remove any residual extracellular antiviral and infected with EHV-1
RacL11 at MOI of 5 (Figure III-6). The pre-treatment of cells with antivirals had no
detectable effect on virus infection at 48 hours post infection as was evident by no change
in the amount of green fluorescence of pre-treated and untreated infected cells (Figure III6, A and B). Treating the cells for longer time and with higher concentration of
metalloporphyrin prior to infection did not yield any detectable inhibition of virus
infection. Mixing the virus and antiviral and either incubating the solution for 1 hour or
using it to immediately infect the cells lead to no infection (Figure III-6, C and D). When
the antiviral containing media was used to overlay the infected cells once the virus was
allowed to attach to the cellular envelope for 1 hour at 4°C, a temperature not permissive
for viral fusion events, there was no effect detected on viral infection at an MOI of 5.
(Figure III-6, E). Metallated tetraporphyrins Cu(II)TPPS4 and Fe(III)TPPS4 at 20 µg/ml
concentration prevented attachment of the EHV-1 RacL11 at MOI of 5 to the RK13 cells
monolayers, but once the virus had attached the compounds had no effect on the virus.
To further evaluate the effect of metallated tetraporphyrins on virus entry events,
the compounds were added to the virus infected cells when the virus had already attached
to the cells and the fusion events of the virus and cellular envelopes were just initiated by
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raising the temperature to 37°C. About 25% decrease in the number of infected cells was
observed at 48 hours post infection (Figure III-6, F). If the antivirals were added post
fusion events, no effect on the virus infection was detected at an MOI of 5 (Figure III-6,
G). Acyclovir at 2 μg/ml was used as control antiviral to show its effect of significant
inhibition of virus infection at post-entry events of virus life cycle (Figure III-6, H). An
acyclovir concentration of 2 μg/mL was selected based on reports of the in vitro
susceptibility of HSV-1 and several EHV-1 isolates to this concentration, a breakpoint
concentration defining in vitro susceptibility of the virus to acyclovir. Virus isolates are
defined as sensitive to acyclovir in vitro at IC50 of <2 μg/mL and resistant to acyclovir if
their IC50 is ≥ 2 μg/mL (Bacon et al., 2003; Safrin et al., 1994).

Quantitative Assessment of Antiviral Effect during Early Stages of Viral
Infection
The above experiment was repeated for MOI of 5, 1, 0.1 and 0.01. Virus or cells
alone or the virus-infected cells during early events of virus infection were subjected to
antiviral treatment (Figure III-7 A and B). The amount of surviving virus was measured by
counting the number of infected cells as percent of untreated control using FluorescentActivated Cell Sorting (FACS). Pretreating the cells with either antiviral had no significant
effect on virus at all MOIs. Treating the virus for 1 hour or infecting the cells in the
presence of either compound inhibited the infection by 100%. Exposing the virus-infected
cells to either antiviral, once the virus has attached to cell surfaces, but prior to the onset of
fusion events or post completion of fusion events had decreased the viral survival from
100% to about 40% as MOI decreased from 5 to 0.01. Exposing the virus-infected cells to
either antiviral during the fusion of the virus particle with cellular membrane decreased the
virus survival by about 20% at an MOI of 5, and by 75% at MOI of 0.01, 0.1 and 1.
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Antiviral Effect on Viral Cell-to-Cell Spread and Syncytium Formation
Although the entry of direct binding of free virions to target cells followed by
fusion, entry and replication is an important initial route of infection, most pathogenic
viruses prefer to move between cells without diffusion through the extracellular
environment, but via cell-to-cell spread. EHV-1 RacL11 virus, being no exception, has
natural propensity to mediate syncytium formation. To evaluate the effect of antiviral
compounds on cell-to-cell spread and syncytium formation, RK-13 cells were infected
with GFP- expressing virus, EHV-1 RacL11 and subjected to the antiviral treatment from 3
to 72 hours post infection. Presence of metalloporphyrins decreased the average number of
infected cells per virus plaque from 50 to 30 cells/plaque (Figure III-8, D). The distribution
of the number of nuclei per syncytia (polykaryocyte) followed a bell-curve shape with the
majority of polykaryocytes within one standard deviation from the mean. The average
number of nuclei per polykaryocyte for Cu(II)TPPS4 was 3.6±1.9. The average number of
nuclei per polykaryocyte for Fe(III)TPPS4 was 1.2±0.8. The number of nuclei per
polykaryocyte of untreated virus was 6±1.3. The size of polykaryocytes decreased by 75%
when treated with Fe(III)TPPS4 and by 40% when treated with Cu(II)TPPS4 as compared
to that of untreated virus infection. Therefore, exposure of the viral infection to
metalloporphyrins had reduced the plaque size by 40% and reduced the extent of cell-tocell fusion by 40-75%.

PEG-mediated Fusion of Antiviral Compound Treated EHV-1
Polyethylene glycol (PEG) is a membrane-fusing reagent that is used to restore
infectivity of the virus blocked at entry by binding of neutralizing compounds to its
envelope. PEG-mediated fusion experiments were conducted to evaluate whether the
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Figure III-7. Time of addition experiment. A) Cu(III)TPPS4. B) Fe(II)TTPS4.
Quantitation of antiviral effects on free virus as well as attachment, fusion and post entry
events of the virus life cycle.
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Figure III-8. Inhibition of Virus Spread. Antiviral effect of porphyrin on plaque
formation of GFP-expressing virus, EHV-1 RAcL11 on RK13 (rabbit kidney) cell
monolayers 72 hpi: untreated (A) and treated with 15 µg/ml Cu(II)TPPS4 (B) or Fe (III)
TPPS4 (C), and corresponding, reduction of plaque size (D) and the extend of cell to cell
fusion (E).

Figure III-9. Polyethylene glycol induced fusion of antiviral compound treated EHV-1
RacL11/EGFP. Virus survival is presented as percent of control.
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porphyrin renders virus particle permanently non-infectious, even if required entry step of
fusion is bypassed by PEG (Figure III-9). The titers of infectious virus were only
marginally increased, indicating that the antiviral permanently disabled the virus particle.

Virus-Free Cell Fusion System
To further evaluate the effect of antivirals on fusion during cell-to-cell spread, a
virus-free cell fusion system was used. Four envelope glycoproteins of the herpesviruses,
gB, gD, and gH/gL complex have been shown capable of inducing cell-to-cell fusion in the
absence of any other viral components, when they are expressed from the plasmid vectors
transfected into the cells (Browne et al., 2001). Glycoproteins were amplified from the
EHV-1 and HSV-1 genomes and cloned into the pcDNA™3.1 vector under the control of
CMV early promoter, so they can be easily expressed in the mammalian cells to high
levels. Co-transfection of these glycoproteins results in syncytia formation in the absence
of active virus infection. The expression of all four glycoproteins together on the same
cellular membrane is required to induce syncytium formation. COS7 cells were used for
the assay, since they can be transfected with much higher efficiency, then RK13 cells.
Expression of HSV-1 gB, gH/gL, and gD resulted in formation of polykaryocytes of about
3 to 20 nuclei each (Figure III-11, A-C). Significant reduction of fusion was observed if
the transfected cells were exposed to Cu(II)TPPS4 (Figure III-11, D-F) or Fe(TPPS4) at 75
µg/ml at 6 hours post transfection. Metallo-porphyrin treated cells formed polykaryocytes

of about 2 to 6 nuclei/cell. The virus-free cell fusion experiment was repeated for EHV-1, a
less established system then HSV-1. In the absence of antiviral, the fusion observed was
about 3 to 15 nuclei/cell (Figure III-12, A-B), while post Cu(II)TPPS4 treatment, the
amount of cell-to-cell fusion has reduced to 2 to 4 nuclei/cell (Figure III-12, C-D).
165

VIRUS-TO-CELL
FUSION

gC
VIRUS FREE CELLTO-CELL FUSION

I. Initial Attachment
gB

II. Stable
Attachment

Heparan
Sulfate Proteoglycans
(Receptor of gC and gB)
gD
HveA
(Receptor of gD)

gC
gH/gL

gB

III. Membrane
Fusion

IV. Capsid
and Tegument
Deposition into the Cytoplasm

PILRalpha
(Receptor
of gB)

HSPG
PILRalpha
HveA

gB
gD
gH/gL
NUCLEUS

NUCLEUS

HveA
PILRalpha

CYTOPLASM

CYTOPLASM

Figure III-10. Diagram of the viral envelope glycoproteins and their corresponding
cellular envelope receptors.
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Figure III-11. Virus-free cell fusion system. COS7 were cells co-transfected with HSV-1
gB1511, gH/gL, and gD-V5. At 6 hours post transfection, cells were either mock treated
(A-C) or treated with 75 µg/ml of Cu(II)TPPS4 ( D-E). The cells were than stain with V5
antibody for visualization of syncytia formation (65X magnification).

Figure III-12. Virus-free cell fusion system. COS7 cells co-transfected with EHV-1 gBV5, gH-V5, gL-V5, and gD-V5. A-B). No antiviral added. C-D). Antiviral (Cu(II)TPPS4)
added at 6 hours post transfection at 75 µg/ml (65X magnification).
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DISCUSSION
Chemical Structure and Function
Two synthetic compounds were selected for detailed studies based of their virucidal
and antiviral properties against EHV-1 as well as their low cytotoxicity in cell culture
assays. These compounds, Cu(II)TPPS4 and Fe(III) TPPS4, were derived by insertion of
Cu(II) or Fe(III) into 5,10,15,20 –tetrakis(4’-sulfophenyl) porphyrin (H2TPPS4)
respectively. H2TPPS4 is a sulfonated derivative of tetraphenylporphyrin and has been
shown to be active against HIV-1, HSV-1 and HSV-2 (Vzorov et al., 2002). Modification
of porphyrins to extend their chemical structure by sulfonation resulted in improvement of
antiviral properties. Metalloporphyrins, Cu(II)TPPS4 and Fe(III)TPPS4, inactivated all
free virus particles at the concentrations as low as 10 μg/ml. Addition of the metal at the
meso position significantly increased antiviral function of sulfonated tetraporphyrin
compound on virus infection, irrespective of the metal compound added. The addition of
metal, copper or iron chelate also resulted in significant decrease of cytotoxicity due to
elimination of photodynamic properties. The parental compound, H2TPPS4, had extremely
narrow therapeutic range, as expected due to it phototoxic properties. Metalloporphyrins
had sufficiently safe therapeutic index, with iron metalloporphyrin reaching a two-fold
higher therapeutic index then its copper counterpart.
Current legislation demands that new drugs go through extensive toxicity testing
before they are released starting with cytotoxicity testing in vitro. Cytotoxicity is a
complex event in vivo, with a wide spectrum of effects, from simple cell death to subtle
functional change of the cell leading to complex metabolic aberrations. To prove absence
of toxicity would require not only to show cell viability and minimal changes in its growth
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and phenotype, but also a subtle analysis of minor metabolic changes or alterations in cell
to cell signaling, that are beyond the scope of this study. The assay used in this study was
chosen as it is a baseline in modern drug testing, providing sufficient information to
estimate potential therapeutic range of the compounds.

Antiviral Effect of Metalloporphyrins: Reduction of Infectious Virus
Production
Antiviral compounds did not affect the relative growth rate of the virus, but
decreased the production of infectious virus progeny on RK13 cells dramatically, by two
logs throughout infection. In our experiments, the antiviral effect on the sum of the
extracellular free virus in the supernatants and the intracellular infectious virus was
evaluated. Such large difference in virus yield cannot be explained by the metalloporphyrin
inactivation of the extracellular free virus alone, because the intracellular and extracellular
titers of EHV-1 are generally about equal at each time point (Schimmer and Neubauer,
2003), therefore two-times and not two-log difference would have been seen. Thus, the
degree of porphyrin effect on virus infection would depend on ability, quantity and kinetics
of porphyrin diffusion across cellular membranes. While, the parental compound,
H2TPPS4, is known to enter the cells, further experiments would be needed to show if
there is cytoplasmic localization of metalloporphyrins and the effect of metalloporphyrins
on intracellular infectious virus alone.

Antiviral Effect of Metalloporphyrins: Inhibition of Early Stages of Viral
Infection
EHV-1 entry into the cells is a carefully orchestrated process of recognition of
cellular receptors, triggering of fusion, fusion, and release of capsid into the cytoplasm.
Pretreating cells with antivirals prior to infection had no effect on infection. Therefore, it is
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likely that metalloporphyrins do not interact with the cell membrane or receptors directly,
and remain extracellular, and thus, were unable to interfere with infection once removed by
washing the cells. Since the parental compound is able to localize inside the cell, a small
amount of metalloporphyrins is expected to enter the cell, but the antiviral concentration
intracellularly may be too low or metalloporphyrin binding sites quickly saturated to have
any detectable antiviral effect on virus infection. Alteration of cellular membrane by virus
infection may render cell envelope more permissive to metalloporphyrins explaining the
inhibitory effect on intracellular virus fraction seen as drastic decrease in virus production
in the presence of metalloporphyrins.
Metallated tetraporphyrins interfere with ability of the virus to attach to the cell
surface, either by directly binding to the free virus but not the cell, or by interfering with
virus attachment to the cellular membranes in other ways. Since metalloporphyrins do not
interact with cellular envelope as shown by no effect on infection by pretreating cells with
antivirals, they most likely interact with the proteins embedded in the viral envelope and
not with a viral envelope itself, which is derived from a cellular membrane.
Virus that attached to the cellular membranes but did not undergo fusion is also
susceptible to the antivirals, but to a limited degree. The fusion of the viral envelope and
cellular membrane during virus entry is significantly affected by the metalloporphyrins.
The antiviral effect on viral replication events post fusion is evident, but also limited. At all
stages of the virus life cycle, higher amount of virus used for infection resulted in more
virus survival. Thus, more porphyrin compounds were available to interact with fewer
virus particles, indicating a saturation effect on the virus-porphyrin interaction. Complete
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inhibition of the virus at each stage of virus entry may be potentially reached if the
porphyrin to virus ratio is increased further.
PEG experiments suggest that interaction with porphyrin renders the virus particle
permanently non-infectious, even if required entry step of virus-induced fusion is bypassed
by PEG-induced fusion. The study in which the virus is subjected to the antivirals, and
then, purified by ultracentrifugation and used for infection would help to show if the virus
is infectious once antivirals are washed off or does the porphyrin permanently disables the
virus by direct binding. To conduct this experiment we would need to determine if the
porphyrin is still present in association with the virus post purification by ultracentrifugation. However, there is no suitable detection method for metalloporphyrins, short of
mass spectrometry and other analytical techniques.

Antiviral Effect of Metalloporphyrins: Reduction of Cell-to-Cell Spread
and Syncytia Formation
Metalloporphyrins exhibited inhibitory effects on virus spread, reducing the plaque
size and the extent of cell-to-cell fusion. It is highly unlikely that inhibition of viral
replication could account for the mechanism(s) by which compounds achieved almost fivefold inhibition of spread in RK13 cells. Acyclovir by comparison, reduces replication, but
has no effect on the spread of the virus via either virus-to-cell fusion or cell-to-cell fusion.
EHV-1 expresses a number of membrane glycoproteins that function in both entry of virus
particles and movement of virus from an infected cell to an uninfected cell or cell-to-cell
spread.
Multiple, viral proteins are involved in cell-to-cell spread and syncytia formation,
such as gH/gL, gB, gK,UL20, UL11, and gE/gI (Cheshenko and Herold, 2002; Foster et
al., 2008; Navarro et al., 1992; Schimmer and Neubauer, 2003). While, gB, gD, gH/gL are
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required for virus-to-cell fusion during entry, complex of gE/gI is required for efficient
cell-to-cell spread, yet not required for entry fusion events (Polcicova et al., 2005).

Antiviral Effect of Metalloporphyrins: Interaction with Viral
Glycoproteins
The cell-to-cell and the virus-to-cell fusion require direct protein–protein
interactions among gD, gB, and gH/gL. Both metalloporphyrins decreased the syncytium
formation in a virus-free cell fusion system, indicating that the porphyrins have direct
effect on at least one of the four glycoproteins. Glycoprotein B mediates attachment and is
required for virus entry, cell-to-cell spread and syncytia formation and is the primary
candidate for direct inhibition by metalloporphyrins (Cassiani-Ingoni et al., 2005).
Cytoplasmic domain of gB is a potential target for interaction with metalloporphyrins,
based on its known function in cell-to-cell spread (Cassiani-Ingoni et al., 2005).

SUMMARY
The continuous circulation of EHV-1 in equine populations despite regular
vaccinations and apparent ineffectiveness of currently available vaccines in preventing or
ameliorating neurological manifestations of EHV-1 infections as well as limitations of
EHM treatment options, necessitates the discovery of new antiviral drugs that can
effectively manage this important infection of horses.
Glycoprotein conformational changes and interactions induce structural alterations
in the membrane that leads to membrane fusion. Tetraporphyrins block these early phases
of viral infection, exerting maximal effect when the virus is exposed to the antiviral at the
time of initial infection or at any time through the end of the attachment and fusion
processes. Tetraporphyrins also considerably curtail the spread of the virus via virus-to-cell
and cell-to-cell fusion. Our results suggest that tetraporphyrins may be used as effective
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virucidal and antiviral agents to prevent and to treat disseminated disease and neurological
outcomes of EHV-1.
Future work should focus on further delineating the mechanism of antiviral and
virucidal effects of these compounds, their cellular distribution, in depth toxicity studies,
and their effect against in vivo EHV-1 infections of mice, specifically, the efficacy of these
drugs to prevent acute viral infections in respiratory and myeloencephalopathy EHV-1
mouse models.
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CHAPTER IV. CONCLUDING REMARKS
FINAL COMMENTS
EHV-1 antiviral properties and their pharmacological characteristics make
porphyrins auspicious candidates for the treatment of EHV-1 infections. Porphyrin
compounds were shown to specifically inhibit free virus particles as well as membrane
fusion phenomena required for virus entry and virus spread, and the antiviral activity was
enhanced by modification of the chemical structure of the porphyrin compounds via
primary sulfonation and metallation. An initial screening of almost 100 porphyrin and
platinum compounds as well as a detailed screening of 18 different compounds revealed
that Cu (II) tetrasulfonated phenylporphyrin and Fe (III) tetrasulfonated phenylporphyrin
possessed strong virucidal and antiviral activities against EHV-1. These compounds,
Cu(II)TPPS4 and Fe(III)TPPS4, were derived by insertion of Cu(II) or Fe(III) into
5,10,15,20 –tetrakis(4’-sulfophenyl) porphyrin (H2TPPS4) respectively.
The selected two compounds were used to synthesize new compounds of extended
chemical structure. Additional sulfonation of compounds did not lead to improvement in
their antiviral properties against free virus nor virus attached to cell surfaces. Addition of
fluoride or naphthalene groups, also did not improve antiviral properties.
Glycoprotein conformational changes and interactions induce structural alterations
in the cellular membrane that leads to membrane fusion. Antivirals block the early phases
of viral infection, exerting maximal effect when the virus is exposed to the antiviral at the
time of initial infection or at any time at the end of the attachment and throughout fusion
processes. Polyethylene glycol experiments suggest that interaction with porphyrin renders
virus particles permanently non-infectious. Cu(II)TPPS4 and Fe(III)TPPS4 antiviral
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compounds did not affect the relative growth rate of the virus, but decreased the production
of infectious virus progeny on RK13 cells dramatically, by two logs throughout infection,
most likely by direct inactivation of infectious virus progeny. Thus, the degree of
porphyrin effect on virus infection at the stages post entry would depend on ability,
quantity and kinetics of porphyrin diffusion across cellular membranes.
The cell-to-cell and the virus-to-cell fusion require direct protein–protein
interactions among gD, gB, and gH/gL. Both metalloporphyrins decreased the syncytium
formation during virus infection and in virus-free cell fusion system, indicating that the
porphyrins have direct effect on at least one of the four glycoproteins. Cytoplasmic domain
of gB is a potential target for interaction with metalloporphyrins, based on its known
function in cell-to-cell spread.

CURRENT AND FUTURE RESEARCH CHALLENGES
A number of experiments can be performed to add further detail to our
understanding of EHV-1 infection and its inhibition by metalloporphyrin compounds.
Purifying the antiviral treated virus and quantifying infectious particles remaining, would
determine if the effect of the porphyrins on the virus particle is a permanent inactivation or
not. Adsorption of 35S-labeled HSV-1 and detection of bound virus by liquid scintillation
radioisotope counting could be considered for precise quantitation of virus able to bind to
the cells following antiviral treatment in the presence of varied antiviral concentrations.
Further experiments would be needed to show if there is cytoplasmic localization of
metalloporphyrins and to estimate the effect of metalloporphyrins on intracellular
infectious virus alone. Surface Plasmon Resonance (SPR) using a Biacore 2000 instrument
can be considered to study the interaction between the antiviral and virus particles. SPR
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aids the study interactions between a wide range of molecules including proteins,
nucleotides, pharmaceuticals, and surface active agents. In order to limit the spread of the
infection in vivo, a consideration should be made at what dose of medication the horse is to
be treated, the treatment regiment, achievable blood concentration and the cost of the
compound administration, as well as potential side-effects such as hypersensitivity.
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APPENDIX: EHV-1, EHV-4, HSV-1, AND HSV-3 GENE
NOMENCLATURE
EHV-1
ORF
1

EHV4
1

HSV-1

VZV

2

2

unknown

3

3

unknown

4
5

4
5

UL55
UL54

4

6

6

UL53

5

7

7

UL52

6

8
9
10

8
9
10

UL51
UL50
UL49A

7
8
9A

virion morphogenesis
nucleotide metabolism
virion morphogenesis, membrane
fusion

11

11

UL49

9

12

12

UL48

10

13

13

UL47

11

14

14

UL46

12

15

15

UL45

16

16

UL44

14

virion morphogenesis, possibly
RNA transport to uninfected cells
regulation, virion morphogenesis,
transactivates immediate early
genes
possibly regulation, modulates
transactivating tegument protein
VP16, RNA-binding protein
possibly regulation, modulates
transactivating tegument protein
VP16
possibly membrane fusion,
membrane protein, tegumentassociated
cell attachment, binds cell surface
heparan sulphate, binds
complement C3b,

17

17

UL43

15

possibly membrane fusion

18

18

UL42

16

DNA replication, dsDNA-binding

UL56

Function
possibly vesicular trafficking

unknown
RNA metabolism and transport,
RNA-binding protein, shuttles
between nucleus and cytoplasm,
inhibits pre-mRNA splicing,
exports virus mRNA from nucleus,
exerts most effects posttranscriptionally
virion morphogenesis, membrane
fusion
DNA replication
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Product
type 2 membrane protein, UL56
family
type 2 membrane protein,
membrane protein V1
potentially envelope-associated,
myristylated tegument protein
CIRC
nuclear protein UL55
expression regulator

envelope glycoprotein K, type 3
membrane protein, contains a
signal peptide, 4
transmembrane domains
helicase-primase primase
subunit
tegument protein UL51
deoxyuridine triphosphatase
type 1 membrane protein,
contains a signal peptide,
complexed with envelope
glycoprotein M
tegument protein VP22
transactivating tegument protein
VP16
tegument protein VP1314
tegument protein VP1112
membrane protein UL45,type 2
envelope glycoprotein C, type 1
membrane protein, contains a
signal peptide to block
neutralization
envelope protein UL43, type 3
membrane protein, 11
transmembrane domains
DNA polymerase processivity

19

19

UL41

17

20

20

UL40

18

protein
cellular mRNA degradation,
mRNA-specific RNase
nucleotide metabolism

21

21

UL39

19

nucleotide metabolism

22

22

UL38

20

23

23

UL37

21

24

24

UL36

22

25

25

UL35

23

26

26

UL34

24

27

27

UL33

25

28

28

UL32

26

29

29

UL31

27

30

30

UL30

28

31

31

UL29

29

32

32

UL28

30

capsid morphogenesis, complexed
1:2 with capsid triplex subunit 2 to
connect capsid hexons and pentons
virion morphogenesis, complexed
with large tegument protein
capsid transport, complexed with
tegument protein UL37, ubiquitinspecific protease (N-terminal
region)
capsid morphogenesis, possibly
capsid transport, located externally
on capsid hexons
nuclear egress, type 2 membrane
protein, interacts with nuclear
egress lamina protein
DNA encapsidation, interacts with
DNA packaging terminase subunit
2
DNA encapsidation, possibly capsid
transport
nuclear egress, interacts with
nuclear egress membrane protein
DNA replication, DNA polymerase
catalytic subunit
DNA replication, possibly
regulation
DNA encapsidation

33

33

UL27

31

34
35

34
35

UL26

32
33

35.5

35.5

UL26.5

33.5

36

36

UL25

34

37
38
39

37
38
39

UL24
UL23
UL22

35
36
37

cell entry, cell-to-cell spread,
possible membrane fusogen, binds
cell surface heparan sulphate
unknown
capsid morphogenesis, serine
protease (N-terminal region), minor
scaffold protein (remainder of
protein, clipped near C terminus)
capsid morphogenesis, clipped near
C terminus
DNA encapsidation, located on
capsid near vertices,
possiblystabilizes the capsid and
retains the genome
unknown
nucleotide metabolism,
cell entry, cell-to-cell spread,
possible membrane fusogen,
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subunit
tegument host shutoff protein
ribonucleotide reductase
subunit 2, small
ribonucleotide reductase
subunit 1, large
capsid triplex subunit 1
tegument protein UL37
large tegument protein

small capsid protein
nuclear egress membrane
protein
DNA packaging protein UL33
DNA packaging protein UL32
nuclear egress lamina protein

single-stranded DNA-binding
protein,contains a zinc-finger
DNA packaging terminase
subunit 2
envelope glycoprotein B, type 1
membrane protein, contains a
signal peptide
protein V32
capsid maturation protease, Nterminal protease domain acts
in capsid maturation and is a
capsid protein , C-terminal
domain is the minor capsid
scaffold protein
Major capsid scaffold protein
DNA packaging tegument
protein UL25
nuclear protein UL24
thymidine kinase
envelope glycoprotein H, type 1
membrane protein, contains a

complexed with envelope
glycoprotein L
virion morphogenesis, interacts
with microtubules
virion morphogenesis, membrane
fusion

40

40

UL21

41

41

UL20

42

42

UL19

40

43

43

UL18

41

44/47

44/47

UL15

42/45

45

45

UL17

43

46

46

UL16

44

48
49

48
49

UL14
UL13

46
47

50

50

UL12

48

51

51

UL11

49

52

52

UL10

50

53

53

UL9

51

DNA replication

54
55
56

54
55
56

UL8
UL7
UL6

52
53
54

57

57

UL5

55

DNA replication
virion morphogenesis
DNA encapsidation dodecamer
located at one capsid vertex in place
of a penton
DNA replication

58

58

UL4

56

59

59

-

57

60

60

UL3

58

61
62

61
62

UL2
UL1

59
60

63

63

RL2

61

capsid morphogenesis, 6 copies
form hexons, 5 copies form pentons
capsid morphogenesis, complexed
2:1 with capsid triplex subunit 1 to
connect capsid hexons and pentons
DNA encapsidation contains an
ATPase domain
DNA encapsidation, capsid
transport, capsid-associated product
possibly virion morphogenesis
product
virion morphogenesis
protein phosphorylation, PK family
product
DNA processing, maturation and
packaging of DNA
virion morphogenesis envelopeassociated
virion morphogenesis, complexed
with envelope glycoprotein N

Unknown, colocalizes with
regulatory protein ICP22 and
nuclear protein UL3 in small, dense
nuclear bodies
possibly virion morphogenesis
product
unknown colocalizes with
regulatory protein ICP22 and
nuclear protein UL4 in small, dense
nuclear bodies
DNA repair
cell entry, cell-to-cell spread
complexed with envelope
glycoprotein H
regulation, cellular protein
degradation, latency contains a
RING finger, disrupts ND10,
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signal peptide
tegument protein UL21
envelope protein UL20, type 3
membrane protein, 4
transmembrane domains
major capsid protein
capsid triplex subunit 2
DNA packaging terminase
subunit 1
DNA packaging tegument
protein UL17
tegument protein UL16
tegument protein UL14
tegument serine/threonine
protein kinase
deoxyribonuclease
myristylated tegument protein
envelope glycoprotein M,
membrane fusion type 3
membrane protein, 8
transmembrane domains
DNA replication origin-binding
helicase
helicase-primase subunit
tegument protein UL7
Minor capsid portal protein
helicase-primase helicase
subunit
nuclear protein UL4

protein V57
nuclear protein UL3

uracil-DNA glycosylase
envelope glycoprotein L,
contains a signal peptide
ubiquitin E3 ligase, ICP0

64/64.1
65

64
65

RS1
US1

62
63

66
67

66
67

US10
-

64
-

68

68

US2

-

69

69

US3

66

70

70

US4

-

71

71

US5

-

72

72

US6

-

73

73

US7

67

74

74

US8

68

75

75

US8A

-

76

76

US9

65

proteasome-dependent degradation
of several cellular proteins
regulation
regulation, cell cycle regulation
required for expression of a subset
of late genes, host range
determinant
unknown
unknown, colocalizes with nuclear
lamins, Virulence determinant
Unknown, possibly envelopeassociated, interacts with
cytokeratin 18
protein phosphorylation, apoptosis,
nuclear egress tegument protein,
phosphorylates nuclear egress
lamina protein, mediates
phosphorylation of HDAC1 and
HDAC2 and other cellular and viral
proteins, PK family
cell-to-cell spread type 1 membrane
protein, contains a signal peptide,
gD family product
unknown type 1 membrane protein,
contains a signal peptide
cell attachment type 1 membrane
protein, contains a signal peptide,
binds cell surface receptors, gD
family
cell-to-cell spread type 1 membrane
protein, contains a signal peptide,
complexed with envelope
glycoprotein E to form an Fcreceptor, gD family
cell-to-cell spread type 1 membrane
protein, contains a signal peptide,
complexed with envelope
glycoprotein I to form an Fcreceptor, gE family
Unknown, type 2 membrane protein
product
axonal transport type 2 membrane
protein, tegument-associated,
localizes envelope proteins

transcriptional regulator ICP4
regulatory protein ICP22

virion protein US10
virion protein V67
virion protein US2
serinethreonine protein kinase
US3

envelope glycoprotein G
envelope glycoprotein J
envelope glycoprotein D

envelope glycoprotein I

envelope glycoprotein E

membrane protein US8A
membrane protein US9

Proteins that are not conserved in both HSV-1 and VZV are encoded by genes 1, 2,
3, 15, 34, 59, 67, 68, 70, 71, 72 and 75. Poorly conserved are genes 48, 62, 63, 73 and
76. The best conserved proteins have counterparts in all mammalian herpesviruses and
include those involved in DNA replication and packaging and capsid structure, such as
those encoded by genes 42, 43, 47/44 and 57.
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